Targeting the DNA damage response protein ATR kinase in pancreatic cancer by Dunlop, Charles Ross
Targeting the DNA damage response protein  
ATR kinase in pancreatic cancer 
 





Cancer Research UK Cambridge Institute 
University of Cambridge 
 
This dissertation is submitted for the degree of 










This thesis is the result of my own work and includes nothing which is the outcome of work 
done in collaboration except as declared in the preface and specified in the text. 
 
It is not substantially the same as any work that has already been submitted before for any 
degree or other qualification except as declared in the preface and specified in the text. 
 
It does not exceed the prescribed 60,000 word limit for the Clinical Medicine and Clinical 









Name: Charles Ross Dunlop 
Title: Targeting the DNA damage response protein ATR kinase in pancreatic cancer 
 
Therapeutic targeting of the DNA damage response (DDR), coupled with the implementation of 
personalised treatment strategies, has the potential to improve the poor survival outcomes of pancreatic 
ductal adenocarcinoma (PDAC). Many common genetic alterations in PDAC augment replication-
associated DNA damage, or replication stress (RS), which increases reliance on the RS-response factor, 
Ataxia Telangiectasia and Rad3-related (ATR) kinase. Furthermore, many chemotherapies used in the 
treatment of PDAC increase RS, leading to ATR activation which limits the efficacy of these therapies. 
Therefore, there is good rationale for targeting ATR as a strategy for treatment of patients with PDAC. 
In this thesis, I report on investigations into the therapeutic potential of combining the ATR inhibitor, 
AZD6738, with DNA-damaging drugs and DDR-targeted agents in preclinical models of PDAC. My 
primary focus was on maximising the efficacy of combined ATR inhibition and gemcitabine 
(ATRi/gem). I hypothesised that ATRi/gem would most likely benefit specific sub-groups of patients 
with pre-existing aberrations in DDR pathways (i.e. a precision medicine approach to patient selection). 
Accordingly, I investigated the potential for deficiency in the double-strand-break master-regulator, 
Ataxia Telangiectasia Mutated (ATM), to sensitise PDAC models to ATRi/gem. I found that complete 
loss of ATM function - through kinase inhibition or through CRISPR knockout, but not ATM depletion 
by RNA interference - sensitised to ATRi and ATRi/gem in PDAC models. Using flow cytometry and 
quantitative image-based cytometry, I gained insight into the mechanisms by which AZD6738 and 
gemcitabine synergise, finding evidence for replication catastrophe that was significantly augmented in 
ATM-deficient cells. In vivo, I demonstrated that low-dose gemcitabine can be used to sensitise to 
AZD6738, much more effectively in an ATM-deficient setting. My results suggest that ATM-deficiency 
augments the replication catastrophe-mediated cell death induced by ATRi/gem, thus ATM-loss could 
predict response to this combination. The preclinical assessments of AZD6738 and gemcitabine that 
formed part of this project have led to the launch of a phase-I clinical trial (ATRiUM; NCT03669601). 
My data indicate that ATM status should be carefully assessed in tumours from patients with PDAC, 
since the distinction between ATM-low and ATM-null could be crucial in maximising the success of 
trials using ATM expression as a predictive biomarker. In this dissertation, I also present my 
investigations into the combination of AZD6738 with the poly(ADP-ribose) polymerase (PARP) 
inhibitor, olaparib. While AZD6738 and olaparib synergistically inhibited the growth of PDAC cells 
proficient in homologous recombination (HR) in vitro, I identified no anti-tumour effect in HR-
proficient in vivo models. This could indicate that a DDR deficiency would be necessary for this 
combination to be most effective in PDAC, a hypothesis that will be tested in the clinic in the Precision-
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CHAPTER ONE: Introduction to pancreatic cancer and the DNA damage response 
1.1. Pancreatic cancer biology 
Pancreatic cancers can either be exocrine or endocrine, that is, adenocarcinomas of the ductal 
epithelium or neuroendocrine tumours of the islet cells, respectively. By far the most common 
of the two is the exocrine disease, pancreatic ductal adenocarcinoma (PDAC), which represents 
more than 90% of pancreatic cancers  (McGuigan et al., 2018; Zhou et al., 2010). A highly 
lethal malignancy, the mortality rate of PDAC almost matches its incidence, and it is projected 
to become the second leading cause of cancer death by 2030 (Rahib et al., 2014).  
PDAC is caused by the accumulation of genetic mutations. The most frequently mutated gene  
in PDAC is KRAS, with somatic mutations in >90% of cases (Bailey et al., 2016; Witkiewicz 
et al., 2015) (Table 1.1). The majority of these mutations affect residue G12 in the KRAS 
GTPase protein (Forbes et al., 2017), which causes constitutive activity and in turn aberrant 
stimulation of the RAF-MEK-ERK axis (Marais et al., 1995) as well as other pathways that 
promote proliferation. The tumour suppressor gene CDKN2A, which encodes p16INK4a, is 
inactivated in over 90% of PDAC through either mutation or transcriptional silencing (Schutte 
et al., 1997), leading to loss of cell cycle regulation at the G1/S phase border. Additionally, 
somatic mutations in TP53 occur in 60-70% of cases (Bailey et al., 2016; Witkiewicz et al., 
2015) and often abrogate the DNA-binding ability of p53, causing loss of its effector function 
as a transcriptional activator in response to cellular stresses such as DNA damage and hypoxia 
(Kern et al., 1992). The fourth most commonly mutated gene in PDAC is SMAD4, another 
tumour suppressor which, when functional, acts downstream of TGFβ family receptors to 
activate the expression of genes that promote growth inhibition (Cao et al., 2008; Dai et al., 
1998). In addition to these four major drivers, numerous whole-genome-sequencing efforts 
investigating the genetic landscape of PDAC have identified mutations in hundreds of other 
genes, but at lower frequencies (Bailey et al., 2016; Biankin et al., 2012; Liu et al., 2018; Singhi 
et al., 2019). These include axon guidance pathway genes, chromatin remodellers and 
regulators of the DNA damage response.  
Somatic KRAS mutation and loss of CDKN2A are early events during pancreas tumorigenesis, 
as evidence by their regular presence in low-grade PDAC precursor lesions known as 




Table 1.1. The most frequently mutated cancer genes in PDAC. Two separate datasets are displayed. Left = Queensland Centre 
for Medical Genomics (QCMG) dataset, whole-genome and deep-exome sequencing analysis of 383 PDAC samples (Bailey 
et al., 2016). Right = The Cancer Genome Atlas (TCGA) dataset, 179 PDAC samples, https://www.cancer.gov/tcga (Liu et 
al., 2018). Frequency data downloaded from cbioportal.org (Cerami et al., 2012). Genes discussed in this chapter are 
highlighted in bold. 
 
occur later, at the grade-3 PanIN stage which precedes invasion (Fig. 1.1) (Hruban et al., 2000; 
Kanda et al., 2012; Maitra et al., 2003). Low-grade PanINs (PanIN-1) are common, 
microscopic lesions that are often undetectable by standard imaging techniques. Meanwhile 
high-grade PanINs are less common and tend to be detected in pancreata that also have invasive 
PDAC (Kanda et al., 2012). Histologically, invasive PDAC tumours are characterised by a 
dense stroma that is made up of extracellular matrix proteins, fibroblasts and immune cells 
(Karamitopoulou, 2019). These stromal features of the human disease are mimicked in the 
widely used mouse model for PDAC, the Lox-Stop-Lox (LSL)-KrasG12D; LSL-Trp53R172H; 
Pdx1-cre (KPC) mouse (Hingorani et al., 2005), which also exhibits the clinical features of 
advanced disease, including loss of body condition, haemorrhagic ascites and metastases 
(Gopinathan et al., 2015). The desmoplastic stroma has been associated with therapy failure 
through a number of mechanisms, including the impairment of drug delivery (Jacobetz et al., 
2013; Olive et al., 2009), establishment of immune privilege that abrogates anticancer T-cell 







Fig. 1.1. Progression model for PDAC. KRAS mutation and loss of CDKN2A (p16) are early events during pancreas 
tumorigenesis, while p53 alterations and loss of SMAD4 (DPC4) occur later. Figure from Hruban et al., 2000. 
 
1.2. Clinical management of PDAC 
Most cases of PDAC are asymptomatic in the early stages. As a result, diagnoses are often 
made at a late stage when the main symptoms are abdominal pain and weight loss (Gullo et al., 
2001; Kalser et al., 1985). While surgical resection can be curative in some cases, the late 
emergence of symptoms means that most patients have locally advanced or metastatic disease 
at presentation and are ineligible for surgery (Vincent et al., 2011). For the 15-20% of patients 
that do present with operable disease, the majority ultimately relapse with metastases (Griffin 
et al., 2015). The mainstay of treatment for metastatic PDAC is systemic chemotherapy. Since 
a 1997 clinical trial which showed that gemcitabine monotherapy outperformed 5-fluorouracil 
(5-FU) monotherapy in terms of median overall survival (5.65 months vs 4.41 months) (Burris 
et al., 1997), gemcitabine has been used extensively in the treatment of patients with PDAC. 
Gemcitabine, or 2’,2’-difluoro 2’-deoxycytidine (dFdC), is a nucleoside analogue that requires 
intracellular phosphorylation for its activity. dFdC is initially phosphorylated by deoxycytidine 
kinase to give the mono-phosphate, which is sequentially phosphorylated to yield the 
diphosphate (dFdCDP) and triphosphate (dFdCTP) forms that induce cytotoxicity (Mini et al., 
2006). dFdCDP irreversibly inhibits one of the key enzymes that mediates synthesis of 
deoxyribonucleotides, ribonucleotide reductase, leading to a reduction in the cellular pool of 
deoxynucleoside triphosphates (dNTPs) (Mini et al., 2006; Montano et al., 2017). dFdCTP is 
incorporated into nascent DNA to halt chain elongation (Huang et al., 1991; Plunkett et al., 
1995). Both mechanisms inhibit DNA synthesis, which underlies the toxicity that gemcitabine 
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has in highly proliferative tissues such as neoplasms.  While the prodrug, dFdC, has a short 
terminal plasma half-life of 42-94 minutes, the intracellular half-lives of the active metabolites 
dFdCDP and dFdCTP are reported to be up to 19 hours (GEMZAR FDA label).  
In recent years, combinatorial chemotherapy regimens have been incorporated into the clinical 
management of PDAC, replacing single-agent therapy. The plasticity of pancreatic cancer, and 
indeed all solid tumours, enables therapeutic adaptation to single-agent treatments, while 
tumour heterogeneity allows pre-existing, drug-resistant clones to frequently emerge in 
patients receiving monotherapy. Combination therapy, meanwhile, aims to overcome some of 
these obstacles. Delivering two or more anticancer agents at once can combat the plasticity that 
drives therapeutic adaptation and also reduces the likelihood that multi-drug resistant clone 
will expand from the tumour. In 2011, it was shown that combining gemcitabine with albumin-
bound paclitaxel (nab-paclitaxel), an anti-mitotic agent, marginally improved survival in 
PDAC patients. The combination group showed 8.5 months median overall survival (mOS) 
compared to 6.7 months in the gemcitabine monotherapy group (Von Hoff et al., 2013). The 
combinatorial regimen FOLFIRINOX (5-FU, leucovorin, irinotecan and oxaliplatin) was also 
found to be superior to gemcitabine-alone, giving a mOS of 11.1 months vs 6.8 months (Conroy 
et al., 2011). One of the advantages of a multi-drug cocktail such as FOLFIRINOX is that, 
while 5-FU, irinotecan and oxaliplatin are all DNA-damaging agents (and the compounding 
effect of this additive damage may enhance cell kill) they each have distinct mechanisms of 
action and therefore may each target distinct cell pools within a heterogenous PDAC tumour 
(cells which are not killed by the 5-FU may be killed by the oxaliplatin, etc). As for the 
gemcitabine and nab-paclitaxel combination, preclinical data suggest that the antitumor effect 
of these drugs is supra-additive (or synergistic) since nab-paclitaxel decreases cytidine 
deaminase levels, stabilising gemcitabine (Frese et al., 2012). Another reason for favouring 
combination therapy is the possibility to use each drug at lower concentrations, such that toxic 
side effects are minimised (provided the toxicities of each drug are not overlapping), thereby 
increasing the therapeutic window. Though combinatorial chemotherapy regimens such as 
FOLFIRINOX represent an improvement in patient outcome compared to gemcitabine 
monotherapy, they still only offer a mOS of less than a year, highlighting the need for better 
therapeutic approaches. This need could be met through more rational drug combinations, that 
is, using insight into the molecular pathways that contribute to tumour cell survival or therapy 
response to inform the drug combination (Boshuizen and Peeper, 2020). The majority of 
chemotherapy currently used in the treatment of PDAC comprises genotoxic agents, thus their 
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efficacy may be improved by targeting the cellular processes that respond to and repair DNA 
damage. 
 
1.3. The DNA damage response  
DNA in cells is constantly subjected to various forms of damage. From external insults such 
as UV radiation, to cell-derived stresses such as free radicals, the integrity of the genome is 
under frequent attack. Consequently, all organisms have evolved cellular mechanisms of DNA 
damage repair. The DNA damage response (DDR) to a particular insult generally involves 
recognition of the lesion, followed by cell-cycle arrest (checkpoint activation) and repair. The 
specific pathways activated depends on the type of damage induced, for example a single-
strand break, DNA-strand crosslink, nucleotide mismatch, stalled replication fork or double-
strand break (DSB) will all evoke distinct responses. The extent of damage also influences the 
outcome of DDR activation, since irreparable genotoxic insult may lead to cell death, evolved 
so as to prevent the passing on to  progeny of potentially harmful genome alterations (Jackson 
and Bartek, 2009).  
There is evidence to suggest that a functioning DDR acts as barrier against tumour 
development. In 2005, two separate research groups demonstrated that replication-associated 
DNA damage can be induced by oncogene-driven cell division (Bartkova et al., 2005; 
Gorgoulis et al., 2005). They showed that the DDR was activated in early pre-cancerous lesions 
and that this activation could be mirrored in vitro by the overexpression of oncogenes. A model 
was proposed whereby hyper-replication in early lesions triggers the DDR, leading to cellular 
arrest or death as a means to nullify tumour development. This generates a selective pressure 
for suppression or breakage of the DDR during tumorigenesis, hence why inactivation of core 
DDR effectors such as p53 is commonplace in almost all cancers (Hollstein et al., 1991). 
Furthermore, the selection for DDR inactivation leads to one of the hallmarks of cancer, 
genomic instability, which accelerates cancer evolution (Hanahan and Weinberg, 2011; 
Negrini et al., 2010). 
This model of DDR activation in early lesions is applicable to PDAC progression, since the 
DNA damage marker phospho- γH2AX (Ser139) has been found to escalate according to grade 
of PanIN (histological scores of 4.34 for PanIN-1, 6.21 for PanIN-2 and 7.50 for PanIN-3) 
(Koorstra et al., 2009). Increased γH2AX and elevated DDR activation compared to normal 
tissue has also been observed in late-stage human PDAC samples (Osterman et al., 2014). This 
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suggests that PDAC tumours harbour intrinsic DNA damage, which may lead to greater 
sensitivity to extrinsic genotoxic insult, thus justifying the use of DNA damaging agents as 
chemotherapies for PDAC.  Furthermore, over a third of PDAC cases harbour a somatic 
mutation in a DDR gene (Aguirre et al., 2018; Bailey et al., 2016; Waddell et al., 2015), most 
commonly ATM, PALB2, BRCA1 and BRCA2 (the function of these will be discussed further 
below). In tumours, the inactivation of one or more genes in a particular DDR pathway often 
creates a dependency on the remaining pathways. Therapeutic targeting of these remaining 
DDR pathways, whilst simultaneously inducing DNA damage, is therefore an attractive 
treatment strategy for PDAC.  
The following section will outline some of the key members of the DDR, their significance in 
cancer and their current role as therapeutic targets.  
 
1.3.1. Ataxia Telangiectasia and Rad3-related kinase 
Activation of oncogenes such as KRAS can cause hyper-replication of DNA and consequently 
DNA damage in S-phase (Di Micco et al., 2006; Denko et al., 1994), or replication stress (RS). 
Broadly, RS refers to events in S-phase that cause slowing or stalling of the replisome 
machinery. In addition to oncogene-induced hyper-replication, RS can be induced by 
nucleotide shortages or DNA lesions that physically impede DNA polymerase (Zeman and 
Cimprich, 2014). Upon stalling of a replication fork, helicase activity continues for a period, 
which generates stretches of single-stranded DNA (ssDNA) (Byun et al., 2005; Pacek and 
Walter, 2004). This becomes coated with replication protein A (RPA), and the ssDNA-RPA 
complex acts as an initial trigger for the cellular response to RS, the core mediator of this 
response being the serine/threonine kinase, Ataxia Telangiectasia and Rad3-related (ATR).  
ATR is a 300 kDa protein belonging to the PIKK family (phosphatidyl inositol 3' kinase-related 
kinases) that acts as an upstream transducer of DDR signals in response to RS. First, the 
essential interactor, ATRIP, binds directly to RPA and in turn recruits ATR (Zou and Elledge, 
2003). Next, the DNA clamp complex Rad9-Rad1-Hus1 (9-1-1) is recruited to the stalled fork 
site, where it coordinates checkpoint activation and DNA repair (Majka et al., 2006; Parrilla-
Castellar et al., 2004). The allosteric activator of ATR, TOPBP1, binds the ATR-ATRIP 
complex and this induces ATR kinase activity (Kumagai et al., 2006; Mordes et al., 2008). 
ATR can phosphorylate hundreds of substrates (Stokes et al., 2007), most notably Chk1 kinase 
(Guo et al., 2000; Liu et al., 2000), which ATR activates to propagate a global anti-RS signal 
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throughout the nucleus. When active, Chk1 inhibits replication origin firing to limit any further 
ssDNA-exposure and thus prevent nuclear exhaustion of RPA (Toledo et al., 2013). Chk1 
induces S-phase or G2 arrest by promoting the degradation of the pro-mitotic CDC25 
phosphatases which, when active, remove inhibitory CDK phosphorylations that are driven by 
WEE1 kinase (e.g. P-CDK1-Tyr15) (Sanchez et al., 1997; Sørensen et al., 2003; Xiao et al., 
2003). This arrest allows time for attempted restart of any stalled forks and completion of DNA 
synthesis in the RS-affected regions. In addition to its activation of Chk1, ATR safeguards 
genome integrity from RS by upregulating the ribonucleotide reductase M2 subunit (RRM2) 
which increases dNTP pools (Buisson et al., 2015) and by promoting recovery or restart of 
failed forks (Mutreja et al., 2018; Trenz et al., 2006) through modulation of chromatin 
remodellers such as SMARCAL1 (Couch et al., 2013), BLM (Davies et al., 2007) and WRN 
(Pichierri et al., 2003). 
ATR/Chk1 function is not only important during periods of high RS but for every round of 
unperturbed replication, due to their critical regulation of origin firing (Petermann et al., 2006, 
2010; Shechter et al., 2004; Syljuåsen et al., 2005). Since ATR and Chk1 are essential for 
proliferating cells, complete loss of either molecule leads to embryonic lethality in mice 
(Brown and Baltimore, 2000; Takai et al., 2000). Low levels of ATR protein, a cellular feature 
of patients with Seckel Syndrome who commonly harbour hypomorphic mutations in ATR, 
leads to microcephaly, craniofacial deformities and growth retardation (Mokrani-Benhelli et 
al., 2013; O’Driscoll and Jeggo, 2003). In cancer, total loss of ATR or Chk1 has never been 
reported. Instead, there is evidence to support an ‘oncogene-addiction’ model, where hyper-
proliferative tumour cells are reliant on RS response factors such as ATR/Chk1 for survival. 
The upregulation or amplification of Chk1 has been reported in numerous cancer types 
(Derenzini et al., 2015; Krajewska et al., 2015; Sarmento et al., 2015), while in vitro 
overexpression of Chk1 increases RAS- or MYC-driven transformation (López-Contreras et 
al., 2012; Ruiz et al., 2015). Furthermore, oncogene activation increases the lethality of ATR 
or Chk1 targeting (Gilad et al., 2010; Murga et al., 2011; Schoppy et al., 2012). Therefore, 
there is good rationale for using pharmacological inhibition of ATR/Chk1 as an anticancer 
strategy.  
The first reported chemical inhibitor of ATR was caffeine, but it is not selective since it also 
inhibits other members of the PIKK family, including fellow DDR kinase ATM (discussed 
later) (Sarkaria et al., 1999). Next, schisandrin B (Nishida et al., 2009), ETP-46464 (Toledo et 
al., 2011) and NU6027 (Peasland et al., 2011) were identified as ATR inhibitors, however none 
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had the required specificity or pharmacokinetic properties to be used clinically. In 2011, Vertex 
Pharmaceuticals reported the discovery of a series of aminopyrazines that potently and 
selectively inhibited ATR (Charrier et al., 2011) and described the cellular activity of one of 
these compounds, VE-821. This molecule induced cell death in several cancer lines and 
synergised with various genotoxic agents, including cisplatin (Reaper et al., 2011). An 
analogue with improved pharmacokinetic properties, VE-822, was later reported to radio-
sensitise PDAC xenografts (Fokas et al., 2012) and this compound is currently in multiple 
clinical trials as VX-970 (or M6620, following transfer of the molecule rights to Merck in 
2017). AstraZeneca first described a new family of ATR inhibitors in 2013, which included 
AZ20 (Foote et al., 2013). Though the water solubility and liver enzyme interactions of AZ20 
made it unsuitable as clinical candidate, it was optimised to derive AZD6738 (ceralasertib) 
(Foote et al., 2018) which is now being assessed clinically in a number of trials. Additionally, 
Bayer have their own ATR inhibitor, BAY1895344, in clinical development (Wengner et al., 
2020). While some of these trials are monotherapy assessments, most are combinatorial, with 
the ATR inhibitors being combined with DNA-damaging agents, other molecularly targeted 
agents or immunotherapeutics, as recently reviewed by Bradbury and colleagues (Bradbury et 
al., 2019). Chk1 inhibition is also being explored by a number of groups, the two main clinical 
candidates being LY2606368 (Prexasertib) from Eli Lily and SRA737 (previously 
CCT245737) from Sierra Oncology (Rundle et al., 2017). 
Several groups have used unbiased screening approaches to identify genetic determinants of 
ATRi sensitivity. These screens aim to identify synthetic lethality between ATR and another 
gene or protein. In genetics, synthetic lethality is where concurrent loss of two genes causes 
death, while in oncology it more broadly refers to the situation where a tumour-specific defect 
creates a vulnerability that can be exploited to induce tumour cell death. In 2014, a siRNA 
screen using a library of 240 genes involved in DNA repair and replication identified synthetic 
lethality between ATR and ERCC1, an endonuclease that aids repair of bulky DNA adducts 
and inter-strand crosslinks (Mohni et al., 2014). The screen was performed using 1 µM VE-
821 in the osteosarcoma line, U2OS. The same group used a synthetic lethal screen to ask 
which pathways sensitise U2OS cells to the combination of ATRi and cisplatin (Mohni et al., 
2015). Loss of REV3 (POLZ), the catalytic subunit of the translesion polymerase ζ, was found 
to increase sensitivity to the combination, as did loss of 53BP1. In 2016, ARID1A was 
identified as a synthetic lethal partner of ATR. A larger siRNA library of 1,280 genes was used 
to screen the breast cancer line HCC1143 and also the non-tumour, mammary epithelial line, 
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MCF12A (Williamson et al., 2016). ARDI1A, which is commonly mutated gene in PDAC 
(Bailey et al., 2016), is a component of the SWI/SNF chromatin-remodelling complex, which 
helps modulate the repair, replication and transcription of DNA (Jeggo and Downs, 2014; 
Roberts and Orkin, 2004). Validation experiments following the siRNA screen suggested 
that ARID1A-loss caused a reduction in the recruitment of topoisomerase II to chromatin and 
also accelerated mitotic entry, perhaps explaining the ATRi-sensitising effect. Screening 
approaches can also be used to identify resistance mechanisms. Notably, in 2016 a genome-
wide CRISPR screen found that cells deficient in CDC25A were highly resistant to ATRi, since 
the ability for ATRi to induce premature mitotic entry and DNA-breakage was CDC25A-
dependent (Ruiz et al., 2016). Other genetic determinants of ATRi sensitivity that have been 
identified include APEX2, ATRIP, C16orf72, C17orf53, KIAA1524 (CIP2A), POLE3, POLE4, 
RNASEH2A, RNASEH2B, RNASEH2C (Hustedt et al., 2019), XRCC1 (Sultana et al., 2013), 
POLD1 (Hocke et al., 2016), PARP14 (Dhoonmoon et al., 2020), PRIM1 (Job et al., 2018), 
GLUT1 (Erber et al., 2019) and STAG2 (Mondal et al., 2019), as well as ATM which is 
discussed in detail in section 1.3.2. 
As inhibitors of ATR and Chk1 progress through phase I/II trials, developing a deep 
understanding of how their potential can be maximised must be a priority for preclinical and 
clinical scientists. This will require thorough interrogation of their mechanisms-of-action, 
development of reliable pharmacodynamic assays and validation of predictive biomarkers of 
response and resistance. The latter is of particular importance, since deficiency in any one DDR 
pathway may not sensitise a tumour to any and all DDR inhibitors. The application of precision 
medicine strategies, where therapies are assigned based on patient-specific tumour 
vulnerabilities, has the potential to improve outcomes for diseases such as PDAC, but a 
thorough knowledge of disease biology and the therapies in question will be essential for such 
a tailored approach to succeed. One molecule being proposed as a potential predictive 
biomarker of response for a range of DDR-related therapies is Ataxia Telangiectasia Mutated 
kinase, which is discussed in detail below. 
 
1.3.2. Ataxia Telangiectasia Mutated kinase 
Ataxia Telangiectasia Mutated (ATM) is a DDR kinase, closely related to ATR, that acts as a 
master regulator of cellular responses to DSBs (Banin et al., 1998; Canman et al., 1998). These 
are highly lethal lesions, as evidence by experiments suggesting that a single unrepaired DSB 
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can be enough to induce cell death (Bennett et al., 1993). There are many potential sources of 
DSBs, including ionising radiation (IR) or the collapse of a stalled replication fork. The 
recruitment of ATM to DSB sites is dependent on its physical interaction with NBS1 (Falck et 
al., 2005; Lee and Paull, 2005), which forms part of the MRE11–RAD50–NBS1 (MRN) 
complex. MRN creates a physical bridge that traverses DSB ends (Stracker and Petrini, 2011), 
where it plays an important role in regulating DSB repair. It has been proposed that, upon DSB 
induction, the usually inactive dimers or multimers of ATM cross-phosphorylate one another 
on serine 1981, causing a dissociation into active monomers (Bakkenist and Kastan, 2003). 
However, more recent structural studies indicate that purified dimeric ATM is enzymatically 
active and can exist in an ‘closed’ or ‘open’ state (Baretić et al., 2017). Upon activation, ATM 
phosphorylates hundreds of substrates including Chk2 which, like Chk1, induces cell cycle 
arrest (Bartek et al., 2001). Serine 15 on p53 is a target for ATM kinase, the phosphorylation 
of which increases the transcriptional activity of p53, which can lead to growth arrest or 
apoptosis (Banin et al., 1998; Kastan et al., 1992; Westphal et al., 1997). Furthermore, ATM 
phosphorylates many of the factors that have direct roles in DSB repair including CtIP (You et 
al., 2009), Artemis (Beucher et al., 2009) and all three components of the MRN complex (Di 
Virgilio et al., 2009; Gatei et al., 2011; Lim et al., 2000). Moreover, ATM mediates chromatin 
relaxation by targeting regulators of chromatin structure such as KRAB-associated protein 1 
(KAP1) (Ziv et al., 2006). Thus, ATM’s role in the response to DSBs is multi-layered, in line 
with its classification as a DSB master-regulator. There is also evidence to suggest that ATM 
is involved in cellular processes outside of the DDR, including metabolism, oxidative stress 
and hypoxia responses (Ditch and Paull, 2012). 
The two major mechanisms of DSB repair are non-homologous end-joining (NHEJ) and 
homologous recombination (HR). ATM can contribute to either process depending on cell 
cycle phase. As its name suggests, NHEJ does not require DNA sequence homology to repair 
a break and can occur at any stage of the cell cycle. Conversely, HR relies on the presence of 
a sister chromatid to be used as a homologous template and thus can only occur during late S 
or G2 phase. In the specific context of IR-induced DSBs outside of S phase, around 80% are 
repaired by NHEJ in a fast process that does not require ATM (Beucher et al., 2009). PIKK 
family member DNA-PKcs (discussed in more detail later) coordinates the end-joining process 
that results in the ligation of DSB ends, but often creates small deletions at the junctions. 
Meanwhile, 15-20% of these non-S-phase IR-induced breaks are repaired by a slower ATM-
dependent re-joining pathway that requires the MRN complex and Artemis (Beucher et al., 
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2009; Riballo et al., 2004). Thus, while ATM is not essential for the core processes of NHEJ 
which operate on directly ligatable ends, there are a subset of breaks in IR-treated G1 cells that 
are repaired with slower kinetics in an ATM-dependent manner, which may represent un-
ligatable ends such as DSBs in heterochromatic regions (Álvarez-Quilón et al., 2014; Goodarzi 
et al., 2008; Riballo et al., 2004). As for DSBs in S-phase, such as those derived from collapsed 
replication forks which may be unsuitable for end-joining, these can be repaired by HR. ATM 
stimulates one of the early events in HR which is resection, where DNA is degraded either side 
of the break (Jazayeri et al., 2006). MRE11 endonuclease initiates the process by nicking the 
5’ strand at a distance from the DSB. From here, exonuclease-I resects DNA in the 5’ to 3’ 
direction and MRE11 resects from 3’ to 5’. This resection process is promoted by BRCA1-
dependent recruitment of CtIP (Sartori et al., 2007; Yu and Chen, 2004; Yun and Hiom, 2009) 
and leaves stretches of ssDNA which becomes coated in RPA (the trigger for ATR activation, 
thus DSBs can lead to ATR signalling) (Cuadrado et al., 2006). BRCA2 then loads RAD51 
onto ssDNA, displacing the RPA (Saeki et al., 2006). The recruitment of BRCA2 to DSBs is 
promoted by BRCA1 and its partner PALB2 (Sy et al., 2009; Xia et al., 2006; Zhang et al., 
2009). Next, RAD51 mediates invasion, where a physical interaction is made between the DNA 
to be polymerised and the homologous duplex DNA template of the sister chromatid.  Finally, 
DNA is synthesised using the invading 3′-end as a primer (Krejci et al., 2012). Owing to its use 
of a DNA template, HR is a mostly error-free process, unlike NHEJ which can generate indels. 
As well as ATM’s regulation of resection in the early stages of HR, there is evidence to suggest 
that ATM is also required for later stages after RAD51-loading (Bakr et al., 2015). Thus, ATM-
deficient cells have been reported to show defective HR function (Kirshner et al., 2009; Köcher 
et al., 2012; Serrano et al., 2013).  
Many of the studies that have investigated the role of ATM in DNA repair made use of cells 
from patients with the hereditary disorder, ataxia-telangiectasia (A-T) syndrome. Homozygous 
germline mutations in ATM cause A-T, which manifests with a range of symptoms including 
immunodeficiency, neurodegeneration, cerebellar ataxia, delayed pubertal development and 
radio-sensitivity (Lavin and Shiloh, 1996; Uhrhammer et al., 1998). Furthermore, patients with 
A-T have a cancer risk that is around 61 to 184 times higher than the general population 
(Morrell et al., 1986), which is likely due to defective DNA repair and genomic instability. 
Heterozygous germline ATM mutations also increase cancer susceptibility around 2-3-fold 
(Swift et al., 1991). Specifically, germline ATM mutations have been associated with increased 
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risk of breast cancer, lung cancer, glioma and PDAC (Liu et al., 2014; Shen et al., 2012; 
Thompson et al., 2005).  
One of the first studies to describe ATM as a PDAC susceptibility gene revealed ATM germline 
mutations at a prevalence of 4.6% in families with high occurrences of PDAC (Roberts et al., 
2012). Another study investigating a panel of 32 cancer susceptibility genes in PDAC patients 
unselected for family history, found germline ATM mutations at a prevalence of 3.3% (Brand 
et al., 2018). In addition, numerous whole-genome-sequencing studies have identified somatic 
ATM mutations in PDAC samples, at a rate of around 3-5% (Bailey et al., 2016; Biankin et al., 
2012; Liu et al., 2018; Singhi et al., 2019). The authors of a recent review article on ATM-
deficiency in PDAC performed a comprehensive literature search that captured 5,234 
pancreatic cancer patients. They estimated that the total prevalence of germline or somatic 
ATM mutations in PDAC was 6.4%, though they uncovered a large range of 1%–34% 
(Armstrong et al., 2019). They noted that, with ATM being a very large gene (146,619 bases 
with 66 exons), mutations occur throughout its functional domains with no recurrent hotspot. 
Many of the ATM mutations found in cancer are missense mutations, the functional 
consequences of which are not always obvious. If an identified mutation correlates with one 
known to cause A-T syndrome, then it is likely that it is an inactivating variant (Choi et al., 
2016). Otherwise, the functional consequence would have to be evaluated, either 
experimentally or using a predictive model. Navrkalova et al. took primary chronic 
lymphocytic leukaemia (CLL) cells from patients with ATM-mutant cancer and used a 
functional test to assess ATM status, whereby p21 expression was assessed following DNA 
damage. They used doxorubicin to induce DSBs and the purine analogue fludarabine to induce 
a broader spectrum of DNA damage, assuming ATM-defective cells would show impaired p21 
induction upon treatment with doxorubicin but not fludarabine (while p53 defects should 
impair p21 induction after exposure to both drugs). All 11 ATM-mutant samples demonstrated 
ATM dysfunction (Navrkalova et al., 2013). In 2016, Weber et al. used irradiation followed by 
western blot analysis of ATM autophosphorylation and several downstream targets to assess 
the ATM activity of 7 lung cancer cell lines with missense ATM mutations. Only 2/7 lines 
(H23 and H1395) displayed a major functional impairment of ATM, while the missense 
mutations in the remaining five cell lines appeared to have no or only limited impact on overall 
ATM function in response to IR (Weber et al., 2016). Thus, the detection of an ATM missense 
mutation in a patient sample will not always inform functional ATM status. 
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In patients with PDAC that have a germline ATM mutation, loss of heterozygosity (i.e. a 
second hit in the tumour) has been reported to occur in 44% of instances (Yurgelun et al., 
2019). As well as DNA mutation analysis, ATM status can also be assessed at the protein level 
using tissue microarrays. These data-sets indicate that low ATM protein expression in PDAC 
occurs at around 12-17% (Kamphues et al., 2015; Kim et al., 2014), however, there is no 
consensus for defining ATM “low” by immunohistochemistry (IHC). ATM expression may be 
downregulated through epigenetic mechanisms such as promoter methylation, which has been 
reported in breast cancer (Vo et al., 2004), brain cancer (Mehdipour et al., 2015) and head and 
neck squamous cell carcinoma (Ai et al., 2004), but has yet to be confirmed in PDAC. 
The loss of ATM in a proportion of cancer samples supports the concept that inactivation of 
DDR factors is actively selected for during tumour progression. While ATM deficiency may 
initially arise in order to escape arrest or apoptosis during periods of oncogene-induced DNA 
damage, this loss of a key DSB regulator could expose tumours to therapeutic vulnerabilities. 
The idea that ATM deficiency may sensitise cancer cells to certain DNA-damaging therapies, 
and thus could be used clinically as a predictive biomarker of response, is an active area of 
investigation. Preclinical studies have indicated that ATM deficiency can sensitise cancer cells 
to radiation (Ayars et al., 2017), doxorubicin (Jiang et al., 2009), topoisomerase poisons and 
antimetabolites (Fedier et al., 2003). Of particular interest is ATR inhibition, since loss of ATM 
has been shown, in some cancer models, to sensitise to ATR inhibitor monotherapy (Reaper et 
al., 2011). For example, primary chronic lymphocytic leukaemia cells with ATM defects 
showed enhanced sensitivity to AZD6738 compared to wild-type or normal cells (Kwok et al., 
2016), and when ATM was knocked-down with small interfering RNA (siRNA) in the gastric 
adenocarcinoma line, SNU-484, AZD6738 IC50 was reduced ≥ 2-fold (Min et al., 2017). 
However, in contrast, when Vendetti et al. used short hairpin RNA (shRNA) to deplete ATM 
in two lung cancer cell lines, the shATM cells appeared more resistant to AZD6738 
monotherapy than control – only when AZD6738 was combined with cisplatin did shATM 
sensitise (Vendetti et al., 2015). In 2017, Ayars et al. reported that MIA PaCa-2 cells treated 
with shATM were no more sensitive to the ATR inhibitor, VE-821, than control cells (Ayars 
et al., 2017). However, work by Perkhofer et al. using mouse models of ATM-deficient PDAC 
suggested that ATM-loss did confer sensitivity to VE-822 (Perkhofer et al., 2017). With this 
lack of consistency in the literature, further investigation into the potential utility of ATM loss 
as a predictive biomarker for ATR inhibition is needed. 
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Since loss of ATM function has the promise to sensitise tumours to numerous therapies, ATM 
kinase inhibitors are currently undergoing clinical development. The selective ATM inhibitor 
AZD0156 (Barlaam and Pike, 2016; Pike et al., 2018) is being assessed in combination with 
FOLFIRINOX and poly(ADP-ribose) polymerase (reviewed in section 1.3.4) inhibition in 
advanced solid tumours (NCT02588105), while the brain-penetrant AZD1390 (Durant et al., 
2018) is being combined with radiotherapy in patients with brain cancer (NCT03423628). 
Increased normal tissue toxicity may of course be a concern when administering ATM 
inhibitors and DNA-damaging therapies, therefore it will be important to monitor the side 
effects of these compounds as they progress through the clinic. 
 
1.3.3. DNA-dependent Protein Kinase catalytic subunit 
Along with ATR and ATM, DNA-PKcs (DNA-dependent protein kinase catalytic subunit) is 
the third PIKK family member that sits at the heart of the DDR (Fig. 1.2). As a catalytic subunit, 
DNA-PKcs forms the full DNA-PK complex by interacting with Ku70 and Ku80. These Ku 
proteins recognise and bind the broken DNA ends of a DSB, and recruit DNA-PKcs to the 
break site (Blier et al., 1993). Here, DNA-PKcs phosphorylates and regulates the activity of 
NHEJ factors, including Artemis, XRCC4, XLF and DNA ligase IV, which ligates DNA ends 
during the final stages of NHEJ. Intriguingly, however, none of these individual 
phosphorylations are independently required for efficient end-joining (Neal and Meek, 2011). 
That said, complete ablation of DNA-PKcs kinase activity causes inefficient DSB repair 
(Kurimasa et al., 1999), thus DNA-PKcs is a critical factor for NHEJ. The process of NHEJ 
often introduces indels which, if occurring within an exonic coding region, can lead to 
frameshift mutations that essentially inactivate the gene. CRISPR/Cas9 gene knockout 
technology depends on the Cas9 nuclease introducing a DSB that is processed by NHEJ, 
leading to gene inactivation (Wang et al., 2013). As well as the direct role for DNA-PKcs in 
NHEJ, there is also evidence to suggest that, in certain instances, DNA-PKcs may complement 
ATM and ATR in the activation of checkpoints (Arlander et al., 2008; Li and Stern, 2005; Lin 
et al., 2014). 
While the addiction of cancers to ATR-driven signalling and the frequency of ATM-loss in 
tumours is fairly well established, the role of DNA-PKcs in cancer is less clear. Deregulated 
DNA-PKcs expression, either up or down, plus genetic mutations in its gene, PRKDC, have 
all been observed in a range of cancers, suggesting that the role of DNA-PKcs in tumorigenesis 
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may depend on the tissue type or cellular context (Evert et al., 2013; Herrero et al., 2015; Hosoi 
et al., 2004; Lee et al., 2005; Tonotsuka et al., 2006). What remains clear is that, as with ATM 
inhibition, targeting DNA-PKcs can sensitise preclinical models of cancer to DSB-inducing 
therapies. Early-generation DNA-PKcs inhibitors, NU7427 and NU7441, sensitised colorectal 
carcinoma cells to IR and etoposide (Zhao et al., 2006), breast cancer cells to IR and 
doxorubicin (Ciszewski et al., 2014), non-small cell lung carcinoma cells to irinotecan (Yanai 
et al., 2017) and B-cell chronic lymphocytic leukaemia cells to the doxorubicin analogue, 
mitoxantrone (Elliott et al., 2011). While useful tool compounds, the selectivity of these 
inhibitors for DNA-PKcs over other PIKK family members was not convincing enough for 
their clinical development. In 2019, AstraZeneca described the discovery of a highly potent 
and selective DNA-PKcs inhibitor, AZD7648 (Goldberg et al., 2019). They demonstrated that 
AZD7648 sensitised multiple in vivo cancer models to IR, doxorubicin and poly(ADP-ribose) 
polymerase inhibition (Fok et al., 2019). Consequently, a clinical trial has commenced to assess 
AZD7648 alone and in combination with other anti-cancer agents in patients with advanced 
cancers (NCT03907969). Additionally, the Celgene Corporation’s dual DNA-PKcs/mTOR 
inhibitor, CC-115 (Dylgjeri et al., 2019; Tsuji et al., 2017), and Merck’s DNA-PKcs inhibitor, 
M3814 (Damstrup et al., 2016; Sun et al., 2019; Wise et al., 2019), are in multiple clinical 
trials. As well as combining M3814 with DSB-inducing therapy, Merck are also exploring the 
possibility of using DNA-PKcs inhibition as a means to limit NHEJ and promote HR following 






Fig. 1.2. ATM, ATR and DNA-PK: the trinity at the heart of the DNA damage response. The left-hand DNA structure 
represents a stalled replication fork, induced by sources of replication stress such as oncogene activation, dNTP shortages or 
DNA-lesions. If ATR fails to resolve a stalled fork (e.g. due to ATR inhibition by AZD6738), the structure may collapse, 
leading to the induction of a double-strand break (DSB) which is depicted on the right side of the image. DSBs activate ATM 
and DNA-PK. 
 
1.3.4. Poly(ADP-Ribose) Polymerase 
Inhibitors of ATM, ATR and DNA-PKcs are all at relatively early stages of clinical 
development, in that no regulatory approvals have yet been granted for these compounds. 
Conversely, the DDR factors that are leading the way as therapeutic targets, with regulatory 
approvals in multiple indications already granted, are poly(ADP-ribose) polymerases (PARPs). 
There are 17 PARP family members, the founding member being PARP1 (Gibson and Kraus, 
2012). As the name suggests, PARPs are not kinases but polymerase enzymes that catalyse the 
poly(ADP)-ribosylation (PARylation) of target proteins, using oxidised nicotinamide adenine 
dinucleotide (NAD+) as a substrate. The DNA-dependent PARPs, PARP1, PARP2 and PARP3 
are activated by DNA lesions, including single-strand breaks (SSBs) (Satoh and Lindahl, 
1992). As a DNA damage sensor, PARP1 binds to a SSB and in turn PARylates itself and 
regions around the break site, leading to the recruitment of PAR-binding, SSB-repair proteins 
(Fisher et al., 2007; Satoh and Lindahl, 1992) such as XRCC1 (El-Khamisy et al., 2003). 
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Though PARP1 has been commonly referred to as a base excision repair (BER) protein, this 
view has been challenged in recent years. The BER process involves the making of a SSB 
incision, which in turn acts as a substrate for SSB repair (SSBR) involving PARP1; thus, while 
PARP1 may be recruited to sites of BER, it is not required for base excision directly (Helleday, 
2011; Ström et al., 2011). The central role for PARP1 in SSBR means that PARP1-null mice 
are hypersensitive to DNA-damaging chemotherapies and to IR (de Murcia et al., 1997).  
In several cancer types, including breast, colorectal, testicular and malignant melanoma, 
overexpression of PARP-1 has been observed and is associated with invasiveness and poor 
clinical prognosis (Mego et al., 2013; Nosho et al., 2006; Rojo et al., 2012; Staibano et al., 
2005). PARP mutations are rare in cancer, but may emerge in response to treatment, since some 
can cause resistance to PARP inhibitor therapy (Pettitt et al., 2018). The first PARP inhibitors 
developed were analogues of nicotinamide (a by-product of NAD+ metabolism by PARP, that 
has weak inhibitory action) (Purnell and Whish, 1980), and in 1980 these early compounds 
were shown to abrogate DNA repair and improve the cytotoxicity of DNA methylating agents 
(Durkacz et al., 1980). Later, more potent second-generation inhibitors, PD128763 and 
NU1025, were developed (Griffin et al., 1995; Suto et al., 1991). These were able to sensitise 
cells to methylating agents, topoisomerase I poisons and IR (Bowman et al., 2001). In the early 
2000s, several third-generation PARP inhibitors with further enhanced potency were 
developed and characterised, including olaparib, rucaparib, veliparib, niraparib and talazoparib 
many of which entered clinical development (Malyuchenko et al., 2015).  
The first PARP inhibitor to be approved by the FDA and EMA was olaparib (AZD2281, 
LynparzaTM), which inhibits PARP1 and PARP2. Initial approval was for the maintenance 
treatment of patients with platinum-sensitive relapsed BRCA-mutated (germline and/or 
somatic) ovarian cancer (Ledermann et al., 2014). The specific selection of a BRCA-mutant 
population had stemmed from seminal preclinical studies showing that tumours deficient in 
BRCA1 or BRCA2 were hypersensitive to PARP inhibition (Bryant et al., 2005; Farmer et al., 
2005).  This synthetic lethality between PARP and BRCA1/2 has been reproduced in multiple 
model systems and cancer types since the seminal studies in 2005 (Grignani et al., 2020). The 
precise mechanisms underlying the mode of action of PARP inhibitors and their toxicity in 
BRCA-deficient cancers have been under frequent debate. Studies suggest that the cytotoxicity 
caused by PARP inhibition is in part caused by PARP1 being “trapped” on DNA, and this may 
be more relevant than the abrogation of SSBR function (Murai et al., 2012). Importantly, 
different PARP inhibitors have varying PARP-trapping abilities (talazoparib >> niraparib ≈ 
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olaparib ≈ rucaparib >> veliparib) which corresponds to their cytotoxic potency (Murai and 
Pommier, 2015). Trapped PARP1 poses an obstacle to the replication machinery during S-
phase. Bypass of this obstacle, or the repair of the ensuing DSB that may arise upon collision 
and fork collapse, requires HR, a process dependent on BRCA1 and BRCA2. Thus, BRCA-
deficient cells are unable to effectively repair these PARP inhibitor-induced DNA lesions, 
leading to cell death (Dréan et al., 2016; Helleday, 2011). 
So far, most clinical approvals for PARP inhibitors have been for monotherapy use in BRCA-
deficient tumours, following clinical trials that have demonstrated impressive survival rates in 
ovarian (Moore et al., 2018), breast (Robson et al., 2017) and pancreatic cancer (Golan et al., 
2019). However, combining PARP inhibition with other therapeutic agents also has 
considerable promise. In the case of olaparib, at the time of writing (Spring 2020) there are 260 
studies listed on ClincalTrials.gov that involve olaparib; 43 are monotherapy studies, while the 
rest are assessments of combinations. For example, olaparib is being combined with cisplatin, 
irinotecan, temozolomide, paclitaxel and radiotherapy, as well as with targeted agents such as 
inhibitors of PI3K, AKT, mTORC1/2 , WEE1, Chk1 and ATR (Dréan et al., 2016).  
The aforementioned significance of PARP trapping (Murai et al., 2012) and its ensuing effects 
on DNA replication have made olaparib and ATR inhibition a particularly attractive therapeutic 
option. The physical obstacles to the replisome that trapped PARP creates may lead to the 
stalling of replication forks, which would require ATR activity to be resolved. In 2012, Huehls 
et al. reported that siRNA depletion of ATR sensitised the BRCA1-methylated cell line 
OVCAR-8 to the PARP inhibitor veliparib (ABT-888), whereas depletion of ATM, Chk1, and 
Ku80 did not sensitise (Huehls et al., 2012). The same research group subsequently showed 
that the ATR inhibitor, VE-821, sensitised ovarian cancer cells to veliparib, independent of 
BRCA status (Huntoon et al., 2013). The lab of Yves Pommier later demonstrated that ATR 
inhibition can overcome a specific resistance mechanism to PARP inhibitors, the inactivation 
of the helicase SLFN11. They took four cancer cell lines with high SLFN11 (prostate DU145, 
leukaemia CCRF-CEM and MOLT4, and Ewing’s sarcoma EW8) and found that VE-821 
enhanced the efficacy of olaparib and talazoparib in all 4 lines, even after PARP inhibitor 
resistance had been induced through the CRISPR/Cas9 deletion of SLFN11 (Murai et al., 
2016). Furthermore, Lee Zou and colleagues cultured the BRCA1-mutant ovarian cell line, 
UWB1.289, in 1.0 µM olaparib for 45 days to derive lines resistant to PARP inhibition, and 
found that VE-821 broadly overcame the resistance (Yazinski et al., 2017). As for HR-
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proficient PDAC models, before this PhD project commenced, published data on the efficacy 
of combined ATR and PARP inhibition in this setting was lacking.   
 
1.4. Project aims 
In this introductory chapter, I have described how targeting the DDR is being pursued as a 
therapeutic strategy in the oncology field. In particular, there is good rationale for using this 
approach in pancreatic cancer, since over a third of PDAC cases harbour a mutation in a DDR 
gene (ATM, PALB2, BRCA1 and BRCA2). Furthermore, many common genetic alterations 
in PDAC (KRAS, CDKN2A, TP53) augment replication-associated DNA damage, which 
increases reliance on the RS-response factor, ATR. Pharmacological inhibition of ATR is likely 
to be most effective when used in combination with other agents, thus identifying the most 
synergistic combinations and understanding how their efficacy could be optimised needs to be 
explored. 
In this thesis, I report on investigations into the therapeutic potential of combining the ATR 
inhibitor, AZD6738, with DNA-damaging drugs and DDR-targeted agents in preclinical 
models of PDAC. My first aim was to compare a panel of such agents in terms of their ability 
to synergise with AZD6738 in human and mouse PDAC cell lines. These data are presented in 
Chapter 3, a short introductory results chapter where I complete an existing dataset and then 
comment on the varying degrees of synergy. AZD6738 and gemcitabine was one of the most 
synergistic combinations. This led to the primary focus of my PhD, which concerned the 
determinants of sensitivity to ATR inhibition and gemcitabine (ATRi/gem) treatment. I 
hypothesised that ATRi/gem would most likely benefit specific sub-groups of patients with 
pre-existing aberrations in DDR pathways (i.e. a precision medicine approach to patient 
selection). Accordingly, I aimed to investigate the potential for deficiency in the DSB master-
regulator, ATM, to sensitise PDAC models to ATRi/gem. These data, evaluating ATM as a 
potential predictive biomarker of response for the novel combination, are presented in Chapter 
4, along with an assessment of the tractability of dual ATM and ATR inhibition as a therapy 
option. Finally, I also aimed to investigate the combination of AZD6738 and the PARP 







CHAPTER TWO: Materials and methods 
2.1. Cell culture and chemicals 
All human cell lines were purchased from ATCC. MIA PaCa-2, PANC-1 and HPAF-II were 
cultured in Dulbecco's Modified Eagles Medium (ThermoFisher #41966029) plus 10% FBS 
(ThermoFisher #10270106). AsPC-1 were cultured in RPMI-1640 Medium (ThermoFisher 
#21875034) plus 10% FBS. The genetic status of ATM and ATR in these human lines is shown 
below (Fig. 2.1) as well as other genes known to contribute to ATRi sensitivity (as described 
in section 1.3.1) The murine cell lines K8484 and DT8082 were previously established from 
KPC mice of the mixed 129/SvJae/C57Bl/6 background (Olive et al., 2009) and were grown 
in DMEM with 5% FBS. All cell lines were subjected to regular STR fingerprinting and 
mycoplasma tests, performed by the CRUK-CI Biorepository Core Facility.  
AZD6738, AZD0156, AZD7648, AZD1775 and AZD2281 (olaparib) were kindly provided by 
AstraZeneca. These agents, plus gemcitabine hydrochloride (Tocris #3259), 5-fluorouracil 
(Sigma #F6627), oxaliplatin (Sigma #O9512), SN38 (7-Ethyl-10-hydroxycamptothecin, 
Sigma #H0165) and MK8776 (Selleckchem #S2735) were dissolved in DMSO, kept at -20°C, 
and used within 3 months. Final DMSO concentrations (0.2%) were kept constant in all 
experiments. 
 
Fig. 2.1. mRNA expression of ATR and genes known to contribute to ATRi sensitivity in four PDAC human cell lines. 
Mutation data is also overlaid on the plot (a rectangle without text indicates that the gene is not mutated in this cell line). Data 
source is the Cancer Cell Line Encyclopaedia, accessed via cBioPortal. RPKM = Reads Per Kilobase Million. 
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2.2. siRNA transfection 
ON-TARGETplus-SMARTpool siRNAs targeting ATM were purchased from Dharmacon 
(#L-003201-00-0005), as well as a Non-Targeting-Control-Pool (#D-001810-10-05). Reverse 
transfection was achieved using Lipofectamine RNAiMax reagent (Invitrogen#13778/150), as 
per manufacturer’s instructions. Briefly, lipofectamine-siRNA mixture was incubated in a 
100mm dish, before cells were seeded on top (final siRNA concentration = 25nM). 48-hours 
later, cells were split and seeded for drug sensitivity assays or immunoblotting. 
 
2.3. CRISPR/Cas9 gene editing 
For generation of ATM knockout MIA PaCa-2 cells, a previously validated all-in-one guide-
RNA-Cas9-GFP plasmid (pAiO-WT-ATM), the human ATM-specific guide-RNA sequence, 
GTTGGTTACATACTTGGACT, cloned into the BbsI site, was kindly provided by Professor 
Stephen Jackson of the Wellcome Trust/CRUK Gurdon Institute, University of Cambridge, 
UK (Balmus et al., 2019). Transfection of the plasmid into MIA PaCa-2 cells was achieved 
using Lipofectamine 3000 Reagent (Invitrogen, #L3000015) as per the manufacturer’s 
instructions for forward transfections in 6-well plate format. 48 hours post-transfection, cells 
were split and single-cell sorted (BD FACS Aria), specifically for the top 3% of GFP-positive 
cells, to enrich for cells that had been positively transfected. Single cell clones were left to 
grow in 96 well plates, before being split into 24 well plates. At the point where clones were 
being split and transferred to 6 well plates, half of each sample was taken for genomic DNA 
extraction (QIAamp DNA Micro Kit #56304). From genomic DNA, the region around the 
sgATM-Cas9 target site was amplified by PCR and sent for Sanger nucleotide sequencing 
(Eurofins LightRun). Sequencing chromatograms were deconvoluted using the Synthego ICE 
web tool (ice.synthego.com). Absence of ATM protein was confirmed by immunoblotting. 
 
2.4. Immunoblotting 
Following media removal and a PBS wash, cell lysis was performed on 60mm dishes using 
50Mm Tris HCl plus 2% SDS, with phosphatase and protease inhibitors (Roche#04906837001, 
Roche#04693159001). Cells were scraped and boiled at 95 °C for 5 minutes, before 
NanoDrop™ 8000 (A280) protein quantification. Proteins were resolved using the SDS-PAGE 
gel system (Life Technologies), detected using IRDye secondary antibodies (LI-COR) and 
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visualised on the Odyssey CLx imaging system (LI-COR). Primary antibodies used were 
obtained from Abcam (ab) or Cell Signaling Technology (CST), unless otherwise stated: ATM 
(ab78), P-ATM-Ser1981 (ab81292), DNA-PKcs (ab44815), P-DNA-PKcs-Ser2056 
(ab18192), KAP1 (ab22553), P-KAP1-Ser82 (ab133440), P-CDK1-Tyr15 (ab76146), RPA32 
(ab2175), RAD50 (ab89), P-Chk2-Thr68 (ab3501), Chk2 (CST3440), P-Rad50-Ser635 
(CST14223S), Chk1 (CST2360), P-Chk1-Ser345 (CST2348), H2AX (CST7631), P-HH3-
Ser10 (CST3377), HH3 (CST9715), cleaved-PARP-Asp214 (CST9544), β-Actin (CST4970), 
β-Tubulin (CST2146), Lamin B1 (CST12586), Vinculin (CST13901), GAPDH (CST5174), 
ATR (Santa Cruz Biotechnology#SC-1887), P-ATR-Thr1989 (Genetex#GTX128145), 
ƴH2AX-Ser139 (Millipore#05-636), P-RPA32-Ser4/8 (Bethyl#A300-245A). 
 
2.5. Fractionation 
Fractionation, to derive cytoplasmic and nuclear fractions, was performed as described by 
Warren and Eastman in 2019 (Warren and Eastman, 2019). 
 
2.6. SRB assay 
Cells were seeded in Corning black flat-bottom 96-well plates, 24 hours before drug treatment. 
For single-agent and combinatorial drug sensitivity assays, cells were treated for 72 hours 
unless otherwise stated. Following the allotted drug treatment, medium was aspirated and the 
cells washed once with phosphate-buffered saline (PBS), before the addition of 100 µL of 3% 
trichloroacetic acid (TCA) to each well. After incubation at 4°C for 1 hour, the TCA was 
removed and each well was washed once with 100 µL of cold water. 50 µL of 0.057% 
Sulforhodamine B (SRB) solution (Sigma-Aldrich, #230162) in 1% acetic acid was added to 
each well to allow staining at room temperature for 30 minutes. Plates were rinsed four times 
with 1% acetic acid using an automated plate washer (Biotek Elx405 Select CW). After drying, 
200 µL of 10 mM Tris base solution (pH 10.5) was added to each well and the solubilisation 
of protein-bound dye was achieved by placing plates on a gyratory shaker for 5 minutes. The 
SRB signal was measured at excitation and emission wavelengths of 488 nm and 585 nm 
respectively, using a PHERAstar FS plate reader (BMG Labtech). The fluorometric signal 
values were used as surrogates for cell number. For combination studies, synergy was assessed 
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using Combenefit software (Di Veroli et al., 2016). Combenefit uses Bliss and Loewe 
additivity models, which use the following definitions: 
 
Synergy distribution 
With the hypothetical combination of two agents A and B at concentrations a and b 
respectively, the effectiveness of a drug combination can be assessed in terms of the amount 
of "extra-effect" that is obtained when combining the drugs. Thus, effects can be described as 
following: 
𝐸(𝑎, 𝑏) = 𝑅(𝑎, 𝑏) + 𝑆(𝑎, 𝑏) 
or 
𝑆(𝑎, 𝑏) = 𝐸(𝑎, 𝑏) − 𝑅(𝑎, 𝑏) 
E(a,b) is the observed effect, i.e. what is actually measured during the experiment.  
R(a,b) is the reference effect (model prediction), i.e. a baseline which should be obtained in 
an experiment when the combination does not amplify or reduce cell kill.  
S(a,b) is the amount of extra-effect, also termed synergistic effect (when this extra-effect is 
negative, it is termed antagonistic).  
 
In order to identify synergy or antagonism, the combined reference effect R(a,b) is first 
derived based on single agent dose-response curves. Reference surfaces depend on the 
mathematical model which is used to define non-synergistic effects. 
 
Bliss model 
For the Bliss model, the reference effect for the combination (a,b) is obtained by taking the 
product of the effects at these concentrations: 
          𝑅𝐴𝐵_𝐵𝑙𝑖𝑠𝑠(𝑎, 𝑏) = 𝐸𝐴(𝑎) · 𝐸𝐵(𝑏) 
Loewe model 
For the Loewe model, the reference effect for the combination (a,b) is calculated by finding 
two doses aU and bU such that: 
𝐸𝐴(𝑎𝑢) = 𝐸𝐵(𝑏𝑢) 







These two equations are solved numerically for (au,bu). The numerical solution is used to 
define the reference effect as: 
𝑅𝐴𝐵_𝐿𝑜𝑒𝑤𝑒(𝑎, 𝑏) = 𝐸(𝑎𝑢) = 𝐸𝐵(𝑏𝑢) 
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2.7. Clonogenic assay 
5 hours prior to treatment, cells were plated at 300 cells/well in 6-well plates. Following 24 
hours of drug treatment, the medium was replaced and the cells left to grow for 7 more days 
after the washout. Cells were then fixed and stained with SRB (as above but with TCA and 
SRB volumes increased 10-fold). Colonies were imaged and quantified using the GelCount 
(Oxford Optronix). Plating efficiency was calculated as the ratio of the number of colonies in 
the control well to the number of cells seeded. The number of colonies that arose after treatment 
was expressed as surviving fraction (SF). SF was calculated as the ratio of the number of 
colonies formed after treatment to the number of cells seeded, multiplied by plating efficiency 
of the control. 
 
2.8. IncuCyte time lapse imaging 
96 well plates were placed in the IncuCyte® ZOOM System (Essen Bioscience) with 10X 
objective, which captured images of cells every 3 hours. Average cell confluence was 
calculated from 3 fields of view per well using the IncuCyte in-built algorithm. Cell death was 
measured by adding YOYO™-3 Iodide (Invitrogen #Y3606) to each well at 100 nM final 
concentration.  
 
2.9. Flow cytometry 
Cells were plated in a Corning 60mm dishes 24 hours prior to drug treatment. At the designated 
timepoint the cell culture media was collected, the plates washed with PBS, cells trypsinised 
and then combined with the collected media and the wash. Samples were centrifuged, the 
resulting cell pellets washed with PBS, then cells were fixed with 1 mL ice-cold 70% ethanol 
overnight at -20°C. For DNA content analysis, fixed cells were centrifuged, washed once with 
PBS, then resuspended in 0.5 mL of blocking solution (PBS, 2% BSA, 0.1% Tween-20, 0.1% 
Triton X100) for 1 hour to increase membrane permeability. Finally, cells were treated with 
0.5mL FxCycle Violet Stain (Invitrogen #F10347), prepared in blocking solution at 1:1000 
dilution, and transferred to FACS tubes. Samples were run on the BD Biosciences 




2.10. Quantitative image-based cytometry  
Cells were seeded in Corning black flat-bottom 96-well plates 24 hours before drug treatment. 
At the designated timepoint, cells were fixed with 4% paraformaldehyde for 10 minutes, then 
washed twice with PBS. Permeabilisation was achieved by incubating with 0.1% Triton X-100, 
0.1% Tween-20, 1xPBS (PBSTT) for 10 minutes at room temperature. Cells were blocked for 
30 minutes with blocking solution, PBSTT + 2% Bovine Serum Albumin (Roche 
#10735094001). Primary antibody in blocking solution was added for 1 hour at room 
temperature (mouse anti-ƴH2AX S139, Millipore #05-636, 1:2000 and rabbit anti-phospho-
RPA32 S4/8, Bethyl #A300-245A, 1:1000), then wells were washed with PBSTT three times. 
Secondary antibody (Alexa Fluor 488 goat anti-rabbit, Invitrogen #A11034, 1:500 and Alexa 
Fluor 568 goat anti-mouse, Invitrogen #A11019, 1:500) plus Hoechst 33342 (Invitrogen 
#H3570, 1:10,000) in blocking solution was added for 1 hour at room temperature. Plates were 
washed once with PBSTT and a further two times with PBS. Images were acquired using the 
Operetta CLS High-Content Analysis System and analysis performed using Harmony 4.5 
software. The resulting CSV files from these analyses were loaded into RStudioTM for 
reshaping of the tabular data, then exported as FlowJo-compatible CSV files which were 
imported into FlowJo® V10 software to generate pseudo-colour plots. 
 
2.11. Animal experiments 
All mouse experiments were carried out in the CRUK Cambridge Institute BRU, in accordance 
with the UK Animals (Scientific Procedures) Act 1986, with approval from the CRUK 
Cambridge Institute Animal Ethical Review and Welfare Body. Subcutaneous xenografts of 
MIA PaCa-2 cells were formed by implanting 5x106 cells (in 0.2 ml 1:1 matrigel: PBS) in the 
right flank of 7-9-week old female NSG or BALB/c Nude mice (Charles River). Mice with 
established tumours were randomised into treatment groups. AZD6738 (AstraZeneca) was 
dissolved to 5 mg/mL or 10 mg/ml in 10% DMSO, 40% Propylene Glycol, 50% de-ionised 
sterile water and dosed at 5 ml/kg by oral gavage to give 25 mg/kg or 50 mg/kg. Gemcitabine 
(LKT Laboratories, from Cambridge Bioscience) was dissolved in a saline solution (Vetivex) 
to 10 mg/mL and given to mice at 50 mg/kg intraperitoneally. Olaparib (AstraZeneca) was 
prepared to 5mg/mL or 10 mg/mL in 10% v/v DMSO / 50% v/v of 60% w/v HP-B-CD 
(Kleptose) in purified water and dosed at 10 ml/kg by oral gavage to give 50 mg/kg or 100 
mg/kg. AZD0156 (AstraZeneca) was formulated at 1 mg/ml in 10% DMSO, 30% Captisol 
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(Astra Zeneca), and dosed orally at 10 ml/kg to give 10 mg/kg. AZD1390 (AstraZeneca) was 
formulated by preparing a stock suspension at 5 mg/ml in vehicle (0.5% HPMC/ 0.1% Tween 
80), then diluted to working formulation of 0.5 mg/ml or 1 mg/ml with the same vehicle. These 
were dosed orally at 10 ml/kg to give 5 mg/kg or 10 mg/kg. Xenografts were measured twice 
a week using callipers. 
 
2.12. Immunohistochemistry 
Formalin-fixed, paraffin-embedded sections were immuno-stained after heat-induced epitope 
retrieval by sodium citrate at 100°C for 10-20 minutes, using Bond Polymer Refine Detection 
kit on the automated Bond system according to manufacturer’s instructions (Leica). Slides were 
mounted using Leica CV5030 Coverslipper Workstation and scanned using a ScanScopeXT 
(Aperio Technologies). Quantification was performed using the Halo software (Indica Labs). 
Primary antibody used on human xenograft tissue – phospho-Histone H2A.X (Ser139) Rabbit, 
Cell Signaling Technology, #9718. Primary antibody used on mouse tissue (guts) – anti-gamma 
H2A.X (phospho S139) Rabbit, Abcam, #ab195190. 
 
2.13. Ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-
MS/MS)  
For plasma bioanalysis, each plasma sample (25 µL) was prepared using an appropriate dilution 
factor, and compared against an 11-point standard calibration curve (1-10000 nM) prepared in 
DMSO and spiked into blank plasma. Acetonitrile (100 µL) was added with the internal 
standard, followed by centrifugation at 3000 rpm for 10 minutes. Supernatant (50 µL) was then 
diluted in 300 µL water and analysed via UPLC-MS/MS.  
For tumour bioanalysis, tumour was weighed into fast preparation tubes containing Lysing 
Matrix A (MP Biomedicals UK). Water was added as a base for homogenisation (2 times w/v). 
Homogenisation was carried out in FastPrep-24 5G (MP Biomedicals USA) at 6m/s for 30 
seconds, twice. Each tumour homogenate sample (25 µL) was compared against an 11-point 
standard calibration curve (1-10000 nM) prepared in DMSO and spiked into blank tumour 
homogenate. Acetonitrile (100 µL) was added with the internal standard, followed by 
centrifugation at 3000 rpm for 10 minutes. Supernatant (50 µL) was then diluted in 300 µL 
water and analysed via UPLC-MS/MS. Analysis was performed by Aaron Smith, AstraZeneca. 
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2.14. PAR ELISA 
PARylation was analysed using the HT PARP in vivo Pharmacodynamic Assay II ELISA 2nd 
generation ELISA Kit (Trevigen #4520-096-K) as per the manufactures’ instructions, and as 








CHAPTER THREE: Comparison of anti-cancer agents that synergise with the ATR 
inhibitor, AZD6738, in PDAC cell lines 
3.1. Background  
Before this project began, the Jodrell lab had begun to test combinations of the ATR inhibitor, 
AZD6738, with a range of cytotoxic drugs and DDR-targeted agents in a panel of PDAC cell 
lines (Dr Yann Wallez). The aim was to identify synergistic combinations that could then be 
taken forward for more in-depth mechanistic and in vivo studies. The DNA-damaging agents 
assessed were gemcitabine and three components of the combinatorial regimen FOLFIRINOX; 
5-FU, oxaliplatin and SN38 (the active metabolite of topoisomerase I inhibitor, irinotecan). 
The DDR-targeted agents assessed were AZD1775 (WEE1i), MK8776 (Chk1i) and olaparib 
(PARPi). Up to this point, all of these compounds had demonstrated synergism with AZD6738, 
but most had only been tested in KPC mouse cell lines, as a prelude to studies in the KPC in 
vivo models, but not in any human lines. To complete this dataset (Table 3.1), and to allow the 
synergy to be compared and ranked, I aimed to assess the remaining combinations in human 
MIA PaCa-2 and PANC-1 cells. 
 
Table 3.1. Table of combinations to be assessed in PDAC cell lines. Those that had been tested before my arrival, by Dr Yann 
Wallez, are marked in green with a tick. Those assessed by me and presented in this chapter are blank. KPCB denotes a BRCA-
mutant mouse cell line. 
 
3.2 Synergy evaluation of AZD6738-based combinations in human PDAC cell lines 
I first performed growth inhibition assays, with TCA-fixation and SRB staining after 72 hours 
of drug incubation, combining AZD6738 with the individual FOLFIRINOX components 5-
FU, oxaliplatin and SN38 (Figs. 3.1-3.3). I used Combenefit software (Di Veroli et al., 2016) 
to quantify the drug interactions. Combenefit takes the observed growth inhibition data and 
compares them to a model prediction which assumes no interaction between the two agents.  
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Two widely used models are Bliss independence and Loewe additivity. As described by Yadav 
et al. - the Bliss independence model utilises probabilistic theory to model the effects of 
individual drugs in a combination as independent yet competing events, while the Loewe 
additivity model defines the expected effect as if a drug was combined with itself (Yadav et al., 
2015) (see Methods section 2.6. for full Bliss and Loewe equations). A combination is 
classified as synergistic when the actual drug response observed is greater than the model 
prediction, while antagonism is when a lesser effect than expected is observed. There is no 
consensus on whether Bliss independence or Loewe additivity is a more robust model, given 
their differing assumptions, thus I have displayed both throughout this chapter. Many groups 
use the combination-index isobologram method for combination assays, which is based on the 
median effect principle (Chou, 2010). This permits only the analysis of fixed dose ratios of the 
two agents in question. The key feature of Combenefit software is its flexibility in determining 
the expected interaction for any combination of agent concentrations, as well as its scalability 
(numerous experiments all analysed at once). 
 
While synergy between 5-FU and AZD6738 had previously been observed in KPC mouse cell 
lines, I observed no synergy with this combination in the human MIA PaCa-2 and PANC-1 
(Fig. 3.1). Oxaliplatin displayed modest synergy with AZD6738 in the human lines, but at low 
AZD6738 concentrations (100 - 300 nM) I observed an antagonistic interaction with oxaliplatin 
in PANC-1 (Fig. 3.2). Of the three genotoxic agents tested, the topoisomerase I (TOP1) 
inhibitor, SN38, demonstrated the most convincing synergy with AZD6738 in MIA PaCa-2 
(Bliss maximum synergy score = 37; Loewe maximum synergy score = 38) and PANC-1 (Bliss 








Fig. 3.1. MIA PaCa-2 and PANC-1 were treated with increasing concentrations of AZD6738 and 5-FU for 72 hours. Cell 
number at endpoint was determined by measuring total protein content using the SRB assay. Left = growth as % of solvent 
control. Data, mean ± SD, n=3. Middle = Bliss and Loewe model prediction. Right = Combenefit synergy score. Data, mean 








Fig. 3.2. MIA PaCa-2 and PANC-1 were treated with increasing concentrations of AZD6738 and oxaliplatin for 72 hours. Cell 
number at endpoint was determined by measuring total protein content using the SRB assay. Left = growth as % of solvent 
control. Data, mean ± SD, n=3. Middle = Bliss and Loewe model prediction. Right = Combenefit synergy score. Data, mean 







Fig. 3.3. MIA PaCa-2 and PANC-1 were treated with increasing concentrations of AZD6738 and SN38 (the active metabolite 
of TOP1 inhibitor, irinotecan) for 72 hours. Cell number at endpoint was determined by measuring total protein content using 
the SRB assay. Left = growth as % of solvent control. Data, mean ± SD, n=3. Middle = Bliss and Loewe model prediction. 
Right = Combenefit synergy score. Data, mean ± SD, n=3. The greater the difference between the experimental values and the 





The DDR-targeted agents assessed in MIA PaCa-2 and PANC-1 were the WEE1 inhibitor, 
AZD1775, and the Chk1 inhibitor, MK8776. WEE1 inhibition demonstrated high synergy 
scores with AZD6738 in MIA PaCa-2 (Bliss maximum synergy score = 34; Loewe maximum 
synergy score –=31) and PANC-1 (Bliss maximum synergy score = 26; Loewe maximum 
synergy score = 27) (Fig. 3.4), but inhibition of Chk1 was mostly antagonistic in both cell lines 
(Fig. 3.5).  
 
3.3 Comparison of all cytotoxic and DDR-targeted drugs tested across human and mouse 
cell lines 
Completing these combinatorial assays enabled me to a perform broad comparison of the 
agents in question, in terms of their ability to synergise with AZD6738 in human and mouse 
PDAC cell lines. Using the Batch Analysis program of Combenefit, which quantifies the sum 
of synergy and antagonism for a given combination, I was able to rank the DNA-damaging 
agents and DDR-targeted agents respectively (Fig. 3.6).  Of the chemotherapies tested, 
gemcitabine and oxaliplatin had the highest average synergy scores across the 7 cell lines. 
Meanwhile, AZD1775 and olaparib were the two targeted therapies with strongly positive 
synergy scores, unlike MK8776 (Chk1 inhibitor) which exhibited antagonism with AZD6738 





Fig. 3.4. MIA PaCa-2 and PANC-1 were treated with increasing concentrations of AZD6738 and AZD1775 (WEE1 kinase 
inhibitor) for 72 hours. Cell number at endpoint was determined by measuring total protein content using the SRB assay. Left 
= growth as % of solvent control. Data, mean ± SD, n=3. Middle = Bliss and Loewe model prediction. Right = Combenefit 
synergy score. Data, mean ± SD, n=3. The greater the difference between the experimental values and the model prediction, 






Fig. 3.5. MIA PaCa-2 and PANC-1 were treated with increasing concentrations of AZD6738 and MK8776 (Chk1 inhibitor) 
for 72 hours. Cell number at endpoint was determined by measuring total protein content using the SRB assay. Left = growth 
as % of solvent control. Data, mean ± SD, n=3. Middle = Bliss and Loewe model prediction. Right = Combenefit synergy 
score. Data, mean ± SD, n=3. The greater the difference between the experimental values and the model prediction, the greater 







Fig. 3.6. Sum of synergy and antagonism scores across all 7 cell lines and all 7 combinations tested, calculated using the Batch 
Analysis program of Combenefit software. Red bars denote a negative sum score (antagonism), blue bars denote a positive 







In this introductory results chapter, I have presented Combenefit synergy data, assessing the 
interactions of AZD6738 with DNA-damaging agents and DDR-targeted agents. My first 
finding was that 5-FU demonstrated no synergy with AZD6738 in MIA PaCa-2 and PANC-1, 
despite having synergised in KPC mouse cell lines. Like gemcitabine (dFdC), 5-FU is an 
antimetabolite, however its mechanism of action is different to dFdC. There are 3 active 
metabolites of 5-FU, these are (1) fluorodeoxyuridine monophosphate (FdUMP), which 
inhibits the de novo synthesis of deoxythymidine monophosphate (dTMP) by thymidylate 
synthetase (TS), leading to dNTP pool imbalance and DNA damage, (2) fluorodeoxyuridine 
triphosphate (FdUTP), which mis-incorporates into DNA and (3) fluorouridine triphosphate 
(FUTP), which mis-incorporates into RNA, disrupting normal RNA processing and function 
(Longley et al., 2003). Of these mechanisms, TS inhibition by FdUMP and DNA mis-
incorporation of FdUTP are the most likely to activate the ATR pathway and explain the 
synergy seen in the KPC cell lines. One hypothesis for why 5-FU demonstrated no synergy 
with AZD6738 in the human cells could be that, in these cell lines, conversion to FUTP may 
be more dominant leading to RNA-processing disruption that, while toxic, would not induce 
ATR activation. To test this, the proportion of each 5-FU metabolite in KPC mouse lines vs 
human cell lines could be assessed by liquid chromatography with tandem-mass spectrometry. 
However, this is not the direction I chose to take for this project, choosing instead to focus on 
combinations that demonstrated consistent synergy, as I explain at the beginning of the next 
chapter. 
The two additional DNA-damaging agents that constitute FOLFIRINOX, oxaliplatin and 
irinotecan (SN38), did demonstrate synergy with AZD6738 in MIA PaCa-2 and PANC-1 cells. 
Both these agents cause physical obstacles to form on DNA that impede the replication 
machinery, leading to fork stalling which will activate ATR. Oxaliplatin creates adducts by 
forming intra-strand and inter-strand cross-links (Graham et al., 2004), while TOP1 inhibition 
causes catalytic intermediates called TOP1 cleavage complexes to accumulate on DNA 
(Pommier et al., 2010). Potentiation of cisplatin by AZD6738 in lung cancer modes has been 
reported before (Vendetti et al., 2015), however the ability for oxaliplatin to also synergise with 
ATR inhibition has not been previously described. As for combined ATR and TOP1 inhibition, 
the Pommier group have assessed VE-821 and VX-970 (M6620) in combination with 
camptothecin (analogues of camptothecin include irinotecan and topotecan) and novel non-
camptothecin TOP1 inhibitors, LMP400 and LMP776, in preclinical models of breast and 
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colon cancer (Coussy et al., 2020; Jossé et al., 2014), but not in pancreatic models. They have 
since demonstrated in a phase I trial that ATR inhibition using M6620 plus the maximum dose 
of topotecan is tolerable in patients (Thomas et al., 2017). The data I have presented indicate 
that the combination of AZD6738 and irinotecan may be effective in PDAC.  
The two DDR-targeted agents that I assessed in combination with AZD6738 were the WEE1 
inhibitor, AZD1775, and the Chk1 inhibitor, MK8776. WEE1 inhibition synergised with 
AZD6738 in both human cell lines. Though this was not a combination that I explored further 
during my PhD, in 2018 and 2019 two groups using preclinical breast cancer models 
demonstrated efficacy using this approach, citing forced mitotic entry of cells with DNA 
damage and mitotic catastrophe as the mechanism of cell death (Bukhari et al., 2019; Jin et al., 
2018). As for Chk1, I found that the AZD6738 and MK8776 combination was mostly 
antagonistic in MIA PaCa-2 and PANC-1. To some extent, this contradicts the findings 
reported by the Helleday group. They concluded that combined ATR and Chk1 inhibition 
synergistically inhibited growth in U2OS and MCF-7 cells (in their view, because ATR would 
be required for survival during the uncontrolled origin firing induced upon Chk1 inhibition) 
(Sanjiv et al., 2015). However, they were combining the ATR inhibitor (VE-821) with 
AZD7762, which is in fact a dual inhibitor of Chk1 and Chk2, unlike the Chk1-specifc 
MK8776. The use of different inhibitors, as well as the different model systems (i.e. the 
differing genetic backgrounds of the cancer models assessed), may explain the contrasting 
results. Additionally, they primarily used clonogenic survival assays (72-hour drug treatment 
in sparsely seeded 10cm plates, followed by fresh media replacement and further incubation 
for 5–8 days before fixation, staining with methylene blue and manual colony counting) to 
assess the combination in vitro, as opposed to my shorter 72-hour SRB assays in a 96-well 
format. To investigate why AZD6738 antagonises MK8776 in MIA PaCa-2 and PANC-1, I 
would have to look at the changes in DDR signalling (e.g. markers such as P-ATR-T1989, P-
Chk1-S345, P-Chk2-T68, P-CDK1-Y15, ƴH2AX-S139) and cell-cycle alterations that occur 
upon single agent versus combination treatment. It has been reported that in some KRAS-
driven mouse models of PDAC, Chk1 inhibition monotherapy does not induce any detectable 
increase in γH2AX or apoptosis (Murga et al., 2011). The growth inhibition I observed with 
MK8776 alone may not represent cell death, conceivably, the increase in origin firing induced 
by Chk1-inhibiton may cause an ATR-dependent growth arrest (e.g. via ATR-driven activation 




One of the potential limitations of this chapter is the lack of a clear positive control for calling 
synergy. The 5-FU and ATRi combination seemingly displayed no synergy, but to be sure of 
this result one of the combinations from Table 3.1 already know to be synergistic in MIA PaCa-
2 and PANC-1 (e.g. gemcitabine and ATRi) could have been included alongside this set of 
experiments. Another potential limitation is that all experiments used 72-hour drug treatments, 
and it is possible that some of the combinations tested may require longer-term treatments for 
their full effect (i.e. DNA-damage induction and ATR activation) to be observed. If I were to 
repeat this set of experiments, I would perhaps try longer drug treatments for those 
combinations that displayed no synergy.  
Primarily, the reason for adding more MIA PaCa-2 and PANC-1 data to the AZD6738 
combination dataset (Figs. 3.1-3.5) was to be able to compare and rank the respective synergy 
scores (Fig. 3.6). AZD6738 and gemcitabine was ranked as the most synergistic combination 
which was reassuring, since this combination was already being progressed in the Jodrell lab 
into in vivo studies. My own investigations into the AZD6738 and gemcitabine combination 
form the basis of Chapter 4. Meanwhile, the synergy between AZD6738 and olaparib was also 







CHAPTER FOUR: ATM-loss as a predictive biomarker of response for combined ATR 
inhibition and gemcitabine in PDAC 
4.1. Background  
At the time that I started this project, the Jodrell lab had identified AZD6738 and gemcitabine 
(ATRi/gem) as a synergistic combination, which was demonstrating impressive efficacy in in 
vitro and in vivo PDAC models, such that a phase-I clinical trial was proposed (2017), and 
eventually launched (2019) as the ATRiUM trial (NCT03669601) (Wallez et al., 2018). I 
hypothesised that ATRi/gem would most likely benefit specific sub-groups of patients with 
pre-existing aberrations in DDR pathways. I further hypothesised that deficiency in the double-
strand-break master-regulator, ATM, would sensitise tumours to ATRi/gem.  
As discussed in Chapter 1,  germline or somatic ATM mutations in PDAC occur at a prevalence 
of around 6.4%, (Armstrong et al., 2019), while tissue microarray data-sets indicate that low 
ATM protein expression in PDAC occurs at around 12-17% (Kamphues et al., 2015; Kim et 
al., 2014). The loss of ATM in a proportion of PDAC samples, plus the central role it plays in 
DSB repair make ATM a primary candidate for a potential predictive biomarker of response 
for ATRi/gem therapy. In Chapter 1, I described how ATM-deficiency has been linked 
previously, in some cancer models, to greater sensitivity to ATRi. However, there is a lack of 
consistency in the literature, not only in the conclusion but in terms of cancer model assessed, 
ATR inhibitor used, combination tested and the experimental method of ATM depletion 
employed. Synthetic lethal interactions are not always universal and often depend highly on 
the genetic background in which they are studied (Ryan et al., 2018). This led me to undertake 
an assessment of how ATM status affects ATRi sensitivity in PDAC cells, specifically using 
AZD6738 with and without gemcitabine, in alignment with the ATRiUM trial. 
 
4.2. Pharmacological inhibition of ATM sensitises to ATR inhibition in PDAC cell lines 
First, to assess the degree of sensitisation to ATR inhibition associated with loss of ATM 
function in PDAC cells, I used the selective and potent ATM kinase inhibitor, AZD0156 
(Barlaam and Pike, 2016; Hickson et al., 2018; Pike et al., 2018), in combination with the ATR 
inhibitor, AZD6738 (Foote et al., 2018). The key advantage of using pharmacologic ATM 
inhibition initially was the ability to screen multiple lines relatively quickly, as opposed to 
genetic perturbation with can be timely and less scalable. I confirmed full target engagement 
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of AZD0156 in PDAC cells at low nanomolar concentrations (≥10 nM), as assessed by 
abrogation of ATM auto-phosphorylation in response to irradiation (IR) in MIA PaCa-2 (Fig. 
4.1A). In the absence of extrinsic damage, AZD0156 exposure had minimal effect on human 
or mouse PDAC cell growth when used at concentrations ≤100 nM (Fig. 4.1B), at which off-
target activity is minimised.  
 
Fig. 4.1 (A) MIA PaCa-2 were incubated with AZD0156 for 1 hour before exposure to 6 Gy of ƴ-irradiation (IR). 30 mins 
post-IR, cells were harvested for immunoblot analysis. (B) Human and mouse cell lines were exposed to AZD0156 for 72 
hours to generate dose-response curves using the SRB assay. Each point represents the mean of three independent experiments 
± SEM. 
 
I next evaluated the degree of growth inhibition induced by AZD6738 (ATRi) across a range 
of AZD0156 (ATMi) concentrations. ATMi sensitised all 6 of the human and mouse PDAC 
lines tested to ATR inhibition (Fig. 4.2). Calculation of Bliss and Loewe synergy scores using 
Combenefit software (Di Veroli et al., 2016) showed that the ATRi/ATMi combination 
synergistically inhibited growth in all 6 of these lines, albeit modestly in the ATRi-resistant 
PANC-1 (GI50 > 30 µM).  
To assess the long-term proliferation capacity of cells exposed to a 24-hour pulse of AZD6738, 
I then performed clonogenic assays. In this assay, ATMi strikingly sensitised MIA PaCa-2 to 




Fig. 4.2. Human and mouse lines were treated with increasing concentrations of AZD6738 and AZD0156 for 72 hours. Left = 
AZD6738 dose response curve with and without 30 nM AZD0156, mean ± SEM, n=3, with GI50 plus 95% confidence intervals 
shown, plus p value of curve comparison (Extra sum-of-squares F test). Middle = Full dose ranges, growth as % of solvent 






Fig. 4.3. Clonogenic survival of MIA PaCa-2 cells plated at low density and exposed to the indicated drug combinations for 
24 hours before washout. Cells were left to grow for 7 days after washout. Left = representative image of wells. Middle = 
surviving fraction values quantified using the GelCount. Each point represents the mean of three independent experiments ± 
SEM. Right = the area of the curve (AUC) for AZD6738 and AZD6738 + 30 nM ATMi AUC were generated using GraphPad 
Prism 7. Bars represent mean ±SD.; p = result of two-tailed Student’s t test. 
 
4.3. ATM protein depletion by siRNA knockdown does not sensitise PDAC cells to ATR 
inhibition 
Having identified that pharmacological inhibition of ATM in PDAC cell lines can sensitise to 
ATRi, I next evaluated the potential for siRNA knockdown of ATM to confer ATRi sensitivity 
in three human cell lines – MIA PaCa-2, PANC-1 and HPAF-II. Despite achieving durable 
ATM knockdown (average 88% knockdown efficiency across 3 lines) (Fig. 4.4A), this did not 
significantly sensitise any of the 3 cell lines to 72-hour exposure to AZD6738 (Fig. 4.4B). Due 
to this disparity between kinase inactivation (ATMi) and protein depletion (siATM), I 





Fig. 4.4 (A) ATM protein expression in human cell lines at the start (T0) of the drug sensitivity assay (3 days post-transfection) 
and at the 72-hour assay endpoint (6 days post-transfection). Two different “exposures” of the ATM blot are shown (by 
adjusting brightness of the IRDye image in LiCor Image Studio). Percentage knockdown values versus siCTR are displayed, 
derived using LiCor Image Studio quantification software. (B) AZD6738 dose-response curves of human lines, having been 
transfected with either a non-targeting siRNA control pool (siCTR) or with an ATM-targeting siRNA pool (siATM). Assay 
duration was 72-hours. Each point represents the mean of three independent experiments ± SEM. p values of curve 
comparisons (Extra sum-of-squares F test) are also shown. 
 
4.4. Deletion of ATM using CRISPR/Cas9 does significantly sensitise PDAC cells to ATR 
inhibition 
Having observed a sensitisation effect with the ATMi, but not with siATM, I next used 
CRISPR/Cas9 technology to generate ATM knockout (KO) MIA PaCa-2 single cell clones. By 
Sanger sequencing (Fig. 4.5) and immunoblotting, I identified three clones that did not express 
detectable ATM and showed no phospho-ATM S1981 upon irradiation (Fig. 4.6A).  
These three ATM-null clones were 7-fold more sensitive to AZD6738 than wild-type (WT) 
MIA PaCa-2 cells (mean ATM-null cells GI50 = 0.37 µM; mean ATM-positive cells GI50 = 
2.73 µM) (Fig. 4.6B-C).  As sensitisation occurred upon ATM knock-out, but not knock-down 
with siRNA, this suggests that complete loss of ATM function, not just depletion, is necessary 





Fig.4.5 (A) Genetic characterisation of sgATM-Cas9-transfected MIA PaCa-2 single cell clones. From genomic DNA, the 
region around the sgATM-Cas9 target site (in exon 59) was amplified by PCR and sent for Sanger nucleotide sequencing. 
Example trace for clone B7 is shown, with the guide RNA sequence (black line) and the NGG protospacer adjacent motif 
(dotted red line) highlighted. (B) Chromatograms were deconvoluted using the Synthego ICE web tool (ice.synthego.com) 
which generated plots showing the relative prevalence of indels in each sample (i.e. in each clone). All indels identified were 
small insertions or deletions, occurring at Valine-2862, in the kinase domain of ATM (e.g. Indels: -1/+2 for clone B7. Allele 




Fig. 4.6 (A) 30 mins post 6 Gy of ƴ-irradiation (IR), MIA PaCa-2 single cell clones from a CRISPR/Cas9 ATM knockout pool 
were harvested for immunoblot analysis to determine the ATM status. Clones B4, B7 and C4 were confirmed ATM-null. (B) 
AZD6738 dose-response curves of MIA PaCa-2 CRISPR clones. Assay duration was 72-hours. Each point represents the mean 
of three independent experiments ± SEM. p value denotes curve comparison (Extra sum-of-squares F test) of ATM-KO curves 
vs MIA PaCa-2 WT (C) AZD6738 GI50 values (the concentration that inhibits growth by 50% relative to control) for MIA 
PaCa-2 CRISPR clones. 
 
4.5. ATM loss of function sensitises to the combination of AZD6738 and gemcitabine 
I next tested whether reduced ATM function could sensitise to the combination of AZD6738 
and gemcitabine (ATRi/gem). Kinase inhibition of ATM conferred sensitivity to 72-hour 
ATRi/gem exposure in MIA PaCa-2 (Fig. 4.7A) but siRNA depletion did not (Fig. 4.7B). 
While siATM induced no shift in the AZD6738 dose response curve in neither the presence 
nor the absence of gemcitabine, genetic deletion of ATM did sensitise MIA PaCa-2 cells to 





Fig. 4.7 (A) The effect of ATM kinase inhibition by AZD0156 on ATRi (AZD6738) & gemcitabine sensitivity in MIA PaCa-
2. (B) The effect of ATM depletion by siRNA on AZD6738 & gemcitabine sensitivity in MIA PaCa-2. (C) The effect of ATM 
deletion by CRISPR/Cas9 on AZD6738 & gemcitabine sensitivity in MIA PaCa-2. In all three panels (A-C), MIA PaCa-2 in 
the conditions listed were treated with increasing concentrations of AZD6738 and gemcitabine for 72 hours. Left = Matrices 
displaying growth as % of solvent control (as assessed by SRB assay), mean ± SD, n=3. Right = AZD6738 dose response 
curves in the presence of 1 nM or 10 nM gemcitabine, mean ± SEM, n=3. p values denote curve comparisons (Extra sum-of-
squares F test) between black and red curves (D) Gemcitabine dose-response curves of MIA PaCa-2 CRISPR clones. Assay 
duration was 72-hours. Each point represents the mean of three independent experiments ± SEM. p values denote curve 
comparisons (Extra sum-of-squares F test) of ATM-KO curves vs MIA PaCa-2 WT (E) Gemcitabine GI50 values (the 




The ATM-KO hypersensitivity to ATRi/gem was particularly evident in assays where the 
ATRi/gem was pulsed for 24-hours with observation of subsequent cell growth by time-lapse 
imaging. A 24-hour pulse of 500 nM AZD6738 and 10 nM gemcitabine had no effect on the 
growth ability of the WT line (growth as percentage of solvent control = 96% +/-7) but 
maintained durable growth inhibition for at least 4 days in the ATM-KO cells (growth as 
percentage of solvent control = 7% +/-1) (Fig. 4.8A-B), with a parallel increase in cell death, 
quantified by YoYo-3 staining (Fig. 4.8A).  
Though the combination of ATRi/gem had a more profound effect in ATM-KO cells, the shift 
in the dose-response curve (between WT vs KO) with gemcitabine was not any greater than 
the shift seen with single agent ATRi (Fig. 4.7C, right). Thus, more mechanistic studies plus 
in vivo experiments were needed to elucidate whether ATM-loss would be a suitable predictive 




Fig. 4.8 (A) MIA PaCa-2 WT and MIA PaCa-2 ATM-KO (clone B7) cells in medium containing the YOYO-3 Iodide cell-
impermeant dye were treated with AZD6738 and gemcitabine in a 6 × 8 concentration grid for 24 hours (grey bar denotes… 
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…period of drug treatment). The drugs were washed out and replaced with fresh YOYO-3-containing medium. Three fields 
per sample were imaged by IncuCyte time lapse microscopy every 3 hours for 125 hours. Phase Object Confluence was 
quantified as the percentage of the image area occupied by cells (upper). Cell death accumulation (lower) was quantified by 
measuring Red Object Confluence, and expressed as a percentage of the total Object Confluence. Each curve is a representative 
of three independent experiments. (B) The same cells from the IncuCyte experiment in (A) were fixed in TCA after 125 hours 
and the relative growth was assessed by SRB assay. Left = growth as % of solvent control, mean ± SD, n=3 independent 
experiments. Right = Combenefit synergy score (Loewe and Bliss). 
 
4.6. ATRi/gem-induced DDR activation persists in the absence of ATM function, due to 
DNA-PK activity 
Having found that targeting ATM, by either pharmacological inhibition or by genetic deletion, 
can sensitise PDAC cells to the combination of AZD6738 and gemcitabine, I next investigated 
the DDR signalling pathways activated by ATRi/gem, in the presence or absence of ATM 
function. 24 hour exposure of MIA PaCa-2 cells to 2000 nM ATRi and 30 nM gemcitabine 
(concentrations known to be synergistic in this line (Wallez et al., 2018)) induced 
phosphorylation of ATM and its downstream targets RAD50, KAP1 and Chk2 (Fig. 4.9A). 
Unexpectedly, because they are reported to be ATM kinase targets, the phospho-ATM S1981, 
phospho-KAP1 S824 and phospho-Chk2 T68 persisted, even in the presence of ATMi 
(AZD0156) (Fig. 4.9A). This persistence was specific to ATRi/gem, since irradiation-induced 
activation of these markers was prevented by 10 nM ATMi (Fig. 4.9A & 4.1A). In the 
ATRi/gem treated samples, I did observe ATMi dose-dependent abrogation of phospho-
RAD50 S635 (Fig. 4.9A), a biomarker of ATM activity (Gatei et al., 2011; Jones et al., 2018), 
suggesting that the ATMi was acting on-target. Therefore, the persistence of phospho-Chk2 
T68 and others could be due to the activity of another kinase, the most likely candidate being 
DNA-PKcs. 
Indeed, the phospho-KAP1 and phospho-Chk2 induced by ATRi or ATRi/gem treatment was 
abrogated by the selective DNA-PKcs inhibitor, AZD7648 (Fok et al., 2019) (Fig. 4.9B). Along 
with phospho-ATM, these phosphorylations were only fully prevented upon combined ATMi 
and DNA-PKcsi. I also probed for ATR and its downstream partner Chk1. Gemcitabine-
induced phospho-ATR T1989 persisted in the presence of ATRi due to ATM-dependent 
phosphorylation (Fig. 4.9B). Meanwhile, phospho-Chk1 S345 was only abrogated upon DNA-
PKcs inhibition (Fig. 4.9B). Thus, I revealed that much of the downstream DDR activation 
induced by ATRi or ATRi/gem was not prevented by ATMi (besides phospho-RAD50 and 
phospho-ATR), because of phosphorylation by DNA-PKcs.  
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Fig. 4.9 (A) Immunoblot analysis of MIA PaCa-2 cells. Cells which received 6 Gy of ƴ-irradiation (IR) were harvested 30 
mins post-IR. All other samples were harvested after 24 hours of drug exposure. ATRi + GEM denotes 2 µM AZD6738 and 
30 nM gemcitabine. ATMi is AZD0156 and was either applied concurrently with ATRi/gem, or administered one hour prior 
to IR, in the case of the two IR samples. (B) Immunoblot analysis of MIA PaCa-2 cells. Cells were harvested after 24 hours 
of drug exposure. ATRi is AZD6738, ATMi is AZD0156, DNA-PKi is AZD7648. 
 
Next, I repeated these immunoblotting experiments in HPAF-II and found the same DNA-
PKcs-dependency for ATR/gem-induced phospho-KAP1, phospho-Chk2 and phospho-Chk1 






Fig. 4.10.  Immunoblot analysis of HPAF-II cells. Cells were harvested after 24 hours of drug exposure. ATRi + GEM 
denotes 2 µM AZD6738 and 30 nM gemcitabine. ATMi is AZD0156, DNA-PKi is AZD7648. 
 
I next interrogated DDR pathway activation in ATM-KO MIA PaCa-2 cells. Once again, 
ATRi/gem treatment upregulated phospho-Chk2, phospho-KAP1 and phospho-Chk1 in both 
the presence and the absence of ATM function (Fig. 4.11). These phosphorylations were DNA-
PKcs driven, as evidenced by their abrogation by AZD7648 (Fig. 4.11). The low baseline levels 
of phospho-RAD50 S635 in untreated ATM-KO MIA PaCa-2 cells appeared to be ATR-
dependent, consistent with recent findings that in ATM-deficient models ATR can 
phosphorylate RAD50 (Jones et al., 2018). Unlike with Chk2 and KAP1, the ability for the 
ATM-KO cells to upregulate phospho-RAD50 S635 upon ATRi/gem was significantly 
impaired in comparison to ATM-WT. The modest phospho-RAD50 S635 that was induced by 
ATRi/gem was DNA-PKcs-dependent (Fig. 4.11). Meanwhile, phosphorylation of ATR T1989 





Fig. 4.11. Immunoblot analysis of MIA PaCa-2 WT and MIA PaCa-2 ATM-KO cells (clone B7). Cells were harvested after 
24 hours of drug exposure. ATRi is AZD6738, DNA-PKi is AZD7648. 
 
Despite the contribution of DNA-PKcs to many of the DDR phosphorylations in ATRi-treated 
cells, Bliss and Loewe cytotoxicity synergy scores showed consistently less synergy for the 
AZD6738 and AZD7648 (DNAPKi) combination than for AZD6738 and AZD0156 (ATMi) 




Fig. 4.12. Cells were treated with increasing concentrations of AZD6738 (ATRi) and AZD7648 (DNA-PKi) for 72 hours. Left 







Fig. 4.13. Synergy comparison of the AZD6738 & AZD0156 combination (ATRi + ATMi, see Fig. 1C & 1D) vs the AZD6738 
& AZD7648 combination (ATRi + DNAPKi). Combenefit software was used to calculate the sum of synergy and antagonism 
across the dose ranges tested. 
 
Furthermore, in triple combination SRB experiments, the addition of DNA-PKcsi to ATRi/gem 
led to only moderate sensitisation compared to ATMi (Fig. 4.14A-B). As with MIA PaCa-2 
WT, DNA-PKcsi also had minimal effect on the sensitivity of ATM-KO MIA PaCa-2 to ATRi 
or ATRi/gem (Fig. 4.14D-E). This suggests that ATM function is more critical to cell survival 
during ATRi or ATRi/gem exposure than DNA-PKcs activity. It also implies that the 
Chk1/Chk2 phosphorylations that arise through DNA-PKcs activity do not play a major 
protective role in ATRi/gem-exposed PDAC cells. To test this one could carry out genetic 
experiments where Chk1/Chk2 are deleted or downregulated before assessing response to 




Fig. 4.14 (A) The effect of DNA-PK inhibition on AZD6783 & gemcitabine sensitivity in MIA PaCa-2. Values denote growth 
as % of solvent control (as assessed by SRB assay), mean ± SD, n=3. (B) Visualisation of how much more effect ATM 
inhibition has compared to DNA-PKcs inhibition, on the growth of ATRi/gem-treated MIAPaCa-2. Left = the %Control values 
of the MIA PaCa-2 + 1 µM DNA-PKi matrix from Fig. 4.13 (A) were subtracted from those of the MIA PaCa-2 + DMSO 
matrix from Fig. 4.13 (A). Right = the %Control values of the MIA PaCa-2 + 30 nM ATMi matrix from Fig. 4.7 (A) were 
subtracted from those of the MIA PaCa-2 + DMSO matrix from Fig. 4.7 (A). (C) AZD7648 (DNA-PKi) dose response curves 
in WT and ATM-KO MIA PaCa-2 (clone B7). (D) Effect of DNA-PKi on ATRi sensitivity in WT and ATM-KO MIA PaCa-
2. (E) Effect of DNA-PKi on ATRi/gem sensitivity in ATM-KO MIA PaCa-2. Assay duration was 72-hours. Each point 
represents the mean of three independent experiments ± SEM. 
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4.7. ATRi/gem-induced replication catastrophe is augmented in ATM-null PDAC cells 
I next investigated the effect of AZD6738 and gemcitabine treatment on the cell cycle profile 
of ATM-proficient and ATM-deficient PDAC cells. Treatment with 500 nM AZD6738 and 10 
nM gemcitabine for 24 hours had little-to-no effect on the cell cycle profile of WT MIA PaCa-
2 cells. Conversely, 10 nM gemcitabine induced intra-S accumulation in the ATM-KO MIA 
PaCa-2, along with a reduction in the G2-M proportion (Fig. 4.15A). This was augmented by 
the addition of 500 nM AZD6738, which also increased the sub-G1 fraction, indicating 
induction of cell death. When the higher concentration of 2000 nM AZD6738 was used, I 
observed modest intra-S accumulation with ATRi-monotherapy, which was specific to the 
ATM-null cells, while addition of 30 nM gemcitabine could induce S-phase arrest in both the 
ATM-WT and ATM-KO cells (Fig. 4.15B). 
 
Fig. 4.15 (A) DNA content of MIA PaCa-2 WT and MIA PaCa-2 ATM-KO (clone B7) cells following 24-hour exposure of 
the indicated drugs. 500 nM AZD6738 and 10 nM gemcitabine are synergistic concentrations in ATM-KO MIA PaCa-2 (see 
Fig. 4.8B). Left = Representative DNA content histograms, x = FxCycle Violet fluorescence (DNA content), y = cell count… 
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…Right = cell cycle distribution. Each bar represents the mean of 3 independent experiments ± SD. A one-way ANOVA 
analysis, comparing the % S phase fractions, was performed with Tukey’s multiple comparisons tests, * indicates p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001.  (B) DNA content of MIA PaCa-2 WT and MIA PaCa-2 ATM-KO cells following 24-hour exposure 
of the indicated drugs. 2000 nM AZD6738 and 30 nM gemcitabine are synergistic concentrations in both WT and ATM-KO 
MIA PaCa-2 (see Fig. 4.8B). Left = Representative DNA content histograms, x = FxCycle Violet fluorescence (DNA content), 
y = cell count. Right = cell cycle distribution. Each bar represents the mean of 3 independent experiments ± SD. 
 
Through immunoblotting I had found that treatment with 2000 nM AZD6738 and 30 nM 
gemcitabine induced DNA-PKcs-driven activation of the checkpoint proteins, Chk1 and Chk2.  
However, co-treating with the DNA-PKi AZD7648 did not alter the cell cycle profiles in any 
of the ATRi/gem conditions (Fig. 4.15B), indicating that the intra-S phase arrests I observed 
were independent of checkpoint activation. An alternative reason for the intra-S accumulation, 
independent of a checkpoint, could be induction of replication catastrophe. This is defined as 
the widespread breakage of multiple replication forks, resulting from a global exhaustion of 
RPA and subsequent degradation of unprotected ssDNA at stalled forks (Toledo et al., 2017, 
2013; Warren and Eastman, 2019). I found that 500 nM AZD6738 and 10 nM gemcitabine 
caused RPA32 to deplete from the cytosol and accumulate in the nucleus over time, with a 
parallel increase in nuclear ƴH2AX S139, in the ATM-KO MIA PaCa-2 (Fig. 4.16).   
 
 
Fig. 4.16 Immunoblot analysis of MIA PaCa-2 WT and MIA PaCa-2 ATM-KO cells treated as indicated, separated by 




Next, using quantitative image-based cytometry (Fig. 4.17), I assessed the degree of replication 
catastrophe induced by ATRi and ATRi/gem in ATM-WT vs ATM-KO, by quantifying the 
emergence of cells with pan-nuclear ƴH2AX S139 and pan-nuclear phospho-RPA32 S4/8 (Fig. 
4.18). After 24–hour exposure to 500 nM AZD6738 alone, 1.4% of WT MIA PaCa-2 cells 
were pan-nuclear for both markers, compared to 8.7% of ATM-KO cells (Fig. 4.18A).  
 
 
Fig. 4.17. Representative images showing the pan-nuclear emergence of ƴH2AX S139 and phospho-RPA32 S4/8 upon 24-
hour exposure to 500 nM AZD6738 and 10 nM gemcitabine.  
 
The combination of 500 nM AZD6738 and 10 nM gemcitabine induced pan-nuclear ƴH2AX 
S139 and phospho-RPA32 in both cell types, but much more extensively in the ATM-KO cells 
(9.9% WT double-positive vs 58.2% ATM-KO double-positive after 24 hours) (Fig. 4.18B). 
Hoechst quantification indicated that cells with pan-nuclear damage typically had DNA 
contents between 2n and 4n, consistent with S-phase failure (Fig. 4.19).  This observation of 
increased replication catastrophe in the ATM-KO cells suggests that ATM protects against 




Fig. 4.18. Quantitative image-based cytometry to determine the proportion of cells pan-nuclear for both ƴH2AX S139 and 
phospho-RPA32 S4/8, at the timepoints indicated. Images were acquired using the Operetta CLS High-Content Analysis 
System and analysis performed using Harmony 4.5 software. The resulting data were imported into FlowJo as CSV files to 
generate the pseudo-colour plots shown. Percentages of double-positive cells are shown. (A) ATRi = 500 nM AZD6738. (B) 




Fig. 4.19 DNA content (Hoechst) of MIA PaCa-2 cells vs ƴH2AX S139 signal, as determined by quantitative image-based 
cytometry. Images were acquired using the Operetta CLS, analysis performed using Harmony 4.5 software, with the resulting 
data imported into FlowJo to generate the pseudo-colour plots shown. ATRi = 500 nM AZD6738, GEM = 10 nM gemcitabine.  
 
4.8. AZD6738 monotherapy causes growth delay in ATM-deficient PDAC xenografts, 
while combined treatment with gemcitabine induces regression 
Next, I assessed the efficacy of AZD6738 monotherapy in vivo. NSG mice bearing either 
MIA PaCa-2 WT or MIA PaCa-2 ATM-KO xenografts were treated with 50 mg/kg 
AZD6738 (oral gavage, once daily, 5 consecutive days a week) for three weeks. No efficacy 
was seen in the ATM-proficient model, whereas in the ATM-KO tumours I observed 61% 
tumour growth inhibition (TGI) after 3 weeks of treatment (Fig. 4.20A). Subsequently, I 
assessed the combination of gemcitabine and AZD6738 using the same in vivo models. 
Previous tolerance studies with ATRi/gem (Yann Wallez, unpublished) had concluded that 25 
mg/kg AZD6738, once daily for 5 days per week, plus 100 mg/kg gemcitabine twice per 
week (the maximum tolerated gemcitabine dose (Bapiro et al., 2014)) was a tolerable 
schedule. However, rather than drop the AZD6738 to 25 mg/kg, I chose to continue using 50 
mg/kg (same as Fig. 4.20A) and assess whether a comparatively lower dose of gemcitabine 
(50 mg/kg) could be used as a sensitiser to AZD6738, to perhaps improve on the already 
impressive response seen with ATRi alone in the ATM-KO model.
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Fig. 4.20 (A) Tumour volumes of MIA PaCa-2 WT and MIA PaCa-2 ATM-KO (clone B7) xenografts in NSG mice, with 
AZD6738 monotherapy at 50 mg/kg, OG, once daily, 5 days on & 2 days off. Grey bars denote the 5-day dosing cycles. 
Data, mean ± SEM. WT-Vehicle group, n=10. WT-AZD6738 group, n=9. ATM KO-Vehicle group, n=9. ATM KO-
AZD6738 group, n=9. (B) AZD6738 and gemcitabine combination. AZD6738 was given at 50 mg/kg, OG, once daily…  
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…5 days on & 2 days off. Gemcitabine was given at 50 mg/kg, IP, once per week on day 1 of each dosing cycle. Grey bars 
denote the 5-day dosing cycles. MIA PaCa-2 WT-Vehicle group, n=8. WT-Gemcitabine group, n=7. WT-AZD6738 & 
Gemcitabine group, n = 7. One mouse from the WT-Gemcitabine group and one from the WT-AZD6738 & Gemcitabine 
group dropped weight in the first week and their tumour volumes are not included in the mean values shown. MIA PaCa-2 
ATM KO-Vehicle group, n=8. ATM KO-Gemcitabine group, n=9. ATM KO-AZD6738 group, n=8. ATM KO-AZD6738 & 
Gemcitabine group, n=9. (C) Changes in individual tumour volume from start to the end of the combination study (day 0 to 
day 21), as a percentage of starting volume. A one-way ANOVA analysis was performed (with multiple comparisons tests 
assuming unequal variances), * indicates p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. 
 
Regression is rare in MIA PaCa-2 xenograft studies, but adding low dose gemcitabine (50 
mg/kg, IP, once per week) to the 50 mg/kg AZD6738 schedule induced regression in the ATM-
KO MIA PaCa-2 tumours (mean volume change after 3 weeks = -17.8%, 95% confidence 
interval -2.7% to -32.8%), and growth delay in the WT tumours (46% TGI) (Fig. 4.20B-C). 
Using a Bliss synergy calculation, I found that the addition of gemcitabine to AZD6738 was 
supra-additive in the ATM-KO tumours. The mean final volume as a percentage of the vehicle 
group was 83% for gemcitabine-alone and 32% for AZD6738, giving a Bliss predicted 
(reference) combination effect (83% x 32%) of 27%; the actual effect seen in the combination 
group was 15%, giving a synergy score (27% - 15%) of 12%. 
The dose-schedules used were well tolerated such that, across the two studies, just two mice 
experienced notable weight loss, one in ATRi/gem group (1/17) and one in the low dose 
gemcitabine-alone group (1/17) (Fig. 4.21A), even though NSG mice are typically sensitive to 
DNA damaging agents, due to the Prkdcscid mutation. Endpoint blood cell counts showed no 
significant difference between the ATRi/gem combination group and gemcitabine single agent 
(Fig. 21B). Though subcutaneous xenografts in immunocompromised mice do have some 
limitations, such as the lack of intra-tumoural heterogeneity, absence of immune responses and 
reduced ability to recapitulate the tumour microenvironment, this type of model can offer some 
advantages over orthotopic models, as previously reported (Dorado et al., 2018), including ease 
of use, reproducibility and earlier tumour detection. If I had used a syngeneic tumour model in 
immune competent mice I would have expected the overall result to be the same, with ATM-
KO sensitising to ATRi/gem, however it is possible that I would have seen a different toxicity 
profile, particularly in the white blood cell counts. Additionally, it has been reported that loss 
of ATM in mouse tissue can prime the type-I interferon response (Härtlova et al., 2015), thus 
the immune response to syngeneic ATM-KO tumours may differ to that in ATM-WT tumours.  
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IHC quantification of ƴH2AX percent positive nuclei in the tumours, in half of each cohort 
fixed 6 hours after the final dose (day 21), revealed an increase in the ATRi/gem groups 
compared to vehicle; mean ƴH2AX positivity increased from 5.7% to 11.4% in WT tumours 
with ATRi/gem (p < 0.01), and from 7.3% to 15.4% in ATM-KO tumours with ATRi/gem 
compared to vehicle (p <0.0001) (Fig. 4.21C). ƴH2AX positivity was higher in the ATM-KO 
tumours following ATRi/gem treatment compared to the ATM-WT (p<0.05). Analysis of the 
other half of the cohort, with tumours fixed 24 hours after the final dose, revealed that in both 
ATM-WT and ATM-KO tumours, the ƴH2AX positivity persisted for at least 24 hours after 
dosing (Fig. 4.21C). Meanwhile in the small intestine, the high ƴH2AX induced at 6 hours by 
gemcitabine or ATRi/gem did not persist at 24 hours (Fig. 4.21D), indicative of DNA repair in 
normal tissue. 
In agreement with the in vitro findings, these in vivo experiments suggest that ATM-loss could 





Fig. 4.21 (A) Individual body weights during treatment, as a percentage of the starting weight upon enrolment, for NSG mice 
bearing MIA PaCa-2 WT or ATM-KO (clone B7) xenografts. Both sets of mice from Figure 6A (monotherapy study) and 
Figure 6B (subsequent combination study) are plotted. Just two mice showed significant weight loss, Mouse#220_42 
(Gemcitabine group) and Mouse#220_42 (ATRi/gem group). (B) Blood was taken at endpoint and run on the Mythic 18 
Haematology Analyser. The title of each sub-plot denotes the blood component measurement and its units. RBC = red blood 
cells, PLT = platelets, HGB= haemoglobin; WBC = white blood cells, Lym = lymphocytes, Mon = monocytes, Gra = 
granulocytes. Each point represents the reading from one mouse. Bars =mean ± SD.  (C & D) Nuclear ƴH2AX S139 positivity 
in the formalin-fixed tumours (B) and the small intestine (C) from the combination study was assessed by IHC and quantified 
using Halo software. Each point represents data from one histological section from an individual mouse. Horizontal bars… 
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…denote the mean. A one-way ANOVA analysis was performed with Tukey’s multiple comparisons tests, * indicates p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. 
 
4.9. Normal tissue toxicity prevents the use of pharmacodynamically effective dose 
schedules of ATMi and ATRi in vivo 
My data so far suggested that ATM-KO PDAC tumours are sensitive to ATRi (Fig. 4.20A).  
Since only a minority of PDAC patients have ATM-deficient tumours, one might assume that 
only these patients may stand to benefit from any understanding of ATM/ATR synthetic 
lethality. Having said that, I had also shown earlier that pharmacological inhibition of ATM 
sensitises (otherwise ATM-proficient) PDAC cell lines to ATRi in vitro (Fig. 4.2). With these 
in vitro results in mind, the question remained – could ATMi and ATRi be combined in vivo 
to produce an anti-tumour effect? If so, and if ATMi could perhaps mimic the in vivo 
sensitisation effect seen with ATM-KO, then the synthetic lethality between ATM and ATR 
could even be exploited in ATM-proficient tumours. I posited that the success of co-targeting 
both kinases pharmacologically in animal models would likely rest on the toxicity profile of 
the combination, since ATMi may sensitise all normal tissue to ATRi, and not just the tumour.  
For my in vitro experiments I had used the ATMi, AZD0156. While AZD0156 is a potent and 
selective ATM kinase inhibitor, the analogue, AZD1390, is being prioritised for clinical 
development. Unlike AZD0156, AZD1390 is not a substrate for the efflux transporters P-
glycoprotein (ABCB1/MDR1) (Roninson et al., 1986; Thiebaut et al., 1987) and breast cancer 
resistance protein (ABCG2/BCRP) (Doyle and Ross, 2003), which are multidrug resistance 
protein (MRP) family members that are expressed by endothelial cells of the blood-brain-
barrier. As a result, AZD1390 is more brain-penetrant than AZD0156 and is being assessed 
clinically as a radiosensitiser in central nervous system malignancies (Durant et al., 2018). 
MRP efflux pumps have also been found to be overexpressed in numerous cancer types, 
including in PDAC (König et al., 2005) and have been associated with resistance to 
chemotherapies such as gemcitabine (Hagmann et al., 2010) and 5-FU (Nambaru et al., 2011).  
By mining RNA-seq data from the Cancer Cell Line Encyclopaedia, I found that many 
commonly used human PDAC cell lines express MRP family members to varying degrees (Fig. 
4.22). PANC-1, which is highly resistant to AZD6738, gemcitabine, Chk1 inhibition and other 




Fig. 4.22. mRNA transcript expression of multidrug resistance protein (MRP) family member genes in commonly used human 
PDAC cell lines. Source data, Cancer Cell Line Encyclopaedia (CCLE), extracted using EBI Expression Atlas. Numbers 
denote transcripts per kilobase million. 
 
I hypothesised that AZD1390 would penetrate PDAC tumours more effectively than 
AZD0156. Therefore, before assessing ATRi and ATMi in vivo, I first designed a 
pharmacokinetic (PK) study to test this theory. At the time that this experiment was devised, I 
was still carrying out the ATRi/gem combination study shown in Fig. 4.20B, thus Dr Brajesh 
Kaistha kindly acted as PIL holder for the PK study, liaising with CRUK-CI PGE core facility 
members who undertook dosing and necropsy duties.  
KPC mice with PDAC tumour confirmed by ultrasound scan by the CRUK-CI PGE core were 
given of single dose of either 10 mg/kg AZD0156 or 10 mg/kg AZD1390, and killed at fixed 
timepoints after dosing. UPLC-MS/MS was then used to quantify the drug concentrations in 
flash-frozen plasma and tumour samples. While similar plasma concentrations of AZD0156 
and AZD1390 were measured, AZD1390 outperformed AZD0156 in terms of tumour 
penetrance at every timepoint assessed (Fig. 4.23). This confirmed that, for in vivo studies 






Fig. 4.23 (A) Plasma concentrations from KPC mice dosed with either 10 mg/kg AZD0156 or 10 mg/kg AZD1390. (B) Tumour 
concentrations from KPC mice dosed with either 10 mg/kg AZD0156 or 10 mg/kg AZD1390. Horizontal lines denote mean, 
± SEM. In (B), samples below the limit of quantification (<10 nM) were given nominal value of 1 nM for this plot. One mouse 
in the 2-hour AZD1390 group had ascites that was discovered upon necropsy, and this was the only mouse which had an 
AZD1390 tumour concentration above 10 µM. Dr Brajesh Kaistha kindly acted as PIL holder for this study, with the CRUK-
CI PGE core facility members undertaking dosing and necropsy duties. UPLC-MS/MS was performed by Dr Aaron Smith, 
AstraZeneca. 
 
Next, I designed an AZD6738 and AZD1390 tolerance study in BALB/c nude mice (NSG mice 
were avoided since they are mutant for the DNA-PKcs gene, Prkdc, and so would almost 
certainly fail to tolerate combined ATRi and ATMi). Since one of the reasons for assessing this 
combination was to ascertain if ATMi could mimic ATM-KO in terms of in vivo AZD6738 
sensitisation (Fig. 4.20A), mice were inoculated with MIA PaCa-2 xenografts. 7 different 
ATRi/ATMi dose-schedules were assessed, with 3 mice per group, while 4 mice were dosed 




Fig. 4.24. Dose-schedules assessed in AZD6738 and AZD1390 tolerance study. Each square represents one day of a 7-day 
dosing cycle. Both drugs were administered by oral gavage. On days where both drugs were administered, AZD1390 was 
given 1 hour after the AZD6738 dose. 
 
Over the course of three 7-day dosing cycles, notable weight loss (that approached or surpassed 
the limit of 15% of starting weight) was observed in 5 of the 7 combination groups (Fig. 4.25A). 
The only two dose-schedules that did not induce weight loss were schedule B1 (AZD6738 25 
mg/kg - 5d on/2d off; AZD1390 10 mg/kg - 3d on/4d off) and schedule C1 (AZD6738 50 
mg/kg - 3d on - alternate days; AZD1390 10 mg/kg - 2d on - alternate days). However, these 
schedules did not induce any notable tumour growth inhibition compared to the vehicle-treated 
group (Fig. 4.25B). The only schedules with potential signs of anti-tumour activity were those 
that were also toxic to the mice, such as group A3 (AZD6738 25 mg/kg - 5d on/2d off; 
AZD1390 5 mg/kg - 5d on/2d off), in which 3 out of 3 mice had to be killed, due to weight 
loss. This suggests that normal tissue toxicity prevents the use of pharmacodynamically 
effective dose schedules of ATMi and ATRi combination in BALB/c nude mice. The data 
presented in this chapter therefore indicate that using ATM-loss a predictive biomarker of 
response for ATRi or ATRi/gem would be a more effective clinical strategy for PDAC than 




Fig. 4.25 (A) Individual mouse body weights over the course of the AZD6738 and AZD1390 tolerance study in MIA PaCa-2 
xenograft-bearing BALB/c nude mice, expressed as a percentage of starting weight. The final weight measurements of mice 
that had to be killed due to weight loss (approached or surpassed the 85% limit) are marked with a red dot. (B) MIA PaCa-2 







The application of precision medicine strategies, where therapies are assigned based on patient-
specific tumour vulnerabilities, has the potential to improve outcomes for diseases such as 
PDAC. Currently, the leading example is the use of BRCA1/2 mutations to select patients 
whose tumours may be hypersensitive to PARP inhibitor treatment (Bryant et al., 2005; Farmer 
et al., 2005), which has brought impressive survival rates in ovarian (Moore et al., 2018), breast 
(Robson et al., 2017) and pancreatic cancer (Golan et al., 2019). With approvals already granted 
for ovarian and breast cancer, PARP inhibitors are at a later stage of clinical development than 
ATR inhibitors. AZD6738, M6620 and BAY1895344 are ATR inhibitors currently being 
assessed in a range of phase I or phase II trials, as monotherapies and in combination with 
DNA-damaging agents, other molecularly targeted agents or immunotherapeutics.  
One of the challenges when combining DDR inhibitors with genotoxic drugs in the clinic has 
been avoiding increased normal tissue toxicity. For example, in a phase II study that assessed 
olaparib plus carboplatin and paclitaxel, adverse event such as neutropenia and anaemia were 
reported more frequently in the olaparib combination arm than with chemotherapy alone (Oza 
et al., 2015). Furthermore, the large number of possible DDRi/chemotherapy combinations 
heightens the need to predict which patients would most likely respond to a particular 
combination. In alignment with the phase I trial set-up to assess the combination of AZD6738 
and gemcitabine (ATRiUM, NCT03669601), I sought to investigate the potential utility of 
ATM-loss as a predictive biomarker of response for ATRi/gem in PDAC. ATM and ATR have 
been reported to share a synthetic lethal relationship in some cancer types (Kwok et al., 2016; 
Min et al., 2017; Schmitt et al., 2017; Vendetti et al., 2015). However, it has become 
increasingly clear that most synthetic lethal interactions depend highly on the genetic 
background in which they are studied (Ryan et al., 2018). By targeting ATM through multiple 
methods, I assessed how ATM status affects ATRi/gem sensitivity in PDAC cells.  
One of the methods by which I targeted ATM was through CRISPR/Cas9 deletion. I 
demonstrated that ATM was completely dysfunctional in the CRISPR clones by irradiating the 
cells and then immunoblotting for phospho-ATM S1981 (Fig. 4.6A). Additionally, in later 
immunoblotting experiments, I probed for downstream markers of DDR activation in 
ATRi/gem-treated cells, such as for the ATM-specific phospho-RAD50 S635, which was 
abrogated in ATM-KO cells (Fig. 4.11). Another way in which I could have assessed ATM 
functionality could have been to quantify changes in gene expression following DNA damage 
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(i.e. similar to the approach taken by Navrkalova et al., discussed in section 1.3.2) for example 
using RT-qPCR or RNA-Seq. However, all of the cell lines I used were p53-mutant, and since 
much of ATM’s effects on transcriptional programming is often driven via its activation of 
p53, these data would have to have been interpreted carefully. In hindsight, the irradiation plus 
phospho-ATM blotting approach that I took to assess ATM functionality in my CRISPR clones 
could/should have also been applied to my siATM cells. This would have been a positive 
control to show that the extent of ATM suppression was sufficient to inactivate DDR to the 
extent that it could elicit a DDR-related synthetic lethality.  
As for the other approach I took to target ATM, kinase inhibition with AZD0156, I also 
demonstrated abrogation of ATM function by blotting for P-ATM S1981 following IR (Fig. 
4.1A). However, to show that the effect of ATMi on ATRi sensitivity was an on-target effect, 
I could have carried out further experiments, for example by assessing the ATMi and ATRi 
combination in ATM-KO cells. In the immunoblotting experiments involving ATMi and 
ATRi, where I was investigating the DDR signalling pathways activated by ATRi/gem, I 
initially found that phospho-ATM S1981, phospho-KAP1 S824 and phospho-Chk2 T68 all 
persisted in the presence of ATMi (Fig 4.9A). I hypothesised that these phosphorylations could 
be driven by DNA-PKcs, and dissected this using the DNA-PKcs inhibitor, AZD7648. A 
potential problem with using all of the kinase inhibitors at once (AZD6738, AZD0156, 
AZD7648) is that they all target kinases belonging to the same PIKK family and so, though 
designed to be highly selective, they will each partially inhibit these related enzymes to a small 
degree. For example, in the ATRi/gem-treated MIA PaCa-2 cell in Fig 4.9A, the modest 
abrogation of P-RAD50 S635 caused by 5 µM but not 1 µM DNA-PKi may be due to the DNA-
PKi hitting ATM at the higher dose. 
One of the findings from this chapter was that complete loss of ATM function is necessary to 
sensitise PDAC cells to AZD6738 or the AZD6738 and gemcitabine combination. This has 
important implications, as it brings into question how best to assess ATM status in future 
clinical trials. A recent example of a trial where ATM status was assessed is Study 39 
(NCT01063517). This was a phase II efficacy study assessing the combination of olaparib and 
paclitaxel in gastric cancer patients, which identified a greater overall survival benefit in 
patients with “ATM-low” tumours (Bang et al., 2015). Here, “ATM-low” tumours were 
defined as those with ≤10% ATM tumour cell nuclear staining, quantified by an IHC test using 
the ATM (Y170) antibody clone. In the follow-up phase III GOLD trial (NCT01924533), a 
new IHC reporter assay was developed that used the same antibody clone but with different 
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assay configurations and reagents (Miller et al., 2019). The cut-off for “ATM-low” tumours 
was redefined as <25% of ATM tumour cell nuclear staining (to account for increased 
sensitivity of new assay) however this trial failed to meet its primary endpoint and failed to 
confirm the survival benefit in “ATM-low” patients that had been observed previously (Bang 
et al., 2017). It remains unclear whether redefining the cut-off to a lower threshold would bring 
a different result.  
In relation to ATRi/gem in PDAC, my data would support the use of complete ATM-loss, as 
opposed to <10 or 25% staining, since only ATM-null cells appeared to be hypersensitive. This 
leads to the question of how to define ATM-null in a clinical setting. Such tumour samples 
have been identified previously, including in the very first phase I dose escalation trial of an 
ATR inhibitor, which identified a colorectal cancer patient with 100% ATM loss by IHC, who 
showed a complete response (19+ months) to M660 monotherapy (O’Carrigan et al., 2016; 
Yap et al., 2015). Evaluating ATM functionality by IHC, using markers such as phospho-
RAD50-S635, in conjunction with total ATM could add further depth to ATM status 
assessments. Tissue microarray analysis of glioblastoma, gastric, triple negative breast and 
colorectal cancer identified a variability in baseline P-RAD50-S635 levels between patients. 
Most patients expressed modest but detectable levels of P-RAD50-S635 (Jones et al., 2018). If 
phospho-RAD50-S635 were to be used to infer or substantiate ATM status, this would likely 
require patients to be challenged with an DSB-inducing agent prior to biopsy to be most 
informative. The presence of germline or somatic ATM mutations, combined with a low IHC 
score, would add confidence that a patient’s tumour is indeed ATM negative, thus 
incorporating next-generation sequencing (NGS) in parallel with IHC could improve clinical 
biomarker assessments (Sundar et al., 2018). On the whole, if precision medicine techniques 
are to be implemented successfully, it is becoming increasingly apparent that the field will have 
to be more precise and detailed in the characterisation of patients and their tumours, and multi-
modal assessments of patient samples may facilitate this. 
As well as the important distinction between ATM-low and ATM-null, the data I have 
presented in this chapter also reveal further insight into the mechanism of how AZD6738 and 
gemcitabine synergise to induce cell death. The increase in nuclear RPA over time upon 
ATRi/gem exposure, plus the accumulation of S-phase cells pan-nuclear for DNA damage and 
replication stress markers, suggests that the combination induces replication catastrophe (RC) 
(Figs. 4.15-4.19). One potential limitation of the immunofluorescence experiments assessing 
RC is that the only concentrations used were 500 nM ATRi and 10 nM gemcitabine. It is 
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possible that increasing the ATRi to concentrations above 500 nM may have brought about the 
same or similar RC phenotype as observed by adding 10 nM gemcitabine. Having said that, 
2000 nM ATRi was assessed in the flow cytometry cell cycle experiments and this did not 
induce as significant an S-phase arrest as the ATRi/gem combination (Fig. 4.15B)   During the 
catastrophic fork collapse induced by ATRi/gem, Chk1 and Chk2 are phosphorylated by DNA-
PKcs, but the lack of clear ATRi/DNA-PKcsi synergy and the inability for DNA-PKcsi to 
significantly potentiate ATRi/gem (Fig. 4.14), suggests that these DNA-PKcs-driven signals 
may be bystander events during RC. The fact that ATM-deficient cells are hypersensitive to 
ATRi/gem-induced RC indicates that ATM plays a critical role in protecting against this 
widespread fork collapse. A recent study found that topotecan- or olaparib-induced breakage 
of replication forks is lethal in ATM-deficient models due to the induction of  toxic NHEJ 
(Balmus et al., 2019). Their data suggested that the toxic NHEJ was mediated by XRCC4 and 
ligase IV, but not DNA-PKcs.  Here, I found that DNA-PKcsi did not significantly potentiate 
nor attenuate the effect of ATRi/gem in WT or ATM-KO cells. Given more time, it would be 
interesting to interrogate whether the hypersensitivity of ATM-null PDAC cells to ATRi/gem 
is also due to toxic NHEJ.  
As already alluded to, minimising toxicity is a major challenge when combining DDRi and 
chemotherapy in the clinic. Most phase I trials of this type are designed such that the DNA-
damaging cytotoxic is administered at its standard-of-care dose – i.e. at the expected maximum 
tolerated dose – and the DDRi is titrated in at increasing levels. As a result, any increase in 
toxicity will immediately become dose limiting and the true potential of these combinations 
may not be fully explored. The ATRiUM trial design is unique, in that it is using a model-based 
approach to guide dose escalation, starting each drug at dosages that are <100% of the predicted 
or actual single agent dose. In essence, the aim is to use the gemcitabine as a sensitiser to the 
AZD6738, rather than simply administering the cytotoxic at its typical maximum dosage. In 
this chapter, I demonstrated that this strategy can indeed be effective, particularly in an ATM-
deficient setting. I first found that 50 mg/kg AZD6738 monotherapy, once daily for 5 
consecutive days a week, induced significant growth delay in the ATM-null tumours. Rather 
than introduce gemcitabine at its typical pre-clinical single agent dose of 100 mg/kg twice per 
week (Bapiro et al., 2014), I used a comparatively low gemcitabine dose of 50 mg/kg, once per 
week, to allow pharmacodynamically effective dose schedules of AZD6738. This regimen 
induced growth delay in the ATM-WT and tumour regression in the ATM-KO tumours (Fig. 
81 
 
4.20), thus demonstrating proof-of-principle that low dose gemcitabine can be used as a 
sensitiser to AZD6738 in vivo.  
As well as assessing the safety, tolerability and preliminary anti-tumour activity of ATRi/gem 
in a novel model-based approach, the ATRiUM trial is incorporating IHC assessment of 
baseline ATM, NGS of patient DNA and on-treatment biopsies. This will enable some of the 
conclusions that I have made in this chapter to be scrutinised clinically. This could steer the 
design of future precision-medicine based trials that will examine the promise that ATM shows 









CHAPTER FIVE: Combined PARP inhibition and ATR inhibition as a therapeutic 
strategy in PDAC 
5.1. Background  
My investigations into ATM-loss and ATRi/gem from Chapter 4 had initially stemmed from a 
set of experiments performed by myself and others in the Jodrell lab, where AZD6738 had 
been combined with a range of cytotoxic drugs and DDR-targeted agents in a panel of PDAC 
cell lines (Chapter 3). Gemcitabine was not the only drug that had demonstrated synergy with 
AZD6738, in fact, the PARP inhibitor olaparib was one of the agents that also synergised with 
ATRi. As summarised in Chapter 1, PARP inhibition leads to the trapping of PARP on DNA, 
which poses a physical obstacle to the replisome during S-phase, leading to the stalling of 
replication forks. This could explain why PARPi and ATRi synergise to induce cell death, since 
olaparib-induced stalled forks would go unresolved in the absence of ATR activity, resulting 
in fork collapse and the induction of DSBs. Though olaparib monotherapy has primarily been 
explored in BRCA-mutant populations, the combination of ATRi and PARPI had demonstrated 
in vitro synergy in BRCA-proficient PDAC cell lines (Fig. 3.6). Two-thirds of PDAC patients 
harbour no somatic mutations in any DDR genes, thus an effective therapy for these patients 
would fulfil a serious unmet need. Combined AZD6738 and olaparib is currently being 
assessed in patients with gastric cancer and triple negative breast cancer (NCT02264678) 
(Krebs et al., 2018). The combination has also been proposed for future PDAC trials, as part 
of the PRECISION-Panc initiative (Dreyer et al., 2020).   
Dr Yann Wallez carried out an initial efficacy study (code Pr149) to assess the olaparib and 
AZD6738 combination in BALB/c nude mice with MIA PaCa-2 xenografts, using a dose-
schedule recommended by AstraZeneca. No efficacy was observed in either single agent arms, 
nor in the combination arm (Fig. 5.1A). Pharmacokinetic data indicated that the olaparib and 
AZD6738 concentrations measured in the tumours were marginally below the doses required 
for maximal synergy and growth inhibition in vitro (Fig 5.1B-C). This raised the possibility 
that an altered dose-schedule may increase the chances of observing an anti-tumour effect using 
this combination in PDAC models. 
I took on this project, with the aim to further investigate the olaparib and AZD6738 





Fig. 5.1 (A) Tumour volumes of MIA PaCa-2 xenografts in BALB/c Nude mice, from the initial olaparib and AZD6738 
combination study carried out by Dr Yann Wallez (Pr149). Data, mean ± SEM. 10 mice per group. Olaparib was given at 50 
mg/kg, OG, once daily, for the full 28-day dosing period. AZD6738 was given at 25 mg/kg, OG, once daily, (one hour after 
the olaparib dose in the combination arm), 5 days on & 9 days off, for 2 cycles. The horizontal bars below the curves denote 
the dosing period for olaparib (green) and AZD6738 (blue). (B) UPLC-MS/MS was performed by Astra Zeneca (Aaron Smith) 
to quantify the drug concentrations in flash-frozen plasma and tumour samples from the combination study, 3 hours after the 
final AZD6738 dose (4 hours after olaparib). Horizontal bars denote mean ± SEM. (C) Olaparib and AZD6738 combination 
in MIA PaC-2, in vitro, with the tumour drug concentrations measured in study Pr149 highlighted in red boxes. MIA PaCa-2 
were treated with increasing concentrations of olaparib and AZD6738 for 120 hours, and cell number at endpoint was 
determined by measuring total protein content using the SRB assay. Top = Combenefit synergy score (Loewe). Bottom = 





5.2. Supra-micromolar olaparib concentrations induce activation of the intra-S 
checkpoint in PDAC cell lines 
First, to gain more mechanistic insight into the in vitro synergy observed with olaparib and 
AZD6738 in PDAC cell lines, I treated K8484 and MIA PaCa-2 cells with increasing 
concentrations of olaparib, and immunoblotted for markers of ATR activation. 48-hour 
olaparib treatment induced a dose-dependent upregulation of phospho-Chk1 S345 and 
phospho-CDK1 Y15, along with a downregulation of the mitotic marker phospho-Histone H3 
S10, indicating activation of the intra-S checkpoint (Fig. 5.2A).  
 
 
Fig. 5.2 (A) Immunoblot analysis of K8484 (mouse) and MIA PaCa-2 (human). Cells were harvested after 48 hours of drug 




Previously, double-digit nM concentrations of olaparib have been shown to elicit in vitro 
synthetic lethality in BRCA-mutant cell lines (Bryant et al., 2005; Farmer et al., 2005), 
suggesting that even low olaparib concentrations can induce toxic PARP-trapping. However, 
in my experimental setup (BRCA-WT PDAC cell lines, 48-hour treatment), low olaparib 
concentrations such as 0.3 µM did not induce markers of ATR activation. The concentration 
of olaparib measured in the MIA PaCa-2 tumours from the previous in vivo study (Pr149) 
averaged around 0.3 µM, thus I posited that the use of higher olaparib doses in subsequent 
mouse studies may increase the likelihood of observing in vivo efficacy with PARPi and ATRi.  
Combining 3 µM olaparib with increasing concentrations of AZD6738 induced upregulation 
of DSB markers, phospho-KAP1 S824 and ƴH2AX S139, as well as the apoptosis marker, 
cleaved-PARP (Asp214) (Fig. 5.2B). These markers of DNA damage and cell death underly 
the grow inhibition induced by the combination at synergistic doses (Fig. 5.1C). 
 
5.3. Assessment of olaparib and AZD6738 tolerability using a range of in vivo dose-
schedules   
I hypothesised that the previous in vivo assessment of olaparib and AZD6738 in PDAC may 
have shown no efficacy due to either; a) the use of olaparib or AZD6738 doses that were too 
low, b) insufficient coverage of AZD6738, which was given on only the first 5 days of the 14-
day dosing cycle, or c) a combination of both (other factors that may have affected the result, 
including the type of mouse model used, are explained in section 5.4 and in the Discussion, 
section 5.5). I therefore designed a pilot study to assess the tolerability of alternative dose-
schedules in BALB/c nude mice bearing MIA PaCa-2 xenografts (study code, Pr169). 8 





Fig. 5.3. Dose-schedules assessed in olaparib and AZD6738 tolerance study. Each square represents one day of a 7-day dosing 
cycle. Both drugs were administered by oral gavage. On days where both drugs were administered, AZD6738 was given 1 
hour after the olaparib dose, except for in schedule S where it was given 8 hours after. The dose-schedule used in the previous 
efficacy study, Pr149, is also shown for comparison. 
 
During the course of the pilot study, 7 of the 8 schedules appeared tolerable, with no 
considerable weight loss observed in these groups (Fig. 5.4A). Group S, in which 50 mg/kg 
AZD6738 was dosed 8 hours after a 100 mg/kg olaparib dose, was the only schedule that 
induced notable weight loss in both mice (Fig. 5.4A). 
In all other groups, AZD6738 was given 1 hour after the olaparib dose. Since both drugs were 
given orally, it is difficult to know whether the weight loss in the staggered 8-hour group was 
due to a pharmacodynamic effect or simply because of prolonged inappetence – receiving a 
dose in both the morning and the evening may have impacted the food intake of these mice 
differently to those mice receiving both doses in the morning. In any case, the fact that 7 
schedules appeared tolerable was promising and meant a decision had to be made on which to 
take forward. 
Since there were two mice per group, this pilot study was not powered to differentiate tumour 
growth rates between the groups, but did prove useful for PK analysis. One mouse in group B 
had a tumour which seemingly regressed to become undetectable, however the growth curve 
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suggested that this could have due to an inability of the xenograft to take and not necessarily a 
drug-induced effect (Fig. 5.4B). All mice were killed 3 hours after the final AZD6738 dose (4 
hours after olaparib) and tumour samples were flash-frozen, to allow pharmacokinetic analysis.  
 
 
Fig. 5.4 (A) Individual mouse body weights over the course of the olaparib and AZD6738 tolerance study (Pr169), expressed 
as a percentage of starting weight. The final weight measurements of mice that had to be killed due to weight loss (approached 
or surpassed the 85% limit) are marked with a red dot. (B) MIA PaCa-2 tumour volumes over the course of the olaparib and 




Fig. 5.5. UPLC-MS/MS was used to quantify the drug concentrations in flash-frozen plasma and tumour samples from the 
tolerance study, Pr169. Also shown for comparison are the PK data from the previous efficacy study, Pr149. Horizontal bars 
denote mean ± SEM. A one-way ANOVA analysis was performed with Tukey’s multiple comparisons tests, * indicates 
p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 
 
Tumour samples from mice which received 50 mg/kg olaparib had a mean olaparib 
concentration of 0.8 µM, while those that received 100 mg/kg olaparib had a mean of 1.7 µM 
(Fig. 5.5). These were higher concentrations than had been observed in the previous efficacy 
study that used 50 mg/kg olaparib (mean = 0.3 µM). Though unclear as to why 50 mg/kg dosing 
in Pr169 resulted in higher intra-tumour olaparib concentrations than previously, the fact that 
dosing at 100 mg/kg was resulting in olaparib concentrations above 1 µM was promising. Mean 
tumour AZD6738 concentrations from the mice that received 25 mg/kg and 50 mg/kg 
AZD6738 were 5.0 µM and 12.0 µM respectively, once again higher than in the previous study 
(mean = 1.8 µM) (Fig. 5.5). 
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To assess PARP target engagement by olaparib, the remaining half of the tumour samples from 
this study were processed into lysates for PAR ELISA analysis (as part of a collaboration, 
samples were run by Anna Staniszewska, AstraZeneca). 50 mg/kg and 100 mg/kg olaparib 
administration reduced PAR to concentrations below the limit of detection in most samples 
(PAR was undetectable in 6/8 of 50 mg/kg samples and 10/10 of 100 mg/kg samples tested), 
demonstrating that PARP activity was effectively inhibited (Fig. 5.6). 
 
 
Fig. 5.6 Protein lysates from frozen tumour samples were analysed using the PARP In Vivo Pharmacodynamic Assay II ELISA 
kit (Trevigen). Samples were run by Anna Staniszewska, AstraZeneca. 
 
I decided to take forward into an efficacy study the two strongest schedules in terms of dose 
level and/or dose regularity. These were schedule G (olaparib 100 mg/kg, OG, once daily, 5 
days on & 2 days off; AZD6738 50 mg/kg, OG, once daily, 5 days on & 2 days off) and 
schedule D (olaparib 50 mg/kg, OG, 7 days per week; AZD6738 50 mg/kg, OG, once daily, 5 
days on & 2 days off). Both share the same backbone of AZD6738, at a dose and regularity 
higher than the Pr149 study, but differ in their olaparib schedule - 100 mg/kg with a 2-day 






5.4. Olaparib and AZD6738 efficacy studies 
Since I planned to assess two different combinatorial dose-schedules, including each individual 
single agent arm as well as the combination arms would have required a lot of mice. In keeping 
with the principle of the 3Rs in animal research, I decided to first to compare tumour growth 
in the combination groups to a vehicle-treated group. If growth inhibition were observed 
compared to vehicle, I would later enrol mice into the single-agent arms.  
Following three weeks of treatment, neither of the combinatorial regimens demonstrated anti-
tumour effect in BALB/c nude mice with MIA-PaCa-2 xenografts (Fig. 5.7A). Furthermore, 
despite appearing tolerable in the pilot study, weight loss was observed in both drug 
combination groups (3/12 mice in the 50 mg/kg olaparib group and 4/12 mice in the 100 mg/kg 
olaparib group) (Fig. 5.7B).  
This highlights one of the major challenges in cancer research, which is that a drug-induced 
anti-cancer effect observed in vitro does not always translate in vivo. Though MIA PaCa-2 cells 
cultured as a mono-layer in 96 well plates were effectively growth inhibited by olaparib and 
AZD6738 (Fig. 5.1C), when the same cells were used as subcutaneous xenografts, oral dosing 
of the same drugs failed to inhibit tumour growth. This discrepancy between in vitro and in 
vivo results is discussed in more detail in section 5.5 (Discussion). 
Up to this point, all of the in vivo assessments of the AZ6738 and olaparib combination had 
been using human MIA PaCa-2 xenografts in immunocompromised mice. Though easy to use, 
relatively inexpensive and often reproducible, xenograft models have a number of 
disadvantages such as the lack of intra-tumoural heterogeneity, the absence of immune 
responses and the inability to recapitulate the tumour microenvironment (TME) (Richmond 
and Su, 2008). Alternatively, genetically engineered mouse models (GEMM), such as the KPC 
mouse, do successfully model these features of cancer (Gopinathan et al., 2015). The TME 
significantly modulates responses to anticancer agents (McMillin et al., 2013). Though tumour-
stroma interactions are typically associated with drug resistance, their compounding effects on 
the TME can in some instances confer drug sensitivity. For example, a hypoxic TME can 
increase the sensitivity of solid tumours to PARP inhibition (referred to as microenvironment-





Fig. 5.7 (A) Tumour volumes of MIA PaCa-2 xenografts in BALB/c Nude mice, over the course of the olaparib and AZD6738 
combination study. Data, mean ± SEM. 12 mice per group. The horizontal bars below the curves denote the olaparib dosing 
period for combination schedule D (gold - olaparib 50 mg/kg, OG, 7 days per week) and combination schedule G (pink - 
olaparib 100 mg/kg, OG, once daily, 5 days on & 2 days off). Both combination schedules shared the same AZD6738 dosing 
(AZD6738 50 mg/kg, OG, once daily, 1 hour after olaparib dose, 5 days on & 2 days off), as denoted by grey bars. (B) 
Individual mouse body weights over the course of the AZD6738 and olaparib efficacy study, expressed as a percentage of 
starting weight. The final weight measurements of mice that had to be killed due to weight loss (approached or surpassed the 





In addition, the presence of functioning immune cells in the TME will impact drug responses. 
This is not only relevant for immunotherapies, rather, the response of some preclinical tumour 
models to certain DDR-targeting therapies can be dependent on a functioning immune system. 
The Bakkenist group demonstrated that AZD6738 potentiated radiation in syngeneic colorectal 
CT26 tumours in BALB/c mice. The response was diminished upon cytotoxic T cell depletion 
using an anti-CD8 antibody, and also when the experiments were repeated in athymic nudes, 
suggesting that CD8+ T cells are required for maximal efficacy of AZD6738 plus radiation in 
CT26 tumours (Vendetti et al., 2018). As for the AZD6738 and olaparib combination in PDAC 
models, it remained unclear whether assessment in an immune-proficient GEMM that 
recapitulates the TME, such as the KPC mouse, would give a different result than the MIA 
PaCa-2 xenograft experiments.  
The next steps were coordinated with the Jen Morton group at the Beatson Institute in Glasgow, 
who are collaborators through the PRECISION-Panc consortium. They had plans to assess the 
AZD6738 and olaparib combination in KPC-ATM-flox mice. They had generated this model 
by crossing KPC mice with ATM flox mice, the ATM-flox under the PDX1 Cre promotor such 
that ATM is specifically deleted in the pancreas during development. It was agreed that the 
standard KPC colony in Cambridge could be used to contribute ATM-proficient mice. I was 
PIL holder for this time-to-clinical-endpoint (survival) study, with the aim to assess the efficacy 
of 50 mg/kg olaparib (dosed 5 days per week, 2 days rest, repeated each week until clinical 
endpoint reached) and 25 mg/kg AZD6738 (dosed 1 hour after olaparib, 5 days per week, 2 
days rest) in KPC mice (Fig. 5.8A). 
In the ATM-proficient KPC model, though the median survival in the combination arm was 
greater than the vehicle or single agent arms, there was no significant separation in the survival 
curves (Fig. 5.8B). Primary tumour diameters were measured by ultrasound one day prior to 
enrolment and on day 12 (for those mice that survived to day 12). In accordance with RECIST 
criteria, a change in long tumour diameter between -30% and +20% was defined as stable 
disease, while a change greater than +20% was classified as progressive disease. Stable disease 
was observed in 0/6 vehicle-treated mice, 0/8 olaparib-treated mice, 4/9 AZD6738-treated mice 
and 3/8 combination-treated mice (Fig. 5.8C). This suggests that ATR inhibition-alone may 
have induced modest tumour growth control, but this was not enhanced by combined AZD6783 




Fig. 5.8 (A) Dosing schedule for time-to-clinical-endpoint (survival) study in KPC mice (ATM-proficient), assessing efficacy 
of AZD6738 and olaparib. Mice were enrolled when tumour diameter of 3-6mm was confirmed by ultrasound (provided health 
suitable for minimum 12-day study). 50 mg/kg olaparib was dosed 5 days per week, 2 days rest, repeated each week until 
clinical endpoint reached. 25 mg/kg AZD6738 was dosed 1 hour after olaparib, 5 days per week, 2 days rest. 9 mice per group. 
Dosing was carried out by members of the CRUK-CI PGE core (B) Kaplan-Meier curve for KPC mice enrolled onto AZD6738 
and olaparib survival study. Clinical endpoint was determined by body condition score and other clinical signs, as assessed by 
the CRUK-CI PGE core. (C) Change in primary tumour long dimeter from day -1 to day 12, as assessed by ultrasound. The 
number of mice in each group that reached clinical endpoint before day 12 (and so could not have diameters plotted) is 
displayed above each group. In accordance with RECIST criteria, a change in long tumour diameter between -30% and +20% 
was defined as stable disease (SD), while a change greater than 20% was classified as progressive disease.  The number of 
mice in each group that had SD at day 12 is displayed beneath the x axis. 
 
In the KPC ATM-flox mice that were assessed in Glasgow (which, when untreated, show 
poorer survival than their KPC ATM+/+ counterparts (Fig. 5.9A)), the combination of olaparib 
and AZD6738 did extend survival compared to vehicle or olaparib-alone (Fig. 5.9B) and 




Fig. 5.9 (A) Survival comparison of untreated KPC ATM+/+, KPC ATMfl/+ and KPC ATMfl/fl mice. (B&C) The same treatment 
conditions assessed in Fig 5.8 were tested in KPC ATMfl/fl mice. Data courtesy of the Jen Morton group, Beatson Institute, 
Glasgow. 
 
In support of this, I found that ATM-knockout sensitised MIA PaCa-2 to the AZD6738 and 
olaparib combination in vitro (Fig. 5.10). In WT MIA PaCa-2 cells dosed for 72-hours, the 
olaparib GI50 was > 10 µM, while in ATM-KO cells the mean GI50 was calculated as 2 µM 
(Fig. 5.10A). Synergy with olaparib and AZD6738 in WT cells could only be achieved at high 
olaparib doses (3 to 10 µM - note that these were 3-day assays, rather than 5-day as presented 
in Fig. 5.1), whereas in KO cells the surface of synergy was broader, such that even sub-
micromolar doses of olaparib and AZD6738 showed synergy (Fig. 5.10B). This suggests that 






Fig. 5.10 (A) Olaparib dose-response curves of MIA PaCa-2 CRISPR clones. Assay duration was 72-hours. Each point 
represents the mean of three independent experiments ± SEM. (B) AZD6738 and olaparib combination in MIA PaCa-2 WT 
(top) and MIA PaCa-2 ATM-KO (clone B7, bottom). Assay duration was 72-hours. Left = growth as % of solvent control, 






In 2016, there were just two clinical trials assessing combined AZD6738 and olaparib therapy. 
At the time of writing, in Spring 2020, there are at least 15, thus demonstrating the significant 
interest in this combination. There is good rationale for dual targeting of ATR and PARP as 
previously explained. While olaparib monotherapy has primarily been explored in HR-
deficient populations, mechanistically one might predict the combination of AZD6738 and 
olaparib to even show benefit in HR-proficient tumour types. Two-thirds of PDAC patients 
harbour no somatic mutations in any DDR genes, thus an effective therapy for these patients 
would fulfil a serious unmet need. This formed the basis of my in vivo investigations of the 
combination, since the Jodrell group already had evidence that AZD6738 and olaparib 
synergistically inhibited cell growth in HR-proficient PDAC lines in vitro. Unfortunately, none 
of my assessments of AZD6738 and olaparib in HR-proficient tumour models demonstrated 
efficacy. The current preclinical data in PDAC, including those generated by fellow members 
of the PRECISION-Panc consortium, indicate that AZD6738 and olaparib will most likely 
benefit patients DDR-deficiencies such as ATM-loss or BRCA mutations (Jen Morton, 
personal communication). 
With hindsight, one of the strategic faults of this particular section was perhaps expecting the 
in vitro data of the AZD6738 and olaparib combination in MIA PaCa-2 to translate into in vivo 
efficacy with MIA PaCa-2 xenografts. The original AZD6738 and olaparib SRB assays 
presented in Figure 5.1C were performed before my arrival, using 5-days of continuous drug 
exposure. The majority of other SRB experiments presented in this thesis are 3-day assays – 
historically, olaparib combinations were performed differently because, in most PDAC cell 
lines, olaparib monotherapy has minimal effect on cell growth when treated for just 3 days, 
thus making it impossible to generate a dose response curve. The exposure of cancer cells 
growing as a monolayer in a 96-well plate to drug for 5-days continuously, cannot be mimicked 
in a mouse. Nor, indeed, can continuous exposure for 3-days, however one could argue that the 
longer the treatment the less physiologically relevant the results, since drugs such as AZD6738 
and olaparib are rapidly metabolised and excreted when administered in vivo. A prolonged 
exposure to olaparib would give more time for PARP trapping and in turn more chance for 
replication fork stalling, enabling the pronounced synergy with ATR inhibition that is seen in 
Figure 5.1C. When 3-day SRB assays were performed, synergy with olaparib and AZD6738 
could only be achieved at high olaparib doses (Fig. 5.10B), concentrations that were above the 
levels I detected in MIA PaCa-2 tumours from olaparib-dosed mice (Fig. 5.5). Though I had 
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evidence that dosing BALB/c nude mice with 50 mg/kg or 100 mg/kg olaparib could lead to 
inhibition of PARP activity in MIA PaCa-2 tumours (PAR ELISA in Fig. 5.6), I should have 
confirmed that this was actually leading to activation of the ATR/Chk1 pathway. Administering 
single agent olaparib at different dose levels and frequencies and then assessing P-Chk1-S345 
by IHC at various timepoints after dosing, would have given me more insight into the extent 
of olaparib dosing that is required before ATR/Chk1 pathway activation occurs in vivo, if at 
all. 
As previously mentioned, one of the limitations of using immunocompromised mice for 
combination studies is that the response of some preclinical tumour models to certain DDR-
targeting therapies can be dependent on a functioning immune system. In 2019, the Byers group 
showed that PARPi induced activation of innate immune pathways in small cell lung cancer 
models, specifically activation of the DNA sensor cyclic guanosine monophosphate (GMP)–
adenosine monophosphate (AMP) synthase (cGAS) (Sen et al., 2019). The second messenger 
of cGAS, cyclic GMP–AMP (cGAMP), binds and activates the adaptor protein STING, leading 
to TBK1-dependent phosphorylation of IRF3, which then translocates to the nucleus to trigger 
transcription of inflammatory genes such as interferons (Burdette et al., 2011; Sun et al., 2013). 
Byers and colleagues found that PARPi augmented anti–PD-L1–induced antitumor immunity 
in a cGAS-STING-dependent manner (Sen et al., 2019). Other groups have also demonstrated 
the ability for PARPi to induce interferon-mediated anti-tumour immune responses (Reisländer 
et al., 2019; Shen et al., 2019). Though cGAS-STING is an innate immune pathway, and so 
may be functional in immunocompromised mice, the potential downstream effects of STING 
activation on adaptive anticancer immunity would be absent in the Balb/C nude mice studies 
presented here in this chapter. As for the immune-competent KPC mouse studies, it would 
perhaps be interesting to repeat the experiments in Figures 5.8 & 5.9 but with an immune-
checkpoint blockade such as anti-PDL1 added, to see if olaparib, AZD6738 or the PARPi/ATRi 
combination augments anti–PD-L1–induced antitumor immunity in PDAC models, and 
whether this is cGAS-STING-dependent. Combining DDR-targeted therapy with 
immunotherapy does come with challenges, however, since agents such as olaparib and can 
induce leucopoenia and neutropoenia (Thomas et al., 2019; Zhou et al., 2017).  
My experiments using ATM-KO cells, in addition to the KPC-ATM-flox data from Glasgow, 
suggest that AZD6738 and olaparib may be efficacious in ATM-deficient PDAC. Given more 
time, I would perhaps have liked to have studied the effect of ATM-loss on the response of 
human PDAC cells to AZD6738 and olaparib in as much detail as I did with the ATRi/gem 
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combination (Chapter 4), for example asking whether replication catastrophe can be detected 
and if it is augmented in ATM-null cells. However, numerous trials for AZD6738 and olaparib 
are already either underway or in preparation (unlike ATRi/gem) and many will be assessing 
potential predictive biomarkers such as ATM-loss. Thus, ultimately, these clinical experiments 








CHAPTER SIX: Summary and Future Outlook 
In this dissertation, I have presented investigations into the therapeutic potential of combining 
the ATR inhibitor, AZD6738, with DNA-damaging drugs and DDR-targeted agents in 
preclinical models of PDAC. The data presented in Chapter 4 represent the most productive 
and informative section of the thesis, since the conclusions I made have immediately impacted 
the strategy of an ongoing clinical trial. By targeting ATM through multiple methods, my data 
in Chapter 4 indicated that complete loss of ATM function is necessary to sensitise PDAC cells 
to AZD6738 or the AZD6738 and gemcitabine combination. This has brought into question 
how best to assess ATM status clinically, including in the ATRiUM trial. 
As described previously, there have been past examples of trials failing to meet their primary 
endpoint when simply using “low” ATM expression as predictive biomarker. The potential 
importance of distinguishing ATM-null from ATM-low highlights the need for precise 
characterisation of cancer patient samples in the precision medicine era. Accordingly, 
ATRiUM is incorporating IHC assessment of baseline ATM as well as targeted sequencing of 
tumour DNA, with ATM included in the gene panel. In addition to a baseline biopsy during 
the screening period before treatment, patients enrolled into ATRiUM undergo a second biopsy 
on day 10, 2±1 hour after the second, weekly gemcitabine administration. Through techniques 
such as multiplex immunofluorescence or imaging-mass-cytometry, it may be possible to 
assess how certain DDR markers alter post-treatment and compare this to the gemcitabine and 
AZD6738 drug concentrations that will be measured by Mass-Spec Imaging. My 
immunoblotting experiments in Chapter 4 demonstrated that many of the post-translational 
modifications typically attributed to ATM activity, such as P-ATM-S1981, P-Chk2-T68 and 
P-KAP1-S824, may actually be DNA-PK-driven in the specific context of ATRi/gem-induced 
damage. These modifications should therefore be ruled out as reliable indicators of ATM 
activity or ATM status. However, my experiments suggested that ATRi/gem-induced P-
RAD50-S635 is more ATM-specific. Thus, one might predict that any fold-increase in this 
marker following ATRi/gem treatment may be dependent on the ATM status of that patient’s 
tumour. Thus, it will be interesting to correlate any changes in P-RAD50 expression with the 
IHC and NGS assessments of ATM that are to be made during the ATRiUM trial.  
As for AZD6738 and olaparib, the utility of ATM as a predictive biomarker in PDAC 
populations will be assessed in the planned PRECISION-Panc PRIMUS-004 trial 
(ISRCTN16004234). This multi-centre study, targeting patients with advanced pancreatic 
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cancer who have previously been treated with chemotherapy, is an umbrella trial that will offer 
a range of second-line treatment arms with extensive molecular profiling and evaluation of 
multiple candidate selection biomarkers. In alignment with the multi-modal approach to 
biomarker assessment, PRIMUS-004 will not only be assessing the mutation status of HR 
genes such as ATM, BRCA1, BRCA2 and PALB2, but will also incorporate transcriptomic 
profiling to evaluate signatures of HR-deficiency (Davies et al., 2017) and replication stress 
(Dreyer et al., 2018), as well as stratification on the basis of previous platinum response. 
In some ways, a PhD project is akin to a journey. Hypotheses can be formed at the beginnings 
of a project that may be partly answered by other groups later on in the PhD. A notable paper 
that was published during the middle of my project came from Perkhofer and colleagues in 
2017 (Perkhofer et al., 2017). Using a genetically engineered mouse model of PDAC with 
ATM deletion, they showed that ATM-deficiency sensitised in vitro PDAC cell lines to the 
ATR inhibitor, VE-822, and also to olaparib. In addition, using a subcutaneous transplantation 
model, they found that ATM-loss sensitised PDAC tumours to VE-822 and to the combination 
of VE-822 plus gemcitabine (Perkhofer et al., 2017). Differences from my work include: (1) 
the PDAC models they assessed were all p53 wild-type, whereas mine were all p53 mutant, (2) 
they were not using AZD6738 but VE-822 (also known as VX-970, M6620 or berzosertib), 
which, along with having different molecular properties to AZD6738, is typically administered 
to patients by intravenous injection rather than orally, (3) they did not study ATM-loss in any 
human PDAC models, only in mouse backgrounds, and (4)  they did not assess replication 
catastrophe. On the whole our conclusions agreed, in that ATM-loss did sensitise to ATRi/gem 
in our models and in theirs. My work was sufficiently different to theirs and interesting enough 
that it was accepted for publication in the British Journal of Cancer in 2020 (Dunlop et al., 
2020).  
Towards the end of my PhD, another notable observation made externally came from the lab 
of Kent Mouw. Their work suggested that ATM-loss confers greater sensitivity to ATR 
inhibition than PARP inhibition in prostate cancer models (Rafiei et al., 2020). Like myself, 
they used CRISPR/Cas9 to delete ATM and generate ATM-null human cancer cell line clones. 
In agreement with my studies, ATM-KO did sensitise to ATRi (VX-970) in the clones. 
However, results from their prostate cancer cell lines appeared to differ in two key ways to my 
results in PDAC. Firstly, they found that siRNA depletion of ATM did sensitise the human 
prostate line DU145 to ATRi (Rafiei et al., 2020), whereas I had found siATM to be ineffective 
at sensitising in MIA PaCa-2, PANC-1 or HPAF-II (Fig. 4.4). Secondly, in the Mouw lab, 
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ATM-KO did not significantly sensitise prostate cancer cells to olaparib (as expected, BRCA2-
deficiency did), whereas I had observed sensitisation effect with ATM-KO in MIA PaCa-2 
(Fig. 5.10A). This again highlights that synthetic lethalities are not always maintained across 
different genetic backgrounds. The suggestion that ATM-loss does not sensitise to PARPi in 
prostate models, but BRCA1/2-deficiency does, has interesting clinical implications, since the 
recent phase III PROfound trial assessing PARPi in prostate cancer patients had in fact 
compiled men with ATM mutations and men with BRCA1/2mutations together as one analysis 
cohort (de Bono et al., 2020). Progression-free survival was significantly longer in the olaparib 
group than in the control group among the cohort of patients with a BRCA1, BRCA2, or ATM 
mutation, however it remains to be seen if most of this signal was due to the selection of 
BRCA1/2-mutant patients and whether selecting for ATM-mutant patients actually added 
anything. The preclinical data from the Mouw lab, at least, suggests that an ATM-mutant 
prostate cancer patient may benefit more from ATRi therapy than from PARPi treatment. The 
notion that PARPi may not be the best option in an ATM-mutant prostate setting is indeed 
supported by preliminary results from the phase II TRITON2 trial investigating rucaparib in 
prostate cancer patients, which showed an overall response rate of 44% among men with 
BRCA1/2 loss or mutation versus a response rate of 0% for men with ATM loss or mutation 
(Abida et al., 2018). 
Another clinical study, which was published during the write-up period of this thesis and is 
particularly pertinent to my PhD project, is the trial NCT02595892. This was a phase II 
assessment of berzosertib (VX-970/M6620) plus gemcitabine in platinum-resistant high-grade 
serous ovarian cancer (HGSOC) (Konstantinopoulos et al., 2020). Patients were randomly 
assigned (1:1) to receive intravenous gemcitabine (1000 mg/m2) on day 1 and day 8, or 
gemcitabine plus intravenous berzosertib (210 mg/m2) on day 2 and day 9 of a 21-day cycle 
until disease progression or intolerable toxicity. The combination was tolerated and 
demonstrated benefit compared to gemcitabine monotherapy, with median progression-free 
survival of 22.9 weeks (17.9–72.0) in the gemcitabine plus berzosertib group (34 patients) and 
14.7 weeks (90% CI 9.7–36.7) in the gemcitabine-alone group (36 patients) (hazard ratio 0.57, 
90% CI 0.33–0.98; one-sided log-rank test p=0.044). This is the first randomised study of an 
ATRi therapy in any tumour type to be completed and the first suggesting a benefit of adding 
an ATR inhibitor to standard chemotherapy. Interestingly, their analysis indicated that there 
was a benefit of adding ATRi to gemcitabine in more heavily pre-treated patients (i.e. ≥ 2 
previous lines of therapy), suggesting that heavy pre-treatment with chemotherapy may 
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promote resistance mechanisms that render tumours more susceptible to ATR inhibition. These 
results in HGSOC are promising for other ATRi trials, including ATRiUM, which will assess 
the oral drug AZD6738 in solid tumours (with a PDAC expansion arm) and explore various 
dose-schedules. 
As for the combination of ATRi and PARPi, literature exploring this regimen has continued to 
emerge during my PhD, including very recently. In May 2020, colleagues at AstraZeneca 
published preclinical data showing that combined AZD6738 and olaparib potentiates genome 
instability and cell death in ATM-deficient cancer cells (Lloyd et al., 2020). Unlike myself, 
they did not investigate PDAC, but focused on models of hypopharyngeal carcinoma and lung 
adenocarcinoma. They showed that AZD6738 abrogated the olaparib-induced DNA damage 
G2-M checkpoint, independent of ATM status, but detected greater and earlier formation of 
micronuclei in ATM-null cells treated with the combination, plus earlier commitment to 
apoptosis in the absence of ATM. Their demonstration, in head & neck as well as lung cancer 
models, that ATM-loss sensitises to ATRi/PARPi supports my finding in ATM-KO PDAC 
cells, in addition to the KPC-ATM-flox data from Glasgow (Figs 5.9 & 5.10). 
Though myself and others have demonstrated that, across various cancer models, ATM-loss 
can sensitise to ATRi, further mechanistic investigation is still required to pin-down exactly 
how and why this sensitisation occurs. While I have shown augmented replication catastrophe 
in ATM-null cells treated with ATRi (with and without gemcitabine), the precise events that 
lead to this phenotype in the absence of ATM still need to be elucidated. We know that ATRi 
in cancer cells can lead to unscheduled firing of replication origins and breakage of stalled 
forks (Toledo et al., 2013), but the exact role of ATM in responding to these replication-
associated chromosomal aberrations remains to be fully explored. It seems logical that the 
DSBs that arise from these aberrations would be resolved by HR and this form of repair would 
be compromised in ATM-nulls cells. However, the Mouw lab found that ATM-loss, unlike 
BRCA2-loss, did not directly abolish HR function in prostate cancer cells (Rafiei et al., 2020). 
Furthermore, tumours with ATM alterations have been reported to lack the mutational 
signature of HR deficiency that is present in those with BRCA1/2 alterations (Quigley et al., 
2018), thus HR-defects may not explain the hypersensitivity of ATM-null cancer cells to ATRi. 
ATR and ATM do share many targets (as my investigations into the DDR signalling of PDAC 
cells treated with ATRi and ATMi (Fig4.9) further demonstrated), therefore pathway inter-
dependency may partly underly the synthetic lethality between ATR and ATM. Another 
consideration is the aforementioned ‘toxic end-joining’ which has  been shown to be important 
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in the hypersensitivity of ATM-null cells to replication-associated damage induced by olaparib 
(Balmus et al., 2019), but whether this is true for ATRi-induced damage remains to be seen. 
Going forward, biochemical methods that directly assess events occurring at the replication 
fork in ATRi-treated cells may improve our mechanistic understanding of how ATM-loss 
impacts the cellular response to ATRi. For example, the Cortez group have combined a method 
that purifies replication-associated proteins (iPOND - isolation of proteins on nascent DNA) 
with mass spectrometry to analyse the replisome at stalled forks in cells treated with 
hydroxyurea and ATRi (Dungrawala et al., 2015). They found that ATM and HR repair factors 
are the first recruited components to collapsed forks, whereas DNA-PK is instead recruited 
later to the damaged forks generated by new origin firing. This type of technique could perhaps 
be applied to ATM-WT versus ATM-KO cancer cells treated to with ATRi (or ATRi and 
gemcitabine) to further our understanding of how ATM-loss sensitises to ATRi. 
To sum up, though the regulatory approvals of PARP inhibitors in BRCA-mutant populations 
have been transformative in the way we think about DDR-targeting cancer therapies, no other 
synthetic lethal relationship has yet been exploited as successfully in the clinic. Whether the 
use of ATM as a predictive biomarker for ATR inhibitor-based therapies such as ATRi/gem 
succeeds as a clinical strategy, will depend upon well-designed trials that collect as much 
information as possible from every patient. Preclinical investigations, such as those presented 
here, are prerequisites for early phase trials like ATRiUM and PRIMUS-004, which will guide 










Abida, W., Bryce, A.H., Vogelzang, N.J., Amato, R.J., Percent, I., Shapiro, J.D., McDermott, R., 
Hussain, A., Patnaik, A., Petrylak, D., et al. (2018). Preliminary results from TRITON2: A phase II 
study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) 
associated with homologous recombination repair (HRR) gene alterations. Ann. Oncol. 29, viii272. 
Aguirre, A.J., Nowak, J.A., Camarda, N.D., Moffitt, R.A., Ghazani, A.A., Hazar-Rethinam, M., 
Raghavan, S., Kim, J., Brais, L.K., Ragon, D., et al. (2018). Real-time Genomic Characterization of 
Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 8, 1096–1111. 
Ai, L., Vo, Q.N., Zuo, C., Li, L., Ling, W., Suen, J.Y., Hanna, E., Brown, K.D., and Fan, C.-Y. 
(2004). Ataxia-Telangiectasia-Mutated (ATM) Gene in Head and Neck Squamous Cell Carcinoma: 
Promoter Hypermethylation with Clinical Correlation in 100 Cases. Cancer Epidemiol. Prev. 
Biomark. 13, 150–156. 
Álvarez-Quilón, A., Serrano-Benítez, A., Ariel Lieberman, J., Quintero, C., Sánchez-Gutiérrez, D., 
Escudero, L.M., and Cortés-Ledesma, F. (2014). ATM specifically mediates repair of double-strand 
breaks with blocked DNA ends. Nat. Commun. 5, 1–10. 
Arlander, S.J.H., Greene, B.T., Innes, C.L., and Paules, R.S. (2008). DNA-PK-Dependent G2 
Checkpoint Revealed Following Knockdown of ATM in Human Mammary Epithelial Cells. Cancer 
Res. 68, 89–97. 
Armstrong, S.A., Schultz, C.W., Azimi-Sadjadi, A., Brody, J.R., and Pishvaian, M.J. (2019). ATM 
Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. Mol. Cancer 
Ther. 18, 1899–1908. 
Ayars, M., Eshleman, J., and Goggins, M. (2017). Susceptibility of ATM-deficient pancreatic cancer 
cells to radiation. Cell Cycle 16, 991–998. 
Bailey, P., Chang, D.K., Nones, K., Johns, A.L., Patch, A.-M., Gingras, M.-C., Miller, D.K., Christ, 
A.N., Bruxner, T.J.C., Quinn, M.C., et al. (2016). Genomic analyses identify molecular subtypes of 
pancreatic cancer. Nature 531, 47–52. 
Bakkenist, C.J., and Kastan, M.B. (2003). DNA damage activates ATM through intermolecular 
autophosphorylation and dimer dissociation. Nature 421, 499–506. 
Bakr, A., Oing, C., Köcher, S., Borgmann, K., Dornreiter, I., Petersen, C., Dikomey, E., and Mansour, 
W.Y. (2015). Involvement of ATM in homologous recombination after end resection and RAD51 
nucleofilament formation. Nucleic Acids Res. 43, 3154–3166. 
Balmus, G., Pilger, D., Coates, J., Demir, M., Sczaniecka-Clift, M., Barros, A.C., Woods, M., Fu, B., 
Yang, F., Chen, E., et al. (2019). ATM orchestrates the DNA-damage response to counter toxic non-
homologous end-joining at broken replication forks. Nat. Commun. 10, 87. 
Bang, Y.-J., Im, S.-A., Lee, K.-W., Cho, J.Y., Song, E.-K., Lee, K.H., Kim, Y.H., Park, J.O., Chun, 
H.G., Zang, D.Y., et al. (2015). Randomized, Double-Blind Phase II Trial With Prospective 
Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus 
Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. J. Clin. Oncol. Off. J. Am. Soc. 
Clin. Oncol. 33, 3858–3865. 
Bang, Y.-J., Xu, R.-H., Chin, K., Lee, K.-W., Park, S.H., Rha, S.Y., Shen, L., Qin, S., Xu, N., Im, S.-
A., et al. (2017). Olaparib in combination with paclitaxel in patients with advanced gastric cancer who 
108 
 
have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, 
phase 3 trial. Lancet Oncol. 18, 1637–1651. 
Banin, S., Moyal, L., Shieh, S.-Y., Taya, Y., Anderson, C.W., Chessa, L., Smorodinsky, N.I., Prives, 
C., Reiss, Y., Shiloh, Y., et al. (1998). Enhanced Phosphorylation of p53 by ATM in Response to 
DNA Damage. Science 281, 1674–1677. 
Bapiro, T.E., Frese, K.K., Courtin, A., Bramhall, J.L., Madhu, B., Cook, N., Neesse, A., Griffiths, 
J.R., Tuveson, D.A., Jodrell, D.I., et al. (2014). Gemcitabine diphosphate choline is a major 
metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo. Br. J. Cancer 111, 
318–325. 
Baretić, D., Pollard, H.K., Fisher, D.I., Johnson, C.M., Santhanam, B., Truman, C.M., Kouba, T., 
Fersht, A.R., Phillips, C., and Williams, R.L. (2017). Structures of closed and open conformations of 
dimeric human ATM. Sci. Adv. 3, e1700933. 
Barlaam, B., and Pike, K. (2016). Identifying high quality, potent and selective inhibitors of ATM 
kinase: Discovery of AZD0156. Eur. J. Cancer 61, S118–S118. 
Bartek, J., Falck, J., and Lukas, J. (2001). Chk2 kinase — a busy messenger. Nat. Rev. Mol. Cell Biol. 
2, 877–886. 
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., 
Nesland, J.M., Lukas, C., et al. (2005). DNA damage response as a candidate anti-cancer barrier in 
early human tumorigenesis. Nature 434, 864–870. 
Bennett, C.B., Lewis, A.L., Baldwin, K.K., and Resnick, M.A. (1993). Lethality induced by a single 
site-specific double-strand break in a dispensable yeast plasmid. Proc. Natl. Acad. Sci. 90, 5613–
5617. 
Beucher, A., Birraux, J., Tchouandong, L., Barton, O., Shibata, A., Conrad, S., Goodarzi, A.A., 
Krempler, A., Jeggo, P.A., and Löbrich, M. (2009). ATM and Artemis promote homologous 
recombination of radiation-induced DNA double-strand breaks in G2. EMBO J. 28, 3413–3427. 
Biankin, A.V., Waddell, N., Kassahn, K.S., Gingras, M.-C., Muthuswamy, L.B., Johns, A.L., Miller, 
D.K., Wilson, P.J., Patch, A.-M., Wu, J., et al. (2012). Pancreatic cancer genomes reveal aberrations 
in axon guidance pathway genes. Nature 491, 399–405. 
Blier, P.R., Griffith, A.J., Craft, J., and Hardin, J.A. (1993). Binding of Ku protein to DNA. 
Measurement of affinity for ends and demonstration of binding to nicks. J. Biol. Chem. 268, 7594–
7601. 
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K.N., Sartor, O., Agarwal, N., 
Olmos, D., et al. (2020). Olaparib for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. 
Med. 382, 2091–2102. 
Boshuizen, J., and Peeper, D.S. (2020). Rational Cancer Treatment Combinations: An Urgent Clinical 
Need. Mol. Cell 78, 1002–1018. 
Bowman, K.J., Newell, D.R., Calvert, A.H., and Curtin, N.J. (2001). Differential effects of the poly 
(ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity 
in L1210 cells in vitro. Br. J. Cancer 84, 106–112. 
Bradbury, A., Hall, S., Curtin, N., and Drew, Y. (2019). Targeting ATR as Cancer Therapy: A new 
era for synthetic lethality and synergistic combinations? Pharmacol. Ther. 107450. 
109 
 
Brand, R., Borazanci, E., Speare, V., Dudley, B., Karloski, E., Peters, M.L.B., Stobie, L., Bahary, N., 
Zeh, H., Zureikat, A., et al. (2018). Prospective study of germline genetic testing in incident cases of 
pancreatic adenocarcinoma. Cancer 124, 3520–3527. 
Brown, E.J., and Baltimore, D. (2000). ATR disruption leads to chromosomal fragmentation and early 
embryonic lethality. Genes Dev. 14, 397–402. 
Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., Lopez, E., Kyle, S., Meuth, M., 
Curtin, N.J., and Helleday, T. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of 
poly(ADP-ribose) polymerase. Nature 434, 913–917. 
Buisson, R., Boisvert, J.L., Benes, C.H., and Zou, L. (2015). Distinct but Concerted Roles of ATR, 
DNA-PK, and Chk1 in Countering Replication Stress during S Phase. Mol. Cell 59, 1011–1024. 
Bukhari, A.B., Lewis, C.W., Pearce, J.J., Luong, D., Chan, G.K., and Gamper, A.M. (2019). 
Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses 
metastasis. J. Clin. Invest. 129, 1329–1344. 
Burdette, D.L., Monroe, K.M., Sotelo-Troha, K., Iwig, J.S., Eckert, B., Hyodo, M., Hayakawa, Y., 
and Vance, R.E. (2011). STING is a direct innate immune sensor of cyclic di-GMP. Nature 478, 515–
518. 
Burris, H.A., Moore, M.J., Andersen, J., Green, M.R., Rothenberg, M.L., Modiano, M.R., Cripps, 
M.C., Portenoy, R.K., Storniolo, A.M., Tarassoff, P., et al. (1997). Improvements in survival and 
clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a 
randomized trial. J. Clin. Oncol. 15, 2403–2413. 
Byun, T.S., Pacek, M., Yee, M., Walter, J.C., and Cimprich, K.A. (2005). Functional uncoupling of 
MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint. Genes Dev. 
19, 1040–1052. 
Canman, C.E., Lim, D.-S., Cimprich, K.A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, 
M.B., and Siliciano, J.D. (1998). Activation of the ATM Kinase by Ionizing Radiation and 
Phosphorylation of p53. Science 281, 1677–1679. 
Cao, D., Ashfaq, R., Goggins, M.G., Hruban, R.H., Kern, S.E., and Iacobuzio-Donahue, C.A. (2008). 
Differential expression of multiple genes in association with MADH4/DPC4/SMAD4 inactivation in 
pancreatic cancer. Int. J. Clin. Exp. Pathol. 1, 510–517. 
Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., 
Heuer, M.L., Larsson, E., et al. (2012). The cBio cancer genomics portal: an open platform for 
exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404. 
Chan, N., Pires, I.M., Bencokova, Z., Coackley, C., Luoto, K.R., Bhogal, N., Lakshman, M., 
Gottipati, P., Oliver, F.J., Helleday, T., et al. (2010). Contextual Synthetic Lethality of Cancer Cell 
Kill Based on the Tumor Microenvironment. Cancer Res. 70, 8045–8054. 
Charrier, J.-D., Durrant, S.J., Golec, J.M.C., Kay, D.P., Knegtel, R.M.A., MacCormick, S., 
Mortimore, M., O’Donnell, M.E., Pinder, J.L., Reaper, P.M., et al. (2011). Discovery of potent and 
selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as 
potential anticancer agents. J. Med. Chem. 54, 2320–2330. 
Choi, M., Kipps, T., and Kurzrock, R. (2016). ATM Mutations in Cancer: Therapeutic Implications. 
Mol. Cancer Ther. 15, 1781–1791. 
110 
 
Chou, T.-C. (2010). Drug combination studies and their synergy quantification using the Chou-
Talalay method. Cancer Res. 70, 440–446. 
Ciszewski, W.M., Tavecchio, M., Dastych, J., and Curtin, N.J. (2014). DNA-PK inhibition by 
NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. Breast Cancer Res. Treat. 
143, 47–55. 
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, 
J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011). FOLFIRINOX versus gemcitabine 
for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825. 
Couch, F.B., Bansbach, C.E., Driscoll, R., Luzwick, J.W., Glick, G.G., Bétous, R., Carroll, C.M., 
Jung, S.Y., Qin, J., Cimprich, K.A., et al. (2013). ATR phosphorylates SMARCAL1 to prevent 
replication fork collapse. Genes Dev. 27, 1610–1623. 
Coussy, F., El-Botty, R., Château-Joubert, S., Dahmani, A., Montaudon, E., Leboucher, S., Morisset, 
L., Painsec, P., Sourd, L., Huguet, L., et al. (2020). BRCAness, SLFN11, and RB1 loss predict 
response to topoisomerase I inhibitors in triple-negative breast cancers. Sci. Transl. Med. 12. 
Cuadrado, M., Martinez-Pastor, B., Murga, M., Toledo, L.I., Gutierrez-Martinez, P., Lopez, E., and 
Fernandez-Capetillo, O. (2006). ATM regulates ATR chromatin loading in response to DNA double-
strand breaks. J. Exp. Med. 203, 297–303. 
Dai, J.L., Turnacioglu, K.K., Schutte, M., Sugar, A.Y., and Kern, S.E. (1998). Dpc4 transcriptional 
activation and dysfunction in cancer cells. Cancer Res. 58, 4592–4597. 
Damstrup, L., Zimmerman, A., Sirrenberg, C., Zenke, F., and Vassilev, L. (2016). M3814, a DNA-
dependent Protein Kinase Inhibitor (DNA-PKi), Potentiates the Effect of Ionizing Radiation (IR) in 
Xenotransplanted Tumors in Nude Mice. Int. J. Radiat. Oncol. 94, 940–941. 
Davies, H., Glodzik, D., Morganella, S., Yates, L.R., Staaf, J., Zou, X., Ramakrishna, M., Martin, S., 
Boyault, S., Sieuwerts, A.M., et al. (2017). HRDetect is a predictor of BRCA1 and BRCA2 deficiency 
based on mutational signatures. Nat. Med. 23, 517–525. 
Davies, S.L., North, P.S., and Hickson, I.D. (2007). Role for BLM in replication-fork restart and 
suppression of origin firing after replicative stress. Nat. Struct. Mol. Biol. 14, 677–679. 
Denko, N.C., Giaccia, A.J., Stringer, J.R., and Stambrook, P.J. (1994). The human Ha-ras oncogene 
induces genomic instability in murine fibroblasts within one cell cycle. Proc. Natl. Acad. Sci. 91, 
5124–5128. 
Derenzini, E., Agostinelli, C., Imbrogno, E., Iacobucci, I., Casadei, B., Brighenti, E., Righi, S., 
Fuligni, F., Ghelli Luserna Di Rorà, A., Ferrari, A., et al. (2015). Constitutive activation of the DNA 
damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. Oncotarget 
6, 6553–6569. 
Dhoonmoon, A., Schleicher, E.M., Clements, K.E., Nicolae, C.M., and Moldovan, G.-L. (2020). 
Genome-wide CRISPR synthetic lethality screen identifies a role for the ADP-ribosyltransferase 
PARP14 in DNA replication dynamics controlled by ATR. Nucleic Acids Res. 48, 7252–7264. 
Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., Schurra, C., Garre’, 
M., Giovanni Nuciforo, P., Bensimon, A., et al. (2006). Oncogene-induced senescence is a DNA 
damage response triggered by DNA hyper-replication. Nature 444, 638–642. 
111 
 
Di Veroli, G.Y., Fornari, C., Wang, D., Mollard, S., Bramhall, J.L., Richards, F.M., and Jodrell, D.I. 
(2016). Combenefit: an interactive platform for the analysis and visualization of drug combinations. 
Bioinforma. Oxf. Engl. 32, 2866–2868. 
Di Virgilio, M., Ying, C.Y., and Gautier, J. (2009). PIKK-dependent phosphorylation of Mre11 
induces MRN complex inactivation by disassembly from chromatin. DNA Repair 8, 1311–1320. 
Ditch, S., and Paull, T.T. (2012). The ATM protein kinase and cellular redox signaling: beyond the 
DNA damage response. Trends Biochem. Sci. 37, 15–22. 
Dorado, M.R.-M., Gómez, L.M.M., Sánchez, D.A., Arenas, S.P., Praena-Fernández, J.M., Martín, 
J.J.B., López, F.F., Bravo, M.Á.G., Relat, J.M., and Ruiz, J.P. (2018). Translational pancreatic cancer 
research: A comparative study on patient-derived xenograft models. World J. Gastroenterol. 24, 794–
809. 
Doyle, L.A., and Ross, D.D. (2003). Multidrug resistance mediated by the breast cancer resistance 
protein BCRP (ABCG2). Oncogene 22, 7340–7358. 
Dréan, A., Lord, C.J., and Ashworth, A. (2016). PARP inhibitor combination therapy. Crit. Rev. 
Oncol. Hematol. 108, 73–85. 
Dreyer, S.B., Paulus-Hock, V., Lampraki, E., Upstill-Goddard, R., Caligiuri, G., Brunton, H., Serrels, 
B., Cunningham, R., Jamieson, N.B., McKay, C.J., et al. (2018). AB001. S001. Defining DDR 
deficiency and replication stress in pancreatic cancer. Ann. Pancreat. Cancer 1. 
Dreyer, S.B., Jamieson, N.B., Cooke, S.L., Valle, J.W., McKay, C.J., Biankin, A.V., and Chang, D.K. 
(2020). PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic 
Cancer. Clin. Oncol. 32, 1–4. 
Dungrawala, H., Rose, K.L., Bhat, K.P., Mohni, K.N., Glick, G.G., Couch, F.B., and Cortez, D. 
(2015). The replication checkpoint prevents two types of fork collapse without regulating replisome 
stability. Mol. Cell 59, 998–1010. 
Dunlop, C.R., Wallez, Y., Johnson, T.I., Bernaldo de Quirós Fernández, S., Durant, S.T., Cadogan, 
E.B., Lau, A., Richards, F.M., and Jodrell, D.I. (2020). Complete loss of ATM function augments 
replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models. Br. J. 
Cancer 1–13. 
Durant, S.T., Zheng, L., Wang, Y., Chen, K., Zhang, L., Zhang, T., Yang, Z., Riches, L., Trinidad, 
A.G., Fok, J.H.L., et al. (2018). The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes 
and improves survival of preclinical brain tumor models. Sci. Adv. 4, eaat1719. 
Durkacz, B.W., Omidiji, O., Gray, D.A., and Shall, S. (1980). (ADP-ribose) n participates in DNA 
excision repair. Nature 283, 593–596. 
Dylgjeri, E., McNair, C., Goodwin, J.F., Raymon, H.K., McCue, P.A., Shafi, A.A., Leiby, B.E., 
Leeuw, R. de, Kothari, V., McCann, J.J., et al. (2019). Pleiotropic Impact of DNA-PK in Cancer and 
Implications for Therapeutic Strategies. Clin. Cancer Res. 
El-Khamisy, S.F., Masutani, M., Suzuki, H., and Caldecott, K.W. (2003). A requirement for PARP-1 
for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids 
Res. 31, 5526–5533. 
Elliott, S.L., Crawford, C., Mulligan, E., Summerfield, G., Newton, P., Wallis, J., Mainou-Fowler, T., 
Evans, P., Bedwell, C., Durkacz, B.W., et al. (2011). Mitoxantrone in combination with an inhibitor 
112 
 
of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic 
leukaemia. Br. J. Haematol. 152, 61–71. 
Erber, J., Steiner, J.D., Isensee, J., Lobbes, L.A., Toschka, A., Beleggia, F., Schmitt, A., Kaiser, 
R.W.J., Siedek, F., Persigehl, T., et al. (2019). Dual inhibition of GLUT1 and the ATR/CHK1 kinase 
axis displays synergistic cytotoxicity in KRAS-mutant cancer cells. Cancer Res. 
Evert, M., Frau, M., Tomasi, M.L., Latte, G., Simile, M.M., Seddaiu, M.A., Zimmermann, A., Ladu, 
S., Staniscia, T., Brozzetti, S., et al. (2013). Deregulation of DNA-dependent protein kinase catalytic 
subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value. 
Br. J. Cancer 109, 2654–2664. 
Falck, J., Coates, J., and Jackson, S.P. (2005). Conserved modes of recruitment of ATM, ATR and 
DNA-PKcs to sites of DNA damage. Nature 434, 605–611. 
Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N.J., Johnson, D.A., Richardson, T.B., Santarosa, M., 
Dillon, K.J., Hickson, I., Knights, C., et al. (2005). Targeting the DNA repair defect in BRCA mutant 
cells as a therapeutic strategy. Nature 434, 917–921. 
Fedier, A., Schlamminger, M., Schwarz, V.A., Haller, U., Howell, S.B., and Fink, D. (2003). Loss of 
atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. Ann. Oncol. 14, 938–
945. 
Feig, C., Jones, J.O., Kraman, M., Wells, R.J.B., Deonarine, A., Chan, D.S., Connell, C.M., Roberts, 
E.W., Zhao, Q., Caballero, O.L., et al. (2013). Targeting CXCL12 from FAP-expressing carcinoma-
associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. 
Acad. Sci. 110, 20212–20217. 
Fisher, A.E.O., Hochegger, H., Takeda, S., and Caldecott, K.W. (2007). Poly(ADP-Ribose) 
Polymerase 1 Accelerates Single-Strand Break Repair in Concert with Poly(ADP-Ribose) 
Glycohydrolase. Mol. Cell. Biol. 27, 5597–5605. 
Flint, T.R., Janowitz, T., Connell, C.M., Roberts, E.W., Denton, A.E., Coll, A.P., Jodrell, D.I., and 
Fearon, D.T. (2016). Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor 
Immunity. Cell Metab. 24, 672–684. 
Fok, J.H.L., Ramos-Montoya, A., Vazquez-Chantada, M., Wijnhoven, P.W.G., Follia, V., James, N., 
Farrington, P.M., Karmokar, A., Willis, S.E., Cairns, J., et al. (2019). AZD7648 is a potent and 
selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat. 
Commun. 10, 1–15. 
Fokas, E., Prevo, R., Pollard, J.R., Reaper, P.M., Charlton, P.A., Cornelissen, B., Vallis, K.A., 
Hammond, E.M., Olcina, M.M., Gillies McKenna, W., et al. (2012). Targeting ATR in vivo using the 
novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death 
Dis. 3, e441. 
Foote, K.M., Blades, K., Cronin, A., Fillery, S., Guichard, S.S., Hassall, L., Hickson, I., Jacq, X., 
Jewsbury, P.J., McGuire, T.M., et al. (2013). Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-
(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of 
ATR protein kinase with monotherapy in vivo antitumor activity. J. Med. Chem. 56, 2125–2138. 
Foote, K.M., Nissink, J.W.M., McGuire, T., Turner, P., Guichard, S., Yates, J.W.T., Lau, A., Blades, 
K., Heathcote, D., Odedra, R., et al. (2018). Discovery and Characterization of AZD6738, a Potent 
Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an 
Anticancer Agent. J. Med. Chem. 61, 9889–9907. 
113 
 
Forbes, S.A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C.G., Ward, S., 
Dawson, E., Ponting, L., et al. (2017). COSMIC: somatic cancer genetics at high-resolution. Nucleic 
Acids Res. 45, D777–D783. 
Frese, K.K., Neesse, A., Cook, N., Bapiro, T.E., Lolkema, M.P., Jodrell, D.I., and Tuveson, D.A. 
(2012). nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a 
mouse model of pancreatic cancer. Cancer Discov. 2, 260–269. 
Gatei, M., Jakob, B., Chen, P., Kijas, A.W., Becherel, O.J., Gueven, N., Birrell, G., Lee, J.-H., Paull, 
T.T., Lerenthal, Y., et al. (2011). ATM protein-dependent phosphorylation of Rad50 protein regulates 
DNA repair and cell cycle control. J. Biol. Chem. 286, 31542–31556. 
Gibson, B.A., and Kraus, W.L. (2012). New insights into the molecular and cellular functions of 
poly(ADP-ribose) and PARPs. Nat. Rev. Mol. Cell Biol. 13, 411–424. 
Gilad, O., Nabet, B.Y., Ragland, R.L., Schoppy, D.W., Smith, K.D., Durham, A.C., and Brown, E.J. 
(2010). Combining ATR suppression with oncogenic Ras synergistically increases genomic 
instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res. 
70, 9693–9702. 
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M.J., Park, J.-O., Hochhauser, 
D., Arnold, D., Oh, D.-Y., et al. (2019). Maintenance Olaparib for Germline BRCA-Mutated 
Metastatic Pancreatic Cancer. N. Engl. J. Med. 381, 317–327. 
Goldberg, F.W., Finlay, M.R.V., Ting, A.K.T., Beattie, D., Lamont, G.M., Fallan, C., Wrigley, G.L., 
Schimpl, M., Howard, M.R., Williamson, B., et al. (2019). The Discovery of 7-Methyl-2-[(7-
methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-
8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor. J. 
Med. Chem. 
Goodarzi, A.A., Noon, A.T., Deckbar, D., Ziv, Y., Shiloh, Y., Löbrich, M., and Jeggo, P.A. (2008). 
ATM signaling facilitates repair of DNA double-strand breaks associated with heterochromatin. Mol. 
Cell 31, 167–177. 
Gopinathan, A., Morton, J.P., Jodrell, D.I., and Sansom, O.J. (2015). GEMMs as preclinical models 
for testing pancreatic cancer therapies. Dis. Model. Mech. 8, 1185–1200. 
Gorgoulis, V.G., Vassiliou, L.-V.F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., 
Venere, M., DiTullio, R.A., Kastrinakis, N.G., Levy, B., et al. (2005). Activation of the DNA damage 
checkpoint and genomic instability in human precancerous lesions. Nature 434, 907–913. 
Graham, J., Muhsin, M., and Kirkpatrick, P. (2004). Oxaliplatin. Nat. Rev. Drug Discov. 3, 11–12. 
Griffin, J.F., Poruk, K.E., and Wolfgang, C.L. (2015). Pancreatic cancer surgery: past, present, and 
future. Chin. J. Cancer Res. Chung-Kuo Yen Cheng Yen Chiu 27, 332–348. 
Griffin, R.J., Pemberton, L.C., Rhodes, D., Bleasdale, C., Bowman, K., Calvert, A.H., Curtin, N.J., 
Durkacz, B.W., Newell, D.R., and Porteous, J.K. (1995). Novel potent inhibitors of the DNA repair 
enzyme poly(ADP-ribose)polymerase (PARP). Anticancer. Drug Des. 10, 507–514. 
Grignani, G., Merlini, A., Sangiolo, D., D’Ambrosio, L., and Pignochino, Y. (2020). Delving into 
PARP inhibition from bench to bedside and back. Pharmacol. Ther. 206, 107446. 
Gullo, L., Tomassetti, P., Migliori, M., Casadei, R., and Marrano, D. (2001). Do early symptoms of 
pancreatic cancer exist that can allow an earlier diagnosis? Pancreas 22, 210–213. 
114 
 
Guo, Z., Kumagai, A., Wang, S.X., and Dunphy, W.G. (2000). Requirement for Atr in 
phosphorylation of Chk1 and cell cycle regulation in response to DNA replication blocks and UV-
damaged DNA in Xenopus egg extracts. Genes Dev. 14, 2745–2756. 
Hagmann, W., Jesnowski, R., and Löhr, J.M. (2010). Interdependence of gemcitabine treatment, 
transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia N. Y. N 12, 
740–747. 
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of Cancer: The Next Generation. Cell 144, 646–
674. 
Härtlova, A., Erttmann, S.F., Raffi, F.A., Schmalz, A.M., Resch, U., Anugula, S., Lienenklaus, S., 
Nilsson, L.M., Kröger, A., Nilsson, J.A., et al. (2015). DNA damage primes the type I interferon 
system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity 
42, 332–343. 
Helleday, T. (2011). The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing 
up the misunderstandings. Mol. Oncol. 5, 387–393. 
Herrero, A.B., San Miguel, J., and Gutierrez, N.C. (2015). Deregulation of DNA double-strand break 
repair in multiple myeloma: implications for genome stability. PloS One 10, e0121581. 
Hickson, I., Pike, K.G., and Durant, S.T. (2018). Targeting ATM for Cancer Therapy: Prospects for 
Drugging ATM. In Targeting the DNA Damage Response for Anti-Cancer Therapy, J. Pollard, and N. 
Curtin, eds. (Cham: Springer International Publishing), pp. 185–208. 
Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hruban, R.H., Rustgi, A.K., 
Chang, S., and Tuveson, D.A. (2005). Trp53R172H and KrasG12D cooperate to promote 
chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 
7, 469–483. 
Hocke, S., Guo, Y., Job, A., Orth, M., Ziesch, A., Lauber, K., De Toni, E.N., Gress, T.M., Herbst, A., 
Göke, B., et al. (2016). A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic 
approach for POLD1-deficient cancers. Oncotarget 7, 7080–7095. 
Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. (1991). p53 mutations in human 
cancers. Science 253, 49–53. 
Hosoi, Y., Watanabe, T., Nakagawa, K., Matsumoto, Y., Enomoto, A., Morita, A., Nagawa, H., and 
Suzuki, N. (2004). Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal 
cancer. Int. J. Oncol. 25, 461–468. 
Hruban, R.H., Goggins, M., Parsons, J., and Kern, S.E. (2000). Progression Model for Pancreatic 
Cancer. Clin. Cancer Res. 6, 2969–2972. 
Huang, P., Chubb, S., Hertel, L.W., Grindey, G.B., and Plunkett, W. (1991). Action of 2’,2’-
difluorodeoxycytidine on DNA synthesis. Cancer Res. 51, 6110–6117. 
Huehls, A.M., Wagner, J.M., Huntoon, C.J., and Karnitz, L.M. (2012). Identification of DNA repair 
pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase 
inhibitor in a novel drug combination. Mol. Pharmacol. 82, 767–776. 
Huntoon, C.J., Flatten, K.S., Wahner Hendrickson, A.E., Huehls, A.M., Sutor, S.L., Kaufmann, S.H., 
and Karnitz, L.M. (2013). ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy 
independent of BRCA status. Cancer Res. 73, 3683–3691. 
115 
 
Hustedt, N., Álvarez-Quilón, A., McEwan, A., Yuan, J.Y., Cho, T., Koob, L., Hart, T., and Durocher, 
D. (2019). A consensus set of genetic vulnerabilities to ATR inhibition. Open Biol. 9, 190156. 
Jackson, S.P., and Bartek, J. (2009). The DNA-damage response in human biology and disease. 
Nature 461, 1071–1078. 
Jacobetz, M.A., Chan, D.S., Neesse, A., Bapiro, T.E., Cook, N., Frese, K.K., Feig, C., Nakagawa, T., 
Caldwell, M.E., Zecchini, H.I., et al. (2013). Hyaluronan impairs vascular function and drug delivery 
in a mouse model of pancreatic cancer. Gut 62, 112–120. 
Jazayeri, A., Falck, J., Lukas, C., Bartek, J., Smith, G.C.M., Lukas, J., and Jackson, S.P. (2006). 
ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat. 
Cell Biol. 8, 37–45. 
Jeggo, P.A., and Downs, J.A. (2014). Roles of chromatin remodellers in DNA double strand break 
repair. Exp. Cell Res. 329, 69–77. 
Jiang, H., Reinhardt, H.C., Bartkova, J., Tommiska, J., Blomqvist, C., Nevanlinna, H., Bartek, J., 
Yaffe, M.B., and Hemann, M.T. (2009). The combined status of ATM and p53 link tumor 
development with therapeutic response. Genes Dev. 23, 1895–1909. 
Jin, J., Fang, H., Yang, F., Ji, W., Guan, N., Sun, Z., Shi, Y., Zhou, G., and Guan, X. (2018). 
Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast 
Cancer. Neoplasia N. Y. N 20, 478–488. 
Job, A., Schmitt, L.-M., von Wenserski, L., Lankat-Buttgereit, B., Gress, T.M., Buchholz, M., and 
Gallmeier, E. (2018). Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 
Inhibitors. Neoplasia N. Y. N 20, 1135–1143. 
Jones, G.N., Rooney, C., Griffin, N., Roudier, M., Young, L.A., Garcia-Trinidad, A., Hughes, G.D., 
Whiteaker, J.R., Wilson, Z., Odedra, R., et al. (2018). pRAD50: a novel and clinically applicable 
pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry 
and immunohistochemistry. Br. J. Cancer 1. 
Jossé, R., Martin, S.E., Guha, R., Ormanoglu, P., Pfister, T.D., Reaper, P.M., Barnes, C.S., Jones, J., 
Charlton, P., Pollard, J.R., et al. (2014). ATR inhibitors VE-821 and VX-970 sensitize cancer cells to 
topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. 
Cancer Res. 74, 6968–6979. 
Kalser, M.H., Barkin, J., and Macintyre, J.M. (1985). Pancreatic cancer. Assessment of prognosis by 
clinical presentation. Cancer 56, 397–402. 
Kamphues, C., Bova, R., Bahra, M., Klauschen, F., Muckenhuber, A., Sinn, B.V., Warth, A., 
Goeppert, B., Endris, V., Neuhaus, P., et al. (2015). Ataxia-telangiectasia-mutated protein kinase 
levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a 
strong indicator of poor survival. Pancreas 44, 296–301. 
Kanda, M., Matthaei, H., Wu, J., Hong, S.-M., Yu, J., Borges, M., Hruban, R.H., Maitra, A., Kinzler, 
K., Vogelstein, B., et al. (2012). Presence of somatic mutations in most early-stage pancreatic 
intraepithelial neoplasia. Gastroenterology 142, 730-733.e9. 
Karamitopoulou, E. (2019). Tumour microenvironment of pancreatic cancer: immune landscape is 
dictated by molecular and histopathological features. Br. J. Cancer 121, 5–14. 
116 
 
Kastan, M.B., Zhan, Q., el-Deiry, W.S., Carrier, F., Jacks, T., Walsh, W.V., Plunkett, B.S., 
Vogelstein, B., and Fornace, A.J. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 
and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587–597. 
Kern, S.E., Pietenpol, J.A., Thiagalingam, S., Seymour, A., Kinzler, K.W., and Vogelstein, B. (1992). 
Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827–830. 
Kim, H., Saka, B., Knight, S., Borges, M., Childs, E., Klein, A., Wolfgang, C., Herman, J., Adsay, 
V.N., Hruban, R.H., et al. (2014). Having pancreatic cancer with tumoral loss of ATM and normal 
TP53 protein expression is associated with a poorer prognosis. Clin. Cancer Res. Off. J. Am. Assoc. 
Cancer Res. 20, 1865–1872. 
Kirshner, M., Rathavs, M., Nizan, A., Essers, J., Kanaar, R., Shiloh, Y., and Barzilai, A. (2009). 
Analysis of the relationships between ATM and the Rad54 paralogs involved in homologous 
recombination repair. DNA Repair 8, 253–261. 
Köcher, S., Rieckmann, T., Rohaly, G., Mansour, W.Y., Dikomey, E., Dornreiter, I., and Dahm-
Daphi, J. (2012). Radiation-induced double-strand breaks require ATM but not Artemis for 
homologous recombination during S-phase. Nucleic Acids Res. 40, 8336–8347. 
König, J., Hartel, M., Nies, A.T., Martignoni, M.E., Guo, J., Büchler, M.W., Friess, H., and Keppler, 
D. (2005). Expression and localization of human multidrug resistance protein (ABCC) family 
members in pancreatic carcinoma. Int. J. Cancer 115, 359–367. 
Konstantinopoulos, P.A., Cheng, S.-C., Wahner Hendrickson, A.E., Penson, R.T., Schumer, S.T., 
Doyle, L.A., Lee, E.K., Kohn, E.C., Duska, L.R., Crispens, M.A., et al. (2020). Berzosertib plus 
gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a 
multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 
Koorstra, J.-B.M., Hong, S.-M., Shi, C., Meeker, A.K., Ryu, J.K., Offerhaus, G.J.A., Goggins, M.G., 
Hruban, R.H., and Maitra, A. (2009). Widespread activation of the DNA damage response in human 
pancreatic intraepithelial neoplasia. Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc 22, 1439–1445. 
Krajewska, M., Fehrmann, R.S.N., Schoonen, P.M., Labib, S., de Vries, E.G.E., Franke, L., and van 
Vugt, M.A.T.M. (2015). ATR inhibition preferentially targets homologous recombination-deficient 
tumor cells. Oncogene 34, 3474–3481. 
Krebs, M.G., Lopez, J., El-Khoueiry, A., Bang, Y.-J., Postel-Vinay, S., Abida, W., Carter, L., Xu, W., 
Im, S.-A., Pierce, A., et al. (2018). Abstract CT026: Phase I study of AZD6738, an inhibitor of ataxia 
telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with 
advanced solid cancers. Cancer Res. 78, CT026–CT026. 
Krejci, L., Altmannova, V., Spirek, M., and Zhao, X. (2012). Homologous recombination and its 
regulation. Nucleic Acids Res. 40, 5795–5818. 
Kumagai, A., Lee, J., Yoo, H.Y., and Dunphy, W.G. (2006). TopBP1 activates the ATR-ATRIP 
complex. Cell 124, 943–955. 
Kurimasa, A., Kumano, S., Boubnov, N.V., Story, M.D., Tung, C.S., Peterson, S.R., and Chen, D.J. 
(1999). Requirement for the kinase activity of human DNA-dependent protein kinase catalytic subunit 
in DNA strand break rejoining. Mol. Cell. Biol. 19, 3877–3884. 
Kwok, M., Davies, N., Agathanggelou, A., Smith, E., Oldreive, C., Petermann, E., Stewart, G., 
Brown, J., Lau, A., Pratt, G., et al. (2016). ATR inhibition induces synthetic lethality and overcomes 
117 
 
chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood 127, 582–
595. 
Lavin, M.F., and Shiloh, Y. (1996). Ataxia-telangiectasia: a multifaceted genetic disorder associated 
with defective signal transduction. Curr. Opin. Immunol. 8, 459–464. 
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C.L., Meier, 
W., Shapira-Frommer, R., Safra, T., et al. (2014). Olaparib maintenance therapy in patients with 
platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by 
BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852–861. 
Lee, J.-H., and Paull, T.T. (2005). ATM activation by DNA double-strand breaks through the Mre11-
Rad50-Nbs1 complex. Science 308, 551–554. 
Lee, H.S., Yang, H.-K., Kim, W.H., and Choe, G. (2005). Loss of DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs) expression in gastric cancers. Cancer Res. Treat. Off. J. Korean Cancer 
Assoc. 37, 98–102. 
Li, J., and Stern, D.F. (2005). Regulation of CHK2 by DNA-dependent Protein Kinase. J. Biol. Chem. 
280, 12041–12050. 
Lim, D.S., Kim, S.T., Xu, B., Maser, R.S., Lin, J., Petrini, J.H., and Kastan, M.B. (2000). ATM 
phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 404, 613–617. 
Lin, Y.-F., Shih, H.-Y., Shang, Z., Matsunaga, S., and Chen, B.P. (2014). DNA-PKcs is required to 
maintain stability of Chk1 and Claspin for optimal replication stress response. Nucleic Acids Res. 42, 
4463–4473. 
Liu, J., Wang, X., Ren, Y., Li, X., Zhang, X., and Zhou, B. (2014). Effect of single nucleotide 
polymorphism Rs189037 in ATM gene on risk of lung cancer in Chinese: a case-control study. PloS 
One 9, e115845. 
Liu, J., Lichtenberg, T., Hoadley, K.A., Poisson, L.M., Lazar, A.J., Cherniack, A.D., Kovatich, A.J., 
Benz, C.C., Levine, D.A., Lee, A.V., et al. (2018). An Integrated TCGA Pan-Cancer Clinical Data 
Resource to Drive High-Quality Survival Outcome Analytics. Cell 173, 400-416.e11. 
Liu, Q., Guntuku, S., Cui, X.S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., 
DeMayo, F., Bradley, A., et al. (2000). Chk1 is an essential kinase that is regulated by Atr and 
required for the G(2)/M DNA damage checkpoint. Genes Dev. 14, 1448–1459. 
Lloyd, R.L., Wijnhoven, P.W.G., Ramos-Montoya, A., Wilson, Z., Illuzzi, G., Falenta, K., Jones, 
G.N., James, N., Chabbert, C.D., Stott, J., et al. (2020). Combined PARP and ATR inhibition 
potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene 1–15. 
Longley, D.B., Harkin, D.P., and Johnston, P.G. (2003). 5-Fluorouracil: mechanisms of action and 
clinical strategies. Nat. Rev. Cancer 3, 330–338. 
López-Contreras, A.J., Gutierrez-Martinez, P., Specks, J., Rodrigo-Perez, S., and Fernandez-
Capetillo, O. (2012). An extra allele of Chk1 limits oncogene-induced replicative stress and promotes 
transformation. J. Exp. Med. 209, 455–461. 
Maitra, A., Adsay, N.V., Argani, P., Iacobuzio-Donahue, C., De Marzo, A., Cameron, J.L., Yeo, C.J., 
and Hruban, R.H. (2003). Multicomponent analysis of the pancreatic adenocarcinoma progression 
model using a pancreatic intraepithelial neoplasia tissue microarray. Mod. Pathol. Off. J. U. S. Can. 
Acad. Pathol. Inc 16, 902–912. 
118 
 
Majka, J., Binz, S.K., Wold, M.S., and Burgers, P.M.J. (2006). Replication Protein A Directs Loading 
of the DNA Damage Checkpoint Clamp to 5′-DNA Junctions. J. Biol. Chem. 281, 27855–27861. 
Malyuchenko, N.V., Kotova, E.Yu., Kulaeva, O.I., Kirpichnikov, M.P., and Studitskiy, V.M. (2015). 
PARP1 Inhibitors: antitumor drug design. Acta Naturae 7, 27–37. 
Marais, R., Light, Y., Paterson, H.F., and Marshall, C.J. (1995). Ras recruits Raf-1 to the plasma 
membrane for activation by tyrosine phosphorylation. EMBO J. 14, 3136–3145. 
McGuigan, A., Kelly, P., Turkington, R.C., Jones, C., Coleman, H.G., and McCain, R.S. (2018). 
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J. 
Gastroenterol. 24, 4846–4861. 
McMillin, D.W., Negri, J.M., and Mitsiades, C.S. (2013). The role of tumour–stromal interactions in 
modifying drug response: challenges and opportunities. Nat. Rev. Drug Discov. 12, 217–228. 
Mego, M., Cierna, Z., Svetlovska, D., Macak, D., Machalekova, K., Miskovska, V., Chovanec, M., 
Usakova, V., Obertova, J., Babal, P., et al. (2013). PARP expression in germ cell tumours. J. Clin. 
Pathol. 66, 607–612. 
Mehdipour, P., Karami, F., Javan, F., and Mehrazin, M. (2015). Linking ATM Promoter Methylation 
to Cell Cycle Protein Expression in Brain Tumor Patients: Cellular Molecular Triangle Correlation in 
ATM Territory. Mol. Neurobiol. 52, 293–302. 
Miller, R.M., Nworu, C., McKee, L., Balcerzak, D., Pham, L., Pugh, J., Liu, Y.-Z., Gustafson, H., 
Marwah, E., Lamb, T., et al. (2019). Development of an Immunohistochemical Assay to Detect the 
Ataxia-Telangiectasia Mutated (ATM) Protein in Gastric Carcinoma. Appl. Immunohistochem. Mol. 
Morphol. AIMM. 
Min, A., Im, S.-A., Jang, H., Kim, S., Lee, M., Kim, D.K., Yang, Y., Kim, H.-J., Lee, K.-H., Kim, 
J.W., et al. (2017). AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM 
Deficiency in Gastric Cancer Cells. Mol. Cancer Ther. 16, 566–577. 
Mini, E., Nobili, S., Caciagli, B., Landini, I., and Mazzei, T. (2006). Cellular pharmacology of 
gemcitabine. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO 17 Suppl 5, v7-12. 
Mohni, K.N., Kavanaugh, G.M., and Cortez, D. (2014). ATR pathway inhibition is synthetically 
lethal in cancer cells with ERCC1 deficiency. Cancer Res. 74, 2835–2845. 
Mohni, K.N., Thompson, P.S., Luzwick, J.W., Glick, G.G., Pendleton, C.S., Lehmann, B.D., 
Pietenpol, J.A., and Cortez, D. (2015). A Synthetic Lethal Screen Identifies DNA Repair Pathways 
that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. PLOS ONE 10, 
e0125482. 
Mokrani-Benhelli, H., Gaillard, L., Biasutto, P., Le Guen, T., Touzot, F., Vasquez, N., Komatsu, J., 
Conseiller, E., Pïcard, C., Gluckman, E., et al. (2013). Primary microcephaly, impaired DNA 
replication, and genomic instability caused by compound heterozygous ATR mutations. Hum. Mutat. 
34, 374–384. 
Mondal, G., Stevers, M., Goode, B., Ashworth, A., and Solomon, D.A. (2019). A requirement for 
STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant 
cancers. Nat. Commun. 10, 1686. 
Montano, R., Khan, N., Hou, H., Seigne, J., Ernstoff, M.S., Lewis, L.D., and Eastman, A. (2017). Cell 
cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and 
119 
 
bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 
inhibitor. Oncotarget 8, 67754–67768. 
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., 
Floquet, A., Leary, A., Sonke, G.S., et al. (2018). Maintenance Olaparib in Patients with Newly 
Diagnosed Advanced Ovarian Cancer. N. Engl. J. Med. 379, 2495–2505. 
Mordes, D.A., Glick, G.G., Zhao, R., and Cortez, D. (2008). TopBP1 activates ATR through ATRIP 
and a PIKK regulatory domain. Genes Dev. 22, 1478–1489. 
Morrell, D., Cromartie, E., and Swift, M. (1986). Mortality and Cancer Incidence in 263 Patients with 
Ataxia-Telangiectasia. J. Natl. Cancer Inst. 77, 89–92. 
Murai, J., and Pommier, Y. (2015). Classification of PARP Inhibitors Based on PARP Trapping and 
Catalytic Inhibition, and Rationale for Combinations with Topoisomerase I Inhibitors and Alkylating 
Agents. In PARP Inhibitors for Cancer Therapy, N.J. Curtin, and R.A. Sharma, eds. (Cham: Springer 
International Publishing), pp. 261–274. 
Murai, J., Huang, S.N., Das, B.B., Renaud, A., Zhang, Y., Doroshow, J.H., Ji, J., Takeda, S., and 
Pommier, Y. (2012). Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 72, 
5588–5599. 
Murai, J., Feng, Y., Yu, G.K., Ru, Y., Tang, S.-W., Shen, Y., and Pommier, Y. (2016). Resistance to 
PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget 7, 76534–
76550. 
de Murcia, J.M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M., Oliver, F.J., 
Masson, M., Dierich, A., LeMeur, M., et al. (1997). Requirement of poly(ADP-ribose) polymerase in 
recovery from DNA damage in mice and in cells. Proc. Natl. Acad. Sci. U. S. A. 94, 7303–7307. 
Murga, M., Campaner, S., Lopez-Contreras, A.J., Toledo, L.I., Soria, R., Montaña, M.F., Artista, 
L.D., Schleker, T., Guerra, C., Garcia, E., et al. (2011). Exploiting oncogene-induced replicative stress 
for the selective killing of Myc-driven tumors. Nat. Struct. Mol. Biol. 18, 1331–1335. 
Mutreja, K., Krietsch, J., Hess, J., Ursich, S., Berti, M., Roessler, F.K., Zellweger, R., Patra, M., 
Gasser, G., and Lopes, M. (2018). ATR-Mediated Global Fork Slowing and Reversal Assist Fork 
Traverse and Prevent Chromosomal Breakage at DNA Interstrand Cross-Links. Cell Rep. 24, 2629-
2642.e5. 
Nambaru, P.K., Hübner, T., Köck, K., Mews, S., Grube, M., Payen, L., Guitton, J., Sendler, M., 
Jedlitschky, G., Rimmbach, C., et al. (2011). Drug efflux transporter multidrug resistance-associated 
protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-
fluorouracil. Drug Metab. Dispos. Biol. Fate Chem. 39, 132–139. 
Navrkalova, V., Sebejova, L., Zemanova, J., Kminkova, J., Kubesova, B., Malcikova, J., Mraz, M., 
Smardova, J., Pavlova, S., Doubek, M., et al. (2013). ATM mutations uniformly lead to ATM 
dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin. 
Haematologica 98, 1124–1131. 
Neal, J.A., and Meek, K. (2011). Choosing the right path: does DNA-PK help make the decision? 
Mutat. Res. 711, 73–86. 
Negrini, S., Gorgoulis, V.G., and Halazonetis, T.D. (2010). Genomic instability--an evolving 
hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11, 220–228. 
120 
 
Nishida, H., Tatewaki, N., Nakajima, Y., Magara, T., Ko, K.M., Hamamori, Y., and Konishi, T. 
(2009). Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response. Nucleic 
Acids Res. 37, 5678–5689. 
Nosho, K., Yamamoto, H., Mikami, M., Taniguchi, H., Takahashi, T., Adachi, Y., Imamura, A., Imai, 
K., and Shinomura, Y. (2006). Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the 
early stage of colorectal carcinogenesis. Eur. J. Cancer Oxf. Engl. 1990 42, 2374–2381. 
O’Carrigan, B., de Miguel Luken, M.J., Papadatos-Pastos, D., Brown, J., Tunariu, N., Perez Lopez, 
R., Ganegoda, M., Riisnaes, R., Figueiredo, I., Carreira, S., et al. (2016). Phase I trial of a first-in-
class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin 
(CP) incorporating pharmacodynamics (PD) studies. J. Clin. Oncol. 34, 2504–2504. 
O’Driscoll, M., and Jeggo, P.A. (2003). Clinical impact of ATR checkpoint signalling failure in 
humans. Cell Cycle Georget. Tex 2, 194–195. 
Olive, K.P., Jacobetz, M.A., Davidson, C.J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., 
Goldgraben, M.A., Caldwell, M.E., Allard, D., et al. (2009). Inhibition of Hedgehog Signaling 
Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science 324, 1457–
1461. 
Osterman, M., Kathawa, D., Liu, D., Guo, H., Zhang, C., Li, M., Yu, X., and Li, F. (2014). Elevated 
DNA damage response in pancreatic cancer. Histochem. Cell Biol. 142, 713–720. 
Oza, A.M., Cibula, D., Benzaquen, A.O., Poole, C., Mathijssen, R.H.J., Sonke, G.S., Colombo, N., 
Špaček, J., Vuylsteke, P., Hirte, H., et al. (2015). Olaparib combined with chemotherapy for recurrent 
platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 16, 87–97. 
Pabla, N., Huang, S., Mi, Q.-S., Daniel, R., and Dong, Z. (2008). ATR-Chk2 signaling in p53 
activation and DNA damage response during cisplatin-induced apoptosis. J. Biol. Chem. 283, 6572–
6583. 
Pacek, M., and Walter, J.C. (2004). A requirement for MCM7 and Cdc45 in chromosome unwinding 
during eukaryotic DNA replication. EMBO J. 23, 3667–3676. 
Parrilla-Castellar, E.R., Arlander, S.J.H., and Karnitz, L. (2004). Dial 9-1-1 for DNA damage: the 
Rad9-Hus1-Rad1 (9-1-1) clamp complex. DNA Repair 3, 1009–1014. 
Peasland, A., Wang, L.-Z., Rowling, E., Kyle, S., Chen, T., Hopkins, A., Cliby, W.A., Sarkaria, J., 
Beale, G., Edmondson, R.J., et al. (2011). Identification and evaluation of a potent novel ATR 
inhibitor, NU6027, in breast and ovarian cancer cell lines. Br. J. Cancer 105, 372–381. 
Perkhofer, L., Schmitt, A., Romero Carrasco, M.C., Ihle, M., Hampp, S., Ruess, D.A., Hessmann, E., 
Russell, R., Lechel, A., Azoitei, N., et al. (2017). ATM Deficiency Generating Genomic Instability 
Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. Cancer Res. 
77, 5576–5590. 
Petermann, E., Maya-Mendoza, A., Zachos, G., Gillespie, D.A.F., Jackson, D.A., and Caldecott, K.W. 
(2006). Chk1 requirement for high global rates of replication fork progression during normal 
vertebrate S phase. Mol. Cell. Biol. 26, 3319–3326. 
Petermann, E., Woodcock, M., and Helleday, T. (2010). Chk1 promotes replication fork progression 
by controlling replication initiation. Proc. Natl. Acad. Sci. U. S. A. 107, 16090–16095. 
121 
 
Pettitt, S.J., Krastev, D.B., Brandsma, I., Dréan, A., Song, F., Aleksandrov, R., Harrell, M.I., Menon, 
M., Brough, R., Campbell, J., et al. (2018). Genome-wide and high-density CRISPR-Cas9 screens 
identify point mutations in PARP1 causing PARP inhibitor resistance. Nat. Commun. 9, 1–14. 
Pichierri, P., Rosselli, F., and Franchitto, A. (2003). Werner’s syndrome protein is phosphorylated in 
an ATR/ATM-dependent manner following replication arrest and DNA damage induced during the S 
phase of the cell cycle. Oncogene 22, 1491–1500. 
Pike, K.G., Barlaam, B., Cadogan, E., Campbell, A., Chen, Y., Colclough, N., Davies, N.L., de-
Almeida, C., Degorce, S.L., Didelot, M., et al. (2018). The Identification of Potent, Selective, and 
Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of 
AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H- pyran-4-yl)-
1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one). J. Med. Chem. 61, 3823–3841. 
Plunkett, W., Huang, P., Xu, Y.Z., Heinemann, V., Grunewald, R., and Gandhi, V. (1995). 
Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin. Oncol. 22, 3–10. 
Pommier, Y., Leo, E., Zhang, H., and Marchand, C. (2010). DNA Topoisomerases and Their 
Poisoning by Anticancer and Antibacterial Drugs. Chem. Biol. 17, 421–433. 
Purnell, M.R., and Whish, W.J. (1980). Novel inhibitors of poly(ADP-ribose) synthetase. Biochem. J. 
185, 775–777. 
Quigley, D.A., Dang, H.X., Zhao, S.G., Lloyd, P., Aggarwal, R., Alumkal, J.J., Foye, A., Kothari, V., 
Perry, M.D., Bailey, A.M., et al. (2018). Genomic Hallmarks and Structural Variation in Metastatic 
Prostate Cancer. Cell 174, 758-769.e9. 
Rafiei, S., Fitzpatrick, K., Liu, D., Cai, M.-Y., Elmarakeby, H.A., Park, J., Ricker, C., Kochupurakkal, 
B.S., Choudhury, A.D., Hahn, W.C., et al. (2020). ATM Loss Confers Greater Sensitivity to ATR 
Inhibition than PARP Inhibition in Prostate Cancer. Cancer Res. 
Rahib, L., Smith, B.D., Aizenberg, R., Rosenzweig, A.B., Fleshman, J.M., and Matrisian, L.M. 
(2014). Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and 
pancreas cancers in the United States. Cancer Res. 74, 2913–2921. 
Reaper, P.M., Griffiths, M.R., Long, J.M., Charrier, J.-D., Maccormick, S., Charlton, P.A., Golec, 
J.M.C., and Pollard, J.R. (2011). Selective killing of ATM- or p53-deficient cancer cells through 
inhibition of ATR. Nat. Chem. Biol. 7, 428–430. 
Reisländer, T., Lombardi, E.P., Groelly, F.J., Miar, A., Porru, M., Di Vito, S., Wright, B., Lockstone, 
H., Biroccio, A., Harris, A., et al. (2019). BRCA2 abrogation triggers innate immune responses 
potentiated by treatment with PARP inhibitors. Nat. Commun. 10, 3143. 
Riballo, E., Kühne, M., Rief, N., Doherty, A., Smith, G.C.M., Recio, M.-J., Reis, C., Dahm, K., 
Fricke, A., Krempler, A., et al. (2004). A Pathway of Double-Strand Break Rejoining Dependent upon 
ATM, Artemis, and Proteins Locating to γ-H2AX Foci. Mol. Cell 16, 715–724. 
Riches, L.C., Trinidad, A.G., Hughes, G., Jones, G.N., Hughes, A.M., Thomason, A.G., Gavine, P., 
Cui, A., Ling, S., Stott, J., et al. (2019). Pharmacology of the ATM inhibitor AZD0156: potentiation 
of irradiation and olaparib responses pre-clinically. Mol. Cancer Ther. molcanther.1394.2018. 
Richmond, A., and Su, Y. (2008). Mouse xenograft models vs GEM models for human cancer 
therapeutics. Dis. Model. Mech. 1, 78–82. 
122 
 
Riesenberg, S., Chintalapati, M., Macak, D., Kanis, P., Maricic, T., and Pääbo, S. (2019). 
Simultaneous precise editing of multiple genes in human cells. Nucleic Acids Res. 47, e116. 
Roberts, C.W.M., and Orkin, S.H. (2004). The SWI/SNF complex--chromatin and cancer. Nat. Rev. 
Cancer 4, 133–142. 
Roberts, N.J., Jiao, Y., Yu, J., Kopelovich, L., Petersen, G.M., Bondy, M.L., Gallinger, S., Schwartz, 
A.G., Syngal, S., Cote, M.L., et al. (2012). ATM mutations in patients with hereditary pancreatic 
cancer. Cancer Discov. 2, 41–46. 
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S.M., Masuda, N., Delaloge, S., Li, W., Tung, 
N., Armstrong, A., et al. (2017). Olaparib for Metastatic Breast Cancer in Patients with a Germline 
BRCA Mutation. N. Engl. J. Med. 377, 523–533. 
Rojo, F., García-Parra, J., Zazo, S., Tusquets, I., Ferrer-Lozano, J., Menendez, S., Eroles, P., 
Chamizo, C., Servitja, S., Ramírez-Merino, N., et al. (2012). Nuclear PARP-1 protein overexpression 
is associated with poor overall survival in early breast cancer. Ann. Oncol. Off. J. Eur. Soc. Med. 
Oncol. 23, 1156–1164. 
Roninson, I.B., Chin, J.E., Choi, K.G., Gros, P., Housman, D.E., Fojo, A., Shen, D.W., Gottesman, 
M.M., and Pastan, I. (1986). Isolation of human mdr DNA sequences amplified in multidrug-resistant 
KB carcinoma cells. Proc. Natl. Acad. Sci. 83, 4538–4542. 
Ruiz, S., Lopez-Contreras, A.J., Gabut, M., Marion, R.M., Gutierrez-Martinez, P., Bua, S., Ramirez, 
O., Olalde, I., Rodrigo-Perez, S., Li, H., et al. (2015). Limiting replication stress during somatic cell 
reprogramming reduces genomic instability in induced pluripotent stem cells. Nat. Commun. 6, 8036. 
Ruiz, S., Mayor-Ruiz, C., Lafarga, V., Murga, M., Vega-Sendino, M., Ortega, S., and Fernandez-
Capetillo, O. (2016). A genomewide CRISPR screen identifies CDC25A as a determinant of 
sensitivity to ATR inhibitors. Mol. Cell 62, 307–313. 
Rundle, S., Bradbury, A., Drew, Y., and Curtin, N.J. (2017). Targeting the ATR-CHK1 Axis in 
Cancer Therapy. Cancers 9, 41. 
Ryan, C.J., Bajrami, I., and Lord, C.J. (2018). Synthetic Lethality and Cancer - Penetrance as the 
Major Barrier. Trends Cancer 4, 671–683. 
Saeki, H., Siaud, N., Christ, N., Wiegant, W.W., van Buul, P.P.W., Han, M., Zdzienicka, M.Z., Stark, 
J.M., and Jasin, M. (2006). Suppression of the DNA repair defects of BRCA2-deficient cells with 
heterologous protein fusions. Proc. Natl. Acad. Sci. U. S. A. 103, 8768–8773. 
Sanchez, Y., Wong, C., Thoma, R.S., Richman, R., Wu, Z., Piwnica-Worms, H., and Elledge, S.J. 
(1997). Conservation of the Chk1 Checkpoint Pathway in Mammals: Linkage of DNA Damage to 
Cdk Regulation Through Cdc25. Science 277, 1497–1501. 
Sanjiv, K., Hagenkort, A., Calderón-Montaño, J.M., Koolmeister, T., Reaper, P.M., Mortusewicz, O., 
Jacques, S.A., Kuiper, R.V., Schultz, N., Scobie, M., et al. (2015). Cancer-Specific Synthetic 
Lethality between ATR and CHK1 Kinase Activities. Cell Rep. 14, 298–309. 
Sarkaria, J.N., Busby, E.C., Tibbetts, R.S., Roos, P., Taya, Y., Karnitz, L.M., and Abraham, R.T. 
(1999). Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer 
Res. 59, 4375–4382. 
Sarmento, L.M., Póvoa, V., Nascimento, R., Real, G., Antunes, I., Martins, L.R., Moita, C., Alves, 
P.M., Abecasis, M., Moita, L.F., et al. (2015). CHK1 overexpression in T-cell acute lymphoblastic 
123 
 
leukemia is essential for proliferation and survival by preventing excessive replication stress. 
Oncogene 34, 2978–2990. 
Sartori, A.A., Lukas, C., Coates, J., Mistrik, M., Fu, S., Bartek, J., Baer, R., Lukas, J., and Jackson, 
S.P. (2007). Human CtIP promotes DNA end resection. Nature 450, 509–514. 
Satoh, M.S., and Lindahl, T. (1992). Role of poly(ADP-ribose) formation in DNA repair. Nature 356, 
356–358. 
Schmitt, A., Knittel, G., Welcker, D., Yang, T.-P., George, J., Nowak, M., Leeser, U., Buettner, R., 
Perner, S., Peifer, M., et al. (2017). ATM Deficiency Is Associated with Sensitivity to PARP1-and 
ATR Inhibitors in Lung Adenocarcinoma. Cancer Res. 77, 3040–3056. 
Schoppy, D.W., Ragland, R.L., Gilad, O., Shastri, N., Peters, A.A., Murga, M., Fernandez-Capetillo, 
O., Diehl, J.A., and Brown, E.J. (2012). Oncogenic stress sensitizes murine cancers to hypomorphic 
suppression of ATR. J. Clin. Invest. 122, 241–252. 
Schutte, M., Hruban, R.H., Geradts, J., Maynard, R., Hilgers, W., Rabindran, S.K., Moskaluk, C.A., 
Hahn, S.A., Schwarte-Waldhoff, I., Schmiegel, W., et al. (1997). Abrogation of the Rb/p16 tumor-
suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 57, 3126–3130. 
Sen, T., Rodriguez, B.L., Chen, L., Corte, C.D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., 
Diao, L., Li, L., et al. (2019). Targeting DNA damage response promotes anti-tumor immunity 
through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. CD-18-1020. 
Serrano, M.A., Li, Z., Dangeti, M., Musich, P.R., Patrick, S., Roginskaya, M., Cartwright, B., and 
Zou, Y. (2013). DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate 
homologous recombination DNA repair. Oncogene 32, 2452–2462. 
Shechter, D., Costanzo, V., and Gautier, J. (2004). ATR and ATM regulate the timing of DNA 
replication origin firing. Nat. Cell Biol. 6, 648–655. 
Shen, J., Zhao, W., Ju, Z., Wang, L., Peng, Y., Labrie, M., Yap, T.A., Mills, G.B., and Peng, G. 
(2019). PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic 
Efficacy of Immune Checkpoint Blockade Independent of BRCAness. Cancer Res. 79, 311–319. 
Shen, L., Yin, Z.-H., Wan, Y., Zhang, Y., Li, K., and Zhou, B.-S. (2012). Association between ATM 
polymorphisms and cancer risk: a meta-analysis. Mol. Biol. Rep. 39, 5719–5725. 
Singhi, A.D., George, B., Greenbowe, J.R., Chung, J., Suh, J., Maitra, A., Klempner, S.J., Hendifar, 
A., Milind, J.M., Golan, T., et al. (2019). Real-Time Targeted Genome Profile Analysis of Pancreatic 
Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs 
or Used as Biomarkers. Gastroenterology 156, 2242-2253.e4. 
Sørensen, C.S., Syljuåsen, R.G., Falck, J., Schroeder, T., Rönnstrand, L., Khanna, K.K., Zhou, B.-B., 
Bartek, J., and Lukas, J. (2003). Chk1 regulates the S phase checkpoint by coupling the physiological 
turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 3, 247–258. 
Staibano, S., Pepe, S., Lo Muzio, L., Somma, P., Mascolo, M., Argenziano, G., Scalvenzi, M., 
Salvatore, G., Fabbrocini, G., Molea, G., et al. (2005). Poly(adenosine diphosphate-ribose) 
polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck 
region. Hum. Pathol. 36, 724–731. 
124 
 
Stokes, M.P., Rush, J., MacNeill, J., Ren, J.M., Sprott, K., Nardone, J., Yang, V., Beausoleil, S.A., 
Gygi, S.P., Livingstone, M., et al. (2007). Profiling of UV-induced ATM/ATR signaling pathways. 
Proc. Natl. Acad. Sci. 104, 19855–19860. 
Stracker, T.H., and Petrini, J.H.J. (2011). The MRE11 complex: starting from the ends. Nat. Rev. 
Mol. Cell Biol. 12, 90–103. 
Ström, C.E., Johansson, F., Uhlén, M., Szigyarto, C.A.-K., Erixon, K., and Helleday, T. (2011). Poly 
(ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a 
single-strand intermediate. Nucleic Acids Res. 39, 3166–3175. 
Sultana, R., Abdel-Fatah, T., Perry, C., Moseley, P., Albarakti, N., Mohan, V., Seedhouse, C., Chan, 
S., and Madhusudan, S. (2013). Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein 
Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer Cells. PLoS ONE 8. 
Sun, L., Wu, J., Du, F., Chen, X., and Chen, Z.J. (2013). Cyclic GMP-AMP Synthase Is a Cytosolic 
DNA Sensor That Activates the Type I Interferon Pathway. Science 339, 786–791. 
Sun, Q., Guo, Y., Liu, X., Czauderna, F., Carr, M.I., Zenke, F.T., Blaukat, A., and Vassilev, L.T. 
(2019). Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing 
Radiation and the DNA-PK Inhibitor M3814. Mol. Cancer Res. MCR 17, 2457–2468. 
Sundar, R., Miranda, S., Rodrigues, D.N., Chénard-Poirier, M., Dolling, D., Clarke, M., Figueiredo, 
I., Bertan, C., Yuan, W., Ferreira, A., et al. (2018). Ataxia Telangiectasia Mutated Protein Loss and 
Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clin. Colorectal Cancer 17, 
280–284. 
Suto, M.J., Turner, W.R., Arundel-Suto, C.M., Werbel, L.M., and Sebolt-Leopold, J.S. (1991). 
Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-
ribose) polymerase. Anticancer. Drug Des. 6, 107–117. 
Swift, M., Morrell, D., Massey, R.B., and Chase, C.L. (1991). Incidence of cancer in 161 families 
affected by ataxia-telangiectasia. N. Engl. J. Med. 325, 1831–1836. 
Sy, S.M.H., Huen, M.S.Y., and Chen, J. (2009). PALB2 is an integral component of the BRCA 
complex required for homologous recombination repair. Proc. Natl. Acad. Sci. U. S. A. 106, 7155–
7160. 
Syljuåsen, R.G., Sørensen, C.S., Hansen, L.T., Fugger, K., Lundin, C., Johansson, F., Helleday, T., 
Sehested, M., Lukas, J., and Bartek, J. (2005). Inhibition of human Chk1 causes increased initiation of 
DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol. Cell. Biol. 25, 3553–
3562. 
Takai, H., Tominaga, K., Motoyama, N., Minamishima, Y.A., Nagahama, H., Tsukiyama, T., Ikeda, 
K., Nakayama, K., Nakanishi, M., and Nakayama, K. (2000). Aberrant cell cycle checkpoint function 
and early embryonic death in Chk1(-/-) mice. Genes Dev. 14, 1439–1447. 
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I., and Willingham, M.C. (1987). 
Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human 
tissues. Proc. Natl. Acad. Sci. 84, 7735–7738. 
Thomas, A., Redon, C.E., Sciuto, L., Padiernos, E., Ji, J., Lee, M.-J., Yuno, A., Lee, S., Zhang, Y., 
Tran, L., et al. (2017). Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in 
Patients With Advanced Solid Tumors. J. Clin. Oncol. 36, 1594–1602. 
125 
 
Thomas, A., Vilimas, R., Trindade, C., Erwin-Cohen, R., Roper, N., Xi, L., Krishnasamy, V., Levy, 
E., Mammen, A., Nichols, S., et al. (2019). Durvalumab in Combination with Olaparib in Patients 
with Relapsed SCLC: Results from a Phase II Study. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study 
Lung Cancer 14, 1447–1457. 
Thompson, D., Duedal, S., Kirner, J., McGuffog, L., Last, J., Reiman, A., Byrd, P., Taylor, M., and 
Easton, D.F. (2005). Cancer Risks and Mortality in Heterozygous ATM Mutation Carriers. JNCI J. 
Natl. Cancer Inst. 97, 813–822. 
Toledo, L., Neelsen, K.J., and Lukas, J. (2017). Replication Catastrophe: When a Checkpoint Fails 
because of Exhaustion. Mol. Cell 66, 735–749. 
Toledo, L.I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., 
Bischoff, J.R., and Fernandez-Capetillo, O. (2011). A cell-based screen identifies ATR inhibitors with 
synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol. 18, 721–727. 
Toledo, L.I., Altmeyer, M., Rask, M.-B., Lukas, C., Larsen, D.H., Povlsen, L.K., Bekker-Jensen, S., 
Mailand, N., Bartek, J., and Lukas, J. (2013). ATR Prohibits Replication Catastrophe by Preventing 
Global Exhaustion of RPA. Cell 155, 1088–1103. 
Tonotsuka, N., Hosoi, Y., Miyazaki, S., Miyata, G., Sugawara, K., Mori, T., Ouchi, N., Satomi, S., 
Matsumoto, Y., Nakagawa, K., et al. (2006). Heterogeneous expression of DNA-dependent protein 
kinase in esophageal cancer and normal epithelium. Int. J. Mol. Med. 18, 441–447. 
Trenz, K., Smith, E., Smith, S., and Costanzo, V. (2006). ATM and ATR promote Mre11 dependent 
restart of collapsed replication forks and prevent accumulation of DNA breaks. EMBO J. 25, 1764–
1774. 
Tsuji, T., Sapinoso, L.M., Tran, T., Gaffney, B., Wong, L., Sankar, S., Raymon, H.K., Mortensen, 
D.S., and Xu, S. (2017). CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA 
damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro. Oncotarget 8, 
74688–74702. 
Uhrhammer, N., Bay, J.-O., and Bignon, Y.-J. (1998). Seventh International Workshop on Ataxia-
Telangiectasia. Cancer Res. 58, 3480–3485. 
Vendetti, F.P., Lau, A., Schamus, S., Conrads, T.P., O’Connor, M.J., and Bakkenist, C.J. (2015). The 
orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of 
cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget 6, 44289–44305. 
Vendetti, F.P., Karukonda, P., Clump, D.A., Teo, T., Lalonde, R., Nugent, K., Ballew, M., Kiesel, 
B.F., Beumer, J.H., Sarkar, S.N., et al. (2018). ATR kinase inhibitor AZD6738 potentiates CD8+ T 
cell-dependent antitumor activity following radiation. J. Clin. Invest. 128, 3926–3940. 
Vincent, A., Herman, J., Schulick, R., Hruban, R.H., and Goggins, M. (2011). Pancreatic cancer. 
Lancet Lond. Engl. 378, 607–620. 
Vo, Q.N., Kim, W.J., Cvitanovic, L., Boudreau, D.A., Ginzinger, D.G., and Brown, K.D. (2004). The 
ATM gene is a target for epigenetic silencing in locally advanced breast cancer. Oncogene 23, 9432–
9437. 
Von Hoff, D.D., Ervin, T., Arena, F.P., Chiorean, E.G., Infante, J., Moore, M., Seay, T., Tjulandin, 
S.A., Ma, W.W., Saleh, M.N., et al. (2013). Increased survival in pancreatic cancer with nab-
paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703. 
126 
 
Waddell, N., Pajic, M., Patch, A.-M., Chang, D.K., Kassahn, K.S., Bailey, P., Johns, A.L., Miller, D., 
Nones, K., Quek, K., et al. (2015). Whole genomes redefine the mutational landscape of pancreatic 
cancer. Nature 518, 495–501. 
Wallez, Y., Dunlop, C.R., Johnson, T.I., Koh, S.-B., Fornari, C., Yates, J.W.T., Fernández, S.B. de Q., 
Lau, A., Richards, F.M., and Jodrell, D.I. (2018). The ATR Inhibitor AZD6738 Synergizes with 
Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression. Mol. 
Cancer Ther. 17, 1670–1682. 
Wang, H., Yang, H., Shivalila, C.S., Dawlaty, M.M., Cheng, A.W., Zhang, F., and Jaenisch, R. 
(2013). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated 
genome engineering. Cell 153, 910–918. 
Wang, X.Q., Redpath, J.L., Fan, S.T., and Stanbridge, E.J. (2006). ATR dependent activation of 
Chk2. J. Cell. Physiol. 208, 613–619. 
Warren, N.J.H., and Eastman, A. (2019). Inhibition of checkpoint kinase 1 following gemcitabine-
mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe. J. Biol. 
Chem. 294, 1763–1778. 
Weber, A.M., Drobnitzky, N., Devery, A.M., Bokobza, S.M., Adams, R.A., Maughan, T.S., and 
Ryan, A.J. (2016). Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated 
gene in non-small cell lung cancer. Oncotarget 7, 60807–60822. 
Wengner, A.M., Siemeister, G., Lücking, U., Lefranc, J., Wortmann, L., Lienau, P., Bader, B., Bömer, 
U., Moosmayer, D., Eberspächer, U., et al. (2020). The Novel ATR Inhibitor BAY 1895344 Is 
Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising 
Therapies in Preclinical Cancer Models. Mol. Cancer Ther. 19, 26–38. 
Westphal, C.H., Rowan, S., Schmaltz, C., Elson, A., Fisher, D.E., and Leder, P. (1997). atm and p53 
cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation 
toxicity. Nat. Genet. 16, 397–401. 
Williamson, C.T., Miller, R., Pemberton, H.N., Jones, S.E., Campbell, J., Konde, A., Badham, N., 
Rafiq, R., Brough, R., Gulati, A., et al. (2016). ATR inhibitors as a synthetic lethal therapy for 
tumours deficient in ARID1A. Nat. Commun. 7, 13837. 
Wise, H.C., Iyer, G.V., Moore, K., Temkin, S.M., Gordon, S., Aghajanian, C., and Grisham, R.N. 
(2019). Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II 
Inhibitors in Ovarian Cancer Models. Sci. Rep. 9, 18882. 
Witkiewicz, A.K., McMillan, E.A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., 
Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015). Whole-exome sequencing of pancreatic cancer 
defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744. 
Xia, B., Sheng, Q., Nakanishi, K., Ohashi, A., Wu, J., Christ, N., Liu, X., Jasin, M., Couch, F.J., and 
Livingston, D.M. (2006). Control of BRCA2 cellular and clinical functions by a nuclear partner, 
PALB2. Mol. Cell 22, 719–729. 
Xiao, Z., Chen, Z., Gunasekera, A.H., Sowin, T.J., Rosenberg, S.H., Fesik, S., and Zhang, H. (2003). 
Chk1 Mediates S and G2 Arrests through Cdc25A Degradation in Response to DNA-damaging 
Agents. J. Biol. Chem. 278, 21767–21773. 
127 
 
Yadav, B., Wennerberg, K., Aittokallio, T., and Tang, J. (2015). Searching for Drug Synergy in 
Complex Dose–Response Landscapes Using an Interaction Potency Model. Comput. Struct. 
Biotechnol. J. 13, 504–513. 
Yanai, M., Makino, H., Ping, B., Takeda, K., Tanaka, N., Sakamoto, T., Yamaguchi, K., Kodani, M., 
Yamasaki, A., Igishi, T., et al. (2017). DNA-PK Inhibition by NU7441 Enhances Chemosensitivity to 
Topoisomerase Inhibitor in Non-Small Cell Lung Carcinoma Cells by Blocking DNA Damage 
Repair. Yonago Acta Med. 60, 9–15. 
Yap, T.A., Luken, M.J. de M., O’Carrigan, B., Roda, D., Papadatos-Pastos, D., Lorente, D., Tunariu, 
N., Lopez, R.P., Gayle, S., Riisnaes, R., et al. (2015). Abstract PR14: Phase I trial of first-in-class 
ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in 
combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of 
target modulation and antitumor activity. Mol. Cancer Ther. 14, PR14–PR14. 
Yazinski, S.A., Comaills, V., Buisson, R., Genois, M.-M., Nguyen, H.D., Ho, C.K., Kwan, T.T., 
Morris, R., Lauffer, S., Nussenzweig, A., et al. (2017). ATR inhibition disrupts rewired homologous 
recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. 
Genes Dev. 31, 318–332. 
You, Z., Shi, L.Z., Zhu, Q., Wu, P., Zhang, Y.-W., Basilio, A., Tonnu, N., Verma, I.M., Berns, M.W., 
and Hunter, T. (2009). CtIP Links DNA Double-strand Break Sensing to Resection. Mol. Cell 36, 
954–969. 
Yu, X., and Chen, J. (2004). DNA damage-induced cell cycle checkpoint control requires CtIP, a 
phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol. Cell. Biol. 24, 
9478–9486. 
Yun, M.H., and Hiom, K. (2009). CtIP-BRCA1 modulates the choice of DNA double-strand-break 
repair pathway throughout the cell cycle. Nature 459, 460–463. 
Yurgelun, M.B., Chittenden, A.B., Morales-Oyarvide, V., Rubinson, D.A., Dunne, R.F., Kozak, 
M.M., Qian, Z.R., Welch, M.W., Brais, L.K., Da Silva, A., et al. (2019). Germline cancer 
susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected 
pancreatic cancer. Genet. Med. 21, 213–223. 
Zeman, M.K., and Cimprich, K.A. (2014). Causes and Consequences of Replication Stress. Nat. Cell 
Biol. 16, 2–9. 
Zhang, F., Fan, Q., Ren, K., and Andreassen, P.R. (2009). PALB2 functionally connects the breast 
cancer susceptibility proteins BRCA1 and BRCA2. Mol. Cancer Res. MCR 7, 1110–1118. 
Zhao, Y., Thomas, H.D., Batey, M.A., Cowell, I.G., Richardson, C.J., Griffin, R.J., Calvert, A.H., 
Newell, D.R., Smith, G.C.M., and Curtin, N.J. (2006). Preclinical evaluation of a potent novel DNA-
dependent protein kinase inhibitor NU7441. Cancer Res. 66, 5354–5362. 
Zhou, J., Enewold, L., Stojadinovic, A., Clifton, G.T., Potter, J.F., Peoples, G.E., and Zhu, K. (2010). 
Incidence rates of exocrine and endocrine pancreatic cancers in the United States. Cancer Causes 
Control 21, 853–861. 
Zhou, J.X., Feng, L.J., and Zhang, X. (2017). Risk of severe hematologic toxicities in cancer patients 




Ziv, Y., Bielopolski, D., Galanty, Y., Lukas, C., Taya, Y., Schultz, D.C., Lukas, J., Bekker-Jensen, S., 
Bartek, J., and Shiloh, Y. (2006). Chromatin relaxation in response to DNA double-strand breaks is 
modulated by a novel ATM- and KAP-1 dependent pathway. Nat. Cell Biol. 8, 870–876. 
Zou, L., and Elledge, S.J. (2003). Sensing DNA Damage Through ATRIP Recognition of RPA-
ssDNA Complexes. Science 300, 1542–1548. 
 
